Approved for use through 10/31/2002 348 0651-0031

U.S. Patent and Trademark Office U.S. DEPARTMENT OF COMMERCE

1995, no persons are required to respond to a collection of information unless it contains a valid OME control number

Complete if Known AUS 0 1 2001 & nwork Reduction Act of Under the F

Substitute for Form 1449/A/PTO

DISCLOSURE

(use as many sheets as necessary

			~~,
	Complete if Known	THE C	7
Application Number	09/545,139	- S	7
Filing Date	April 7, 2000	71 0	'n
First Named Inventor	D'Amato et al.	-	世
Group Art Unit	1614	80 20	_
Examiner Name	J. Goldberg	80	
Attorney Docket Number	05213-0650 43170-2	33 681	11
			_

Sheet 1 of 17 At			ttorney Docket Numbe	r 05	213-0650 4	3170-2	§681		
				U.S. PATE	NT DOCUMENTS			~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~	31
			•					<u> </u>	
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAM	IE	CLASS	SUBCLASS	FILI IF AP	NG DATE PROPRIATE
A.	AA	2,830,991	04/15/58	Keller, et al.		260	281		
9	AB	3,560,495	02/02/71	Frankus, E.		260	247.1		
9	AC	3,563,986	02/16/71	Frankus, E.		260	247.1		
2	AD	3,625,946	12/07/71	Heinrich, et al.		260	281		
Q	AE	3,705,162	12/05/72	Graudums, et al.		260	281	-11	7
	AF	4,552,888	11/12/85	Koppel, et al.		514	474		
	AG	4,994,443	02/19/91	Folkman, et al.		514	56		
	АН	5,001,116	03/19/91	Folkman, et al.		514	56		
	ΑI	5,021,404	06/04/91	Folkman, et al.		514	26		
	AJ	5,134,127	07/28/92	Stella, et al.	T DOCUMENTS	514	058	•	
	i		1					TRANSI	ATION
		DOCUMENT NUMBER	DATE	COUNTRY	NAMI			YES	NO.
2	AK	1,182,709	03/04/70	Austria	Kwizda, R.				
	AL	58-131978	08/06/83	- Japan					X
	AM	63-119500	05/24/88	Japan					X
4	AN	0325199	07/26/89	ЕРО	Takeda Chemical I	ndustries	s, LTD		
	AO	0357061	03/07/90	ЕРО	Takeda Chemical I	ndustries	s, LTD		
	AP	WO 91/10424	07/25/91	PCT	Northwestern Univ	ersity		****	
9	AQ	WO 92/14455	09/03/92	PCT	The Rockefeller Ur				
	AR	WO 92/18496	10/29/92	PCT	Grünenthal GMBH			·	X
>	AS	WO 94/20085	09/15/94	PCT	Children's Hospital	Medicla	Center	***	
9	AT	WO 95/04533	02/16/95	PCT	Andrulis Pharmace	ıticals C	orporation		
	AU	WO 00/55134	09/21/00	PCT	Celgene Corporatio	n			
CAMINE	`	mr			DATE CONSIDE	RED d	4/23/01	·	

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

AUG 0 1 2001 Approved for use through 10/31/2001 OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENTOF COMMERCE

Under the Paperwork Reduction Action 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for Form 1449/A/PTO

INFORMATION DISCLOSURE ENT BY APPLICANT

Complete if Known 09/545,139 **Application Number** S April 7, 2000 **Filing Date** D'Amato et al. First Named Inventor 1614 **Group Art Unit** J. Goldberg **Examiner Name** 05213-0650 43176-219681

(use as many sheets as necessary Sheet 2 of 17

Attorney Docket Number U.S. PATENT DOCUMENTS

				U.S. PATENT D	OCCINEITIO			8 U
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CL	ASS	SUBCLASS	FILING DATE IF APPROPRIATE
J,	BA	5,385,901	01/31/95	Kaplan, et al.	51	4	231.5	
4	ВВ	5,399,363	03/21/95	Liversidge, et al.	42	4	490	
<u> </u>	вс	5,405,855	04/11/95	Andrulis, Jr.	51	4	323	
2_	BD	5,434,170	07/18/95	Andrulis, Jr.	51	4	323	
	ВЕ	5,443,824	08/22/95	Piacquadio	42	24	78.02	
	BF	5,502,066	03/26/96	Heinemann	51	.4	360	
	BG	5,605,684	02/25/97	Piacquadio	42	24	78.02	
	вн	5,605,914	02/25/97	Muller	51	.4	339	
	BI	5,643,915	07/01/97	Andrulis, Jr. et al.	51	4	279	
	вј	5,654,312	08/05/97	Andrulis, Jr. et al.	51	4	279	
	вк	5,679,696	10/21/97	Fenton et al.	51	4	354	
J	BL	5,731,325	03/24/98	Andrulis, Jr. et al. CES (Including Author, I	51 Fitle, Date, Pertinen		323 es. Etc.)	_
		OTHERT	CET EIGET	LES (Including Humor, 1	100, 15000, 1 0, 1000	0	,	
	BM	Wounds and to	o Normal ar	Reactions of Normal and ad Neoplastic Transplant	s". J. Nat'l Canc. In:	<i>st</i> ., pp), 73 - 85 (194	(5)
2	BN	nn 124-127 (1	1964)	'inefficacia della Talido				
2	во	and Tumor Pro	Ambs, S. et al., "Interactive Effects of Nitric Oxide and the p53 Tumor Suppressor Gene in Carcinogenesis and Tumor Progression", <i>The FASEB Journal</i> , Vol. 11, pp. 443-448 (1997) Apt, W. "Effect of Thalidomide on the Course of Experimental Chagas' Disease", <i>BOI. Chil. Parasitol</i> , Vol.					
	BP	Apt, W. "Effect of Thalidomide on the Course of Experimental Chagas" Disease, 1801. Crit. 1 at ashet, vol. 20, No. 3, pp. 84-86 (1965) Aronson, et al., "Thalidomide-Induced Peripheral Neuropathy. Effect of Serum Factor on Nerve Cultures",						
Z	BQ	Arch. Dermatol., Vol. 120, No. 11, pp. 1466-1470 (1984) Bach, et al., "Studies on the Possible Anti-Neoplastic Effect of Thalidomide", ACTA Pathologica ET						
	BR	Microbiologic	a Scandina	<i>vica</i> , Vol. 59, pp. 491-49	9 (1963)			
	BS	Bach et al "	Thalidomide	in Cancer Chemotherap	y", <i>The Lancet</i> , Vol	. 1, p.	1271 (1963)
2	BT	Bahmer, F.A.,	"Therapie	pel lymphozytischer Infi s Erythermatosus Hypert	tration", Der Hauta	rzi, V	01. 43, p. 66.	o (1992) ol 67 No 9 nn 813
9	BU	Balabanova, e -815 (1992)	t al., Lupus	s Erythermatosus rrypert	DATE CONSIDERE		11. 11. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1.	oi. or, 110. 7, pp. 012
EXAMIN	ER (A	~				8/23/	0/
1		11100	1 1 1		monog with MDED 400	u. Dro	ur line through	h citation if not in

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Approved for use through 10/31/2002 OMB 9651-00811 U.S. Patent and Trademark Office. U.S. DEPARTMENT OF COMMERCE Under the Paperwork Rection no persons are requir

Substitute for Form 1449/A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary

Sheet 3 of 17

ired to respond to a collection of inf	formation unless it contains a valid	OMB	ontrollinu	mber
	Complete if Known	=		
Application Number	09/545,139			TT
Filing Date	April 7, 2000		—&-	
First Named Inventor	D'Amato et al.	<u></u>	72	<
Group Art Unit	1614	8	8	T
Examiner Name	J. Goldberg	छु		- - -
Attorney Docket Number	05213-0650 43170-	21368	1	

		U.S. PATENT DOCUMENTS
<u></u>		OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, Etc.)
	CA	Barnes, et al., "Tumor Necrosis Factor Production in Patients with Leprosy", Infection and Immunity, Vol. 60,
44	CA	No. 4, pp. 1441-1446 (1992)
4	СВ	Barnhill, et al., "Thalidomide: Use and Possible Mode of Action in Reactional Lepromatous Leprosy and in
	СВ	Various Other Conditions", J. Am. Acad. Dermatol., Vol. 7, No. 3, pp. 317-323 (1982)
1_9	CC	Barnhill, R. et al., "Studies on the Anti-inflammatory Properties of Thalidomide: Effects on
		Polymorphonuclear Leukocytres and Monocytes", J. Am. Acad. Derm., Vol. 11, No. 5, Part 1, pp. 814-819 (1984)
h-	CD	
	CE	Barriere, H., "Traitement par la thalidomide", La Presse Médicale, Vol. 12, No. 15, pp. 963 (1983)
10	CE	Bazzoli, et al., "The Effects of Thalidomide and Two Analogues on the Regenerating Forelimb of the Newt",
Gn-	CF	J. Embryol. Exp. Morph., Vol. 41, pp. 125-135 (1977)
X	CI	Beck, Jr. et al. "Vascular Development: Cellular and Molecular Regulation", <i>The FASEB Journal</i> , Vol. 11, pp. 365-374 (1997)
1- /-	CG	pp. 505-514 (1997)
4		Beccerica, E., "L'approccio terapeutico al paziente anziano con artrite reumatoide", Clin. Ter., Vol. 122, pp. 289-298 (1987)
1	СН	Pp. 207-290 (1907)
	CII	Belaube, P. et al., "Should Thalidomide be Rehabilitated?", Sem. Hop. Paris, Vol. 59, No. 45, pp. 3101-3104 (1983)
1	CI	
		Bensinger, W.I., "Supportive Care in Marrow Transplantation", Curr. Opin. Oncol., Vol. 4, No. 4, pp. 614-623 (1992)
	CJ	Bernal, et al., "Cellular Immune Effects of Thalidomide in Actinic Prurigo", Int'l. J. of Dermat., Vol. 31, No.
		8, pp. 599-600 (1992)
()	CK	Blair, R. et al., "Human Mast Cells Stimulate Vascular Tube Formation", Journal of Clinical Investigation,
		Vol. 99, No. 11, pp. 2691-2700 (1997)
	CL	Blaschke, V. et al., "Chromatographische Racemattrennung von Thalidomid und teratogene Wirkung der
		Enantiomere, Arzneimittel Forsch./Drug Res., Vol. 29, No. II, pp. 1640-1642 (1979)
	CM	Bonifacino, J. et al., "A Peptide Sequence Confers Retention and Rapid Degradation in the Endoplasmic
Y =		Reticulum", Science, Vol. 2, pp. 79-80 (1990)
	CN	Bonnetblanc, et al., "Thalidomide and Recurrent Aphthous Stomatitis: a Follow-up Study", Dermatology,
		Vol. 193, No. 4, pp. 321-323 (1996)
1	CO	Boodman, S.G., "Questions About a Popular Prenatal Test", The Washington Post (1992)
		Bowers, et al., "Effect of Thalidomide on Orogenital Ulceration" Br. Med. Journ. Vol. 287, No. 6305, pp.
> =	CP	799-800 (1983)
(====		Boylen, J.B. et al., "Teratogenic Effects of Thalidomide and its Metabolites on the Developing Chick
7	CQ	Embryo", Canadian Journal of Biochemistry, Vol. 42, pp. 35-42 (1964)
		Braun, et al., "Thalidomide Metabolite Inhibits Tumor Cell Attachment to Concanavalin a Coated Surfaces",
	CR	Biochem. Biophys. Res. Comm., Vol. 98, No. 4, pp. 1029-1034 (1981)
9		Brem, H. et al., "Interstitial Chemotherapy with Drug Polymer Implants for the Treatment of Recurrent
	CS	Gliomas", J. Neurosurg., Vol. 74, pp. 441-446 (1991)
8		Bressler, S. et al., "Clinicopathologic Correlation of Occult Choroidal Neovascularization in Age-Related
حت	CT	Macular Degeneration", Arch. Opthalmol., Vol. 110, p. 827 (1992)
76		Brodthagen, H., "Significant Response of Oral Aphthosis to Thalidomide Treatment" I Am Acad
\mathcal{L}	CU	Dermatol., Vol. 13, No. 3, p. 509 (1985)
0	CV	Brovarone, et al., "Occhio e gravidanza", Minerva Ginecol., Vol. 43, pp. 141-167 (1991)
Op.		Browne, M.J. et al., "Expression of Recombinant Human Plasminogen and Aglycoplasminogen in Hel a
<	CW	Cells, Fibrinolysis, Vol. 5, pp. 257-260 (1991)
30 00 00 00 00 00 00 00 00 00 00 00 00 0	CX	Bubl, et al., "Dysphagia in Dermatologic Disease", Dysphagia Vol. 8, No. 2, pp. 85-90 (1903)
	CY	Buckley, C. et al., "Pyoderma Gangrenosum with Severe Pharyngeal Ulceration" Lot Royal Society of
		Medicine, Vol. 83, pp. 590, 591 (1990)
EXAMINE	R	DATE CONSIDERED POR A CONSIDERED
		0 / 12/0/
EXAMIN	ER: In	itial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in
contorman	ce and n	not considered. Include copy of this form with next communication to applicant

conformance and not considered. Include copy of this form with next communication to applicant.

AUG 0 1 2001

AUG 0 1 2001 Approved for use through 10/31/2002 OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE to Reduction Act of 13/5, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for Form 1449/A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary

Sheet 4 of 17

Complete if Known					
Application Number	09/545,139				
Filing Date	April 7, 2000				
First Named Inventor	D'Amato et al.				
Group Art Unit	1614				
Examiner Name	J. Goldberg				
Attorney Docket Number	05213-0650 43170-219681				

7						
ļ		OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, Etc.)				
R	DA	Buelens, I., "Treatment of a Grade II Astrocytoma with Thalidomide (Phthalylglutamic Acid Imide) [Behandlung eines Astrocytoms II. Grades mit Thaliodmid (N-Phthalylglutaminsäureimid)], ArzneimForsch., Vol. 17, No. 5, pp. 646-648 (1967)				
9	DB	Bullock, W.E., "The Clinical Significance of Erythema Nodosum", Hosp. Pract., Vol. 21, No. 3, pp. 102E-2H, 102K-2L, 102Q-2R pas (1986)				
	DC	Burger, et al., "Epidermolysis Bullosa Acquisita, a Rare Late Complication of Allogeneichone Marrow Transplantation?", Bone Marrow Transplant, Vol. 9, No. 2, pp. 139-141 (1992)				
3	DE	Burrows, N.P., "Thalidomide Modifies Disease", Brit. Med. J., Vol. 307, No. 6909, pp. 939-940 (1993)				
9	DF	Buckley, C. et al., "Pyoderma Gangrenosum with Severe Pharyngeal Ulceration", J. of the Royal Soc. of Med., Vol. 83, pp. 590-591 (1990)				
2	DG	Calnan, et al., "Actinic Prurigo (Hutchinson's Summer Prurigo)", Clin. Exp. Dermatol., Vol. 2, No. 4, pp. 365-372 (1977)				
2	DH	Cant, J.S., "Minor Ocular Abnormalities Associated With Thalidomide", The Lancet, p. 1134 (1966)				
2	DI	Carmichael, et al., "Thalidomide: A Restricted Role", Lancet, Vol. 339, No. 8805, p. 1362 (1992)				
	Dì	Cashin, C.H. et al., "Angiogenesis and Chronic Inflammation", Agents and Actions, Vol. 34, No. 3/4, pp. 332-338 (1991)				
	DK	Casini, G. et al., "Preparazione Di Uno Degli Antipodi Ottici Della 2-Ftalimmidoglutarimmide", <i>Il Pharmaco</i> , Ed. Sc., Vol XIX, Fasc. 6, pp. 563-565 (1964)				
	DL	Caswell, L.R. et al., "Nitrophthaloyl and aminophthaloyl derivatives of amino acids", J. Chem. Eng. Data, Vol. 13, No. 2, pp. 291-292 (1968) (Abstract only)				
	DM	Chapon, et al., "Neuropathies Caused by Thalidomide", Rev. Neurol., Vol. 141, No. 11, pp. 719-728 (1985)				
	DN	Chaudhry, A. et al., "Effects of Prednisolone and Thalidomide on Induced Submandibular Gland tumors in Hampsters", Canc. Res., Vol. 26, No. 9, Part 1, pp. 1884-1886 (1966)				
	DO	Chen, T. et al., "Plasma Pharmacokinetics and Urinary Excretion of Thalidomide after Oral Dosing in Healthy Male Volunteers", <i>The Am. Society for Pharma. and Experi. Therapeutics</i> , Vol. 17, No. 4, pp. 402-405 (1988)				
	DP	Chosidow, O, et al., "Sclerodermatous Chronic Graft-Versus-Host Disease: Analysis of Sevencases", J. Am. Acad. Dermatol., Vol. 26, No. 1, pp. 49-55 (1992)				
	DQ	Claydon, et al., "Gastrointestinal Emergencies in HIV Infection", Balliere's Clin Gastroennterol., Vol. 5, No. 4, pp. 887-911 (1991)				
2	DR	Clemmensen, et al., "Thalidomide Neurotoxicity", Arch. Dermatol, Vol. 120, No. 3, pp. 338-341 (1984)				
5	DS	Colville-Nash, P.R. et al., "Angiogenesis and rheumatoid arthritis: Pathogenic and Therapeutic Implications", Ann. Rheum. Dis., Vol. 51, pp. 919-925 (1992)				
Q	DT	Congy, et al., "Plasma Zinc Levels in Elderly Patients Hospitalized in Long Stay Units. Correlations with Other Nutritional Markers, Immunological Tests and Survival", Sem. Hop. Paris, Vol. 59, No. 45, pp. 3105-3108 (1983)				
9	DU	Costa, et al., "Aseptic Adenitis in a Patient with Pyoderma Gangrenosum", Ann. Dermatol., Vol. 121, No. 8, pp. 550-552 (1994) (Abstract Only)				
0	DV	Crain, E. et al., "The Effect of Thalidomide on Experimental Autoimmune Myasthenia Gravis", J. of Autoimmunity, Vol. 2, pp. 197-202 (1989)				
S	DW	Crawford, C.L., "Letter: Thalidomide in Erythema Nodosum Leprosum", Lancet, Vol. 2, No. 839, pp. 1201-1202 (1973)				
8	DX	Crawford, C.L., "Treatment of Erythema Nodosum Leprosum with Thalidomide", <i>Lancet</i> , Vol. 2, No. 828, pp. 567-568 (1973)				
	DY	Crawford, C.L., "Use of Thalidomide in Leprosy [letter; comment]", BMJ, Vol. 302, No. 6729, pp. 1603-1604 (1991)				
EXAMINE		DATE CONSIDERED 8/23/0/				
EXAMINE conformance	R: In	itial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in ot considered. Include copy of this form with next communication to applicant.				

RECEIVED

AUG 0 3 2001

Approved for use through 10/31/2002 OMB 0651-0031
U.S. Patent and Trademark Office U.S. DEPARTMENT OF COMMERCE sons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for Form 1449/A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

AU6 0 1 2001 &

(use as many sheets as necessary

Sheet 5 of 17

Under the Paperwork Red

Complete if Known						
Application Number	09/545,139					
Filing Date	April 7, 2000					
First Named Inventor	D'Amato et al.					
Group Art Unit	1614					
Examiner Name	J. Goldberg					
Attorney Docket Number	05213-0650 43170-219681					

		U.S. PATENT DOCUMENTS				
		OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, Etc.)				
	Γ 1	Crum, et al., "A New Class of Steroids Inhibits Angiogenesis in the Presence of Heparin or a Heparin				
a	EA	Fragment", Science, Vol. 230, pp. 1375-1378 (1985)				
α		Current Bibliographics in Medicine, "Thalidomide: Potential Benefits and Risks", National Inst. Health,				
	EB	National Library of Medicine, pp. 1-72 (Jan. 1963—July 1997) Dark, et al., "Combretastin A-4, an Agent that Displays Potent and Selective Toxicity Toward Tumor				
8	EC	Vasculature", Cancer Research, Vol. 37, pp. 1829-1834 (1997)				
		David-Bajar, K.M., "Subacute Cutaneous Lupus Erythematosus", J. Invest. Dermatol. Vol. 100, No. 1,				
2	ED	pp. 2s-8s (1993)				
	EE	D'Amato, R. J. et al., "Thalidomide is an Inhibitor of Angiogenesis", <i>Proc. Natl. Acad. Sci.</i> , Vol. 91, pp.				
-	EE	4082-4085 (1994) D'Amato, et al., "Angiogenesis Inhibition in Age-Related Macular Degeneration", Opthalmology, Vol. 102,				
1	EF	No. 9, pp. 1261-1262 (1995)				
		D'Amato, et al., "Microscopic Analysis of Retinal-Vessels Utilizing Fluorescein-Labeled High-Molecular-				
0	EG	Weight Dextrans", Invest. Opthamol. & Visual Science, Vol. 33, No. 4, p. 1082 (1992)				
	EH	De, A.U. et al., "Possible Antineoplastic Agents I", J. of Pharma. Sci., Vol. 64, No. 2, pp. 262-266 (1975)				
	EI	De, A.U. et al., "Possible Antineoplastic agents. III. Synthesis of 6-alkyl-2-[4'-methoxyphthalimido] and 6-alkyl-3-[3'-4'dimethoxyphenyl]glutarimides", J. Indian Chem. Soc., Vol. 53, No. 11, pp. 1122-1125 (1976)				
ing 1	EJ	De, A.U. et al., "Possible Antineoplastic Agents: Part IV-Synthesis & Antineoplastic Potency of N-Substituted				
	23	α -(4,5-Dimethoxyphthalimido)glutarimides and N-Substituted β -(4-Bromophenyl)glutarimides", Indian J. of				
		Chemistry, Vol. 16B, pp. 510-512, (June 1978)				
	EK	De Cock, K., "Treatment of Ulcerative Colitis", Brit. Med. J., Vol. 1, pp. 1356 (1979)				
	EL	DeKlerk, et al., "New Methods of Treatment for Renal Allotransplants Using the Baboon as a Primate				
		Experimental Model", J. Urol. Vol. 102, No. 5, pp. 532-540 (1969)				
-	EM	Dhodapkar, et al., "A Phase II Pilot Study of Anti-Angiogenesis Therapy Using Thalidomide in Patients				
	CNI	with Multiple Myeloma", UARK 98-003, pp. 1-15 on A 1-C Dicken, C. H., "Malignant pyoderma", J. of the Am. Acad. of Dermatol., Vol. 13, No. 6, pp. 1021-1025				
	EN	(1985)				
	EO	DiPaolo, et al., "Thalidomide: Effects on Ehrlich Ascites Tumor Cells in vitro", Science, Vol. 144,				
		pp. 1583 (1964)				
	EP	DiPaolo, "Effect of Thalidomide on a Variety of Transplantable Tumors", Cancer Chemo. Reports,				
	1	Vol. 29, pp. 99-102 (1963)				
1	EQ	DiPaolo, "In Vitro Test Systems for Cancer Chemotheraphy. II. Correlation of In Vitro Inhibition of Dehydrogenase and Growth with In Vivo Inhibition of Ehrlich Ascites Tumor", P.S.E.B.M., Vol. 114,				
\varnothing		pp. 384-387 (1963)				
	ER	DiPaolo et al., "Teratogenesis-oncogenesis: A Study of Possible Relationships", Arch. Path., Vol. 81,				
0		pp. 3-23 (1966)				
2	ES	Dorveaux, et al., "Le Traitement Actuell du Lupus Erythemateux Chronique", Le Concours Med.				
<u> </u>	1	Vol. 106, No. 31, pp. 2957-2961 (1984)				
0	ET	Doutre, et al., "Pyoderma Gangrenosum and Hemopathies. A propos of 2 Cases", Nouv Rev Fr Hematol,				
	EU	Vol. 29, No. 4, pp. 251-254 (1987) Dunn, et al., "Bone Marrow Transplantation and Cataract Development", Arch. Ophthalmol. Vol. 111,				
1	LU	No. 10, pp. 1367-1373 (1993)				
9	EV	(Editorial) "Thalidomide in Dermatology and Leprosy", Lancet, Vol. 2, No. 8446, pp. 80-81 (1985)				
	EW	(Editorial) "Thalidomide Tested for Treatment of AIDS", U.S. Pharm., Vol. 18, No. 8, p. 14 (1993)				
2		Eger, K. et al., "Synthesis, Central Nervous System Activity and Teratogenicity of a Homothalidomide",				
	EX	Arzheim. Forsch/Drug Res., Vol. 40 (II), No. 10, pp. 1073-1075 (1990)				
2	EY	Ehrlich, G.E. "Behcet's Disease: Current Concepts", Comprehensive Therapy, Vol. 15, No. 1, pp. 27-30 (1989)				
EXAMINI	R.	DATE CONSIDERED 2/23/0/				
		Tro-				
		nitial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line throug citation if for in				
conforman	ce and	not considered. Include copy of this form with next communication to applicant.				

Substitute for Form 1449/A/PTO

Sheet 6 of 17

STATEMENT BY APPLICANT

		~
(AUG 0 1 2001 क	U.O. O. J.	PTO/SB/08A (08-00) Approved for use through 10/31/2002 OMB 0651-0031 ademark Office US. DEPARTMENT OF COMMERCE
Under the Raperwork Reduction Actual 1995, no persons are re	U.S. Patent and Tra equired to respond to a collection of inf	formation unless it contains a valid OMB control number
		Complete if Known
r Form 1449/A/PTO	Application Number	09/545,139
INFORMATION DISCLOSURE	Filing Date	April 7, 2000
	First Named Inventor	D'Amato et al.
STATEMENT BY APPLICANT	Group Art Unit	1614
(use as many sheets as necessary	Examiner Name	J. Goldberg
heet 6 of 17	Attorney Docket Number	05213-0650 43170-219681

		U.S. PATENT DOCUMENTS
		OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, Etc.)
<u> </u>	1	Cliner References (including Author), the Date, Fertinent Fages, Etc.)
1	FA	El-Naggar, A.M., et al., "Synthesis of Biologically Active 3,5-dinitrophthaloyl- and 3,5- diaminophthaloyl- amino acids and dipeptide derivatives", Indian J. Chem., Sect. B (1981) pp. 514-17, abstract only
		Elia, et al., "Giant Esophageal Ulcer Treated with Steroids in AIDS Patient(2)", J. Acquired Immune Defic.
A	FB	Syndr., Vol. 5, No. 8, pp. 848-849 (1992)
S	FC	Eisenbud, L. et al., "Recurrent Aphthous Stomatitis of the Behcet's Type: Successful Treatment with Thalidomide", Oral Surgery, Oral Medicine, Oral Pathology, Vol. 64, No. 3, pp. 289-292 (1987)
	FD	Eravelly, J. et al., "Thalidomide in Weber-Christian Disease", <i>The Lancet</i> , Vol. 1, No. 8005, p. 251 (1977)
	+	Eriksson, et al., "Drug Exposure and Flow Cytometry Anaylses in a Thalidomide Treatment Schedule that
2	FE	Prolongs Rat Cardiac Graft Survival", <i>Transplant Proc.</i> , Vol. 24, No. 6, pp. 2560-2561 (1992)
0	FF	Eriksson, S. O. et al., "Synthesis and Alkaline Hydrolysis of Some N-substituted Phthalimides", <i>Acta Pharm. Suecica</i> , Vol. 10, pp. 63-74 (1973)
α	FG	Fabro, S. et al., "The Metabolism of Thalidomide: Some Biological Effects of Thalidomide and its
		Metabolites", Brit. J. Pharmacol., Vol. 25, pp. 352-362 (1965)
(F)	1	Fabro, S. et al., "Teratogenic Activity of Thalidomide and Related Compounds", Life Sci., Vol. 3, pp. 987-
	FH	992 (1964)
	FI	Fabro, S. M.D., "Biochemical Basis of Thalidomide Teratogenicity", The Biochemical Basis of Chemical
	+	Teratogenesis, Chapter 5, pp. 159-178 (1981)
9	FJ	Fajardo, et al., "Dual Role of Tumor Necrosis Factor-α in Angiogenesis", Am. J. Pathol., Vol. 140, No. 3, pp. 539-544 (1992)
	FK	Faure, et al., "PMN Leukocytes Chemotaxis: Inhibition by Thalidomide", Pathol. Biol. (Paris), Vol. 29,
		No. 10, pp. 601-604 (1981)
		Faure, et al., "Inhibition of PMN Leukocytes Chemotaxis by Thalidomide", Arch. Dermatol. Res., Vol. 269,
	FL	No. 3, pp. 275-280 (1980)
	+	
O=		Fazal, N. et al., "Effect of Blocking TNF-α on Intracellular BCG (Bacillus Calmette Guerin) Growth in
	FM	Human Monocyte-Derived Macrophages", FEMS Microbiology Immunology, Vol. 105, pp. 337-346 (1992)
	FN	Fickentscher, K. et al., "Stereochemical Properties and Teratogenic Activity of Some etrahydrophthalimides", Mol. Pharmacol., Vol. 13, pp. 133-141 (1977)
	FO	Field, E. O. et al., "Effect of Thalidomide on Splenomegaly (GVH Reaction) in the Chick Embryo. Treatment
المراتبة الم	10	of Donor Cells Only", Nature, Vol. 211, No. 5055, pp. 1309-1310 (1966)
No.	-	
تحو_ ا	FD	Flohe, L. et al., "Studies on the Hypothetical Relationship of Thalidomide-induced Embryopathy and
	FP	Collagen Biosynthesis", Arzneimitte/Forschung (Germany West), Vol. 31, No. 2, pp. 315-320 (1981)
	FQ	Folkman, J. et al., "Angiogenesis", J. Biol. Chem., Vol. 267, No. 16, pp. 10931-10934 (1992)
I -()	FR	Folkman, J. et al., "Angiogenesis Inhibition and Tumor Regression Caused by Heparin or a Heparin
		Fragment in the Presence of Cortisone", Science, Vol. 221, pp. 719-725 (1983)
D	FS	Folkman, J. et al., "Induction of Angiogenesis During the Transition from Hyperplasia to Neoplasia", <i>Nature</i> , Vol. 339, pp. 58-61 (1989)
\vdash	FT	Folkman, J. et al., "Tumor Behavior in Isolated Perfused Organs: In Vitro Growth and Metastases of Biopsy
2		material in Rabbit Thyroid and Canine Intestinal Segment", Anals of Surgery, pp. 491-502 (1966)
 	FU	Folkman, J., "Tumor Angiogenesis: Therapeutic Implications", <i>The New England J. of Med.</i> , Vol.
×	1.0	285, No. 21, pp. 1182-1186, (1971)
	FV	Folkman, J., "Angiogenesis and Its Inhibitors", <i>Important Advances in Oncology</i> , J.B. Lippincott H.
90		Company, pp. 42-62 (1985)
0	FW	Folkman, J., "Angiogenesis in Cancer, Vascular, Rheumatoid and Other Disease", Nature Medicine, Vol. 1,
		No. 1, pp. 27-30 (1995)
	FX	Folkman, J., "What is the Evidence that Tumors are Angiogenesis Dependent?", J. Naat' Cancer Inst., Vol.
M 504		82, No. 1, (1990)
SQ.	FY	Francois, J., "Embryological Pigment Epithelial Dystrophies", Opthalmologica, Vol. 172, pp. 417-433 (1976)
	 	Fuller, et al., "Thalidomide, Peripheral Neuropathy and AIDS", Int. J. STD AIDS, Vol. 2, No. 5,
9	FZ	pp. 369-370 (1991)
EXAMIN		DATE CONSIDERED COL
		0/20/0/
EXAMIN	ER⊈l	initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in

Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

09/545,139

PTO/SB/08A (08-00)
Approved for use through 10/31/2002 OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE persons are required to respond to a collection of information unless it contains a valid OMB control number Under the Paperwork Complete if Known

Substitute for Form 1449/A/PTO

Sheet | 7 of 17

INFORM STATE

MATION DISCLOSURE	Filing Date	April 7, 2000
	First Named Inventor	D'Amato et al.
MENT BY APPLICANT	Group Art Unit	1614
use as many sheets as necessary	Examiner Name	J. Goldberg
of	Attorney Docket Number	05213-0650 43170-219681

Application Number

U.S. PATENT DOCUMENTS			
		OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, Etc.)	
0	GA	Furner,, B.B., "Treatment of Subacute Cutaneous Lupus Erythematosus", Int. J. Dermatol., Vol. 29, No. 8, pp. 542-547 (1990)	
9	GB	Gad, et al., "Thalidomide Induces Imbalances in T-Lymphocyte Sub-Populations in the Circulating Blood of Healthy Males", Lepr. Rev., Vol. 56, No. 1, pp. 35-39 (1985)	
		Gaetani, M., "Studi Sull'Attivita Antitumorale Della Talidomide", Giornale Italiano diu Chemioterapia, pp.	
۶	GC	83.86 ny date	
9	GD	Gehanno, et al., "Mouth and Pharyngeal Hyperalgesic Syndromes in AIDS", Ann. Otolarygol Chir. Cervicofac, Vol. 107, No. 5, pp. 311-313 (1990)	
9	GE	Genvo, et al., "Treatment of Aphthosis with Thalidomide and with Colchicine", <i>Dermatologica</i> , Vol. 168, No. 4, pp. 182-188 (1984)	
9	GF	Geoghiou, et al., "HIV-Associated Oesophageal Ulcers Treated with Thalidomide", Med. J. of Australia, Vol. 152, pp. 382-383 (1990)	
	GG	Gershbein, "Effect of Transplanted Tumor and Various Agents on Liver Regeneration During Pregnancy", P.S.E.B.M., Vol. 126, pp. 88-92 (1967)	
	GH	Gershbein, L. L., "The Thalidomide Analog, EM 12, Enhances 1,2-dimethylhydrazine-induction of Rat Colon Adenocarcinomas", Canc. Ltrs. Vol. 60, pp. 129-133 (1991)	
9	GI	Gershbein, L. L., "Effect of Various Agents on Liver Regeneration and Walker Tumor Growth in Partially Hepatectomized Rats", Canc. Res., Vol. 26, No. 9, pp. 1905-1908 (1966)	
	GJ	Ghigliotti, G. et al., "Thalidomide: Treatment of Choice for Aphthous Ulcers in Patients Seropositive for Human Immunodeficiency Virus", J. of the Am. Acad. of Dermatol., Vol. 28, No. 2, Part I, pp. 271-272 (1993)	
	GK	Gimbrone, M.A. et al., "Tumor Dormancy in Vivo by Prevention of Neovasularization", Journal of Experimental Medicine, Vol. 136, pp. 261-276 (1972)	
	GL	Gimbrone, M. A. et al., "Tumor Growth and Neovascularization: An Experimental Model Using the Rabbit Cornea", J. Nat. Canc. Instit., Vol. 52, No. 2, pp. 413-419 (1974)	
9	GM		
9	GN Goihman-Yahr, M., et al., "Autoimmune Diseases and Thalidomide II. Adjuvant Disease, Experimental Allergic Encephalomyelitis and Experimental Allergic Neuritis of the Rat", Int. J. Leprosy, Vol. 42, No. 3, pp. 266-275 (1974)		
	GO	Gorin, I., et al., "Thalidomide May Cure AIDS Ulcers", Nurs. Times, Vol. 86, No. 24, p. 10 (1990)	
2			
0	Goulden, V., et al., "Linear Prurigo Simulating Dermatitis Artefacta in Dominant Dystrophicepidermolysis Bullosa", Br. J. Dermatol. Vol. 129, No. 4, pp. 443-446 (1993)		
2	GR Grabstald, H. et al., "Clinical Experiences with Thalidomide in Patients with Cancer", Clinical Pharmacol. and Therapeutics, Vol. 6, pp. 298-302 (1965)		
2	GS Grant, D.S. et al., "Scatter Factor Induces Blood Vessel Formation in vivo", <i>Proc. Natl. Acad. Sci.</i> , Vol. 90, pp. 1937-1941 (1993)		
8	Grinspan, et al., "Treatment of Aphthae with Thalidomide", J. Am. Acad. Dermatol., Vol. 20, No. 6, pp. 1060-1063 (1989)		
2	GU Grinspan, D., "Significant Response of Oral Aphthosis to Thalidomide Treatment", Am. Acad. of Dermatol., Vol. 12, No. 1, Part 1, pp. 85-90 (1985)		
EXAMINE	R	DATE CONSIDERED 8/23/21	
EXAMIN conforman	ER: In ce and n	itial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in oot considered. Include copy of this form with next communication to applicant.	

RECEIVED

AUG 0,3 2001
TECH CENTER 1600/2900

Approved for use through 10/31/2002 OMB 0651-0031
U.S. Patent and Trademark Office U.S. DEPARTMENT OF COMMERCE
Opersons are required to respond to a collection of information unless it contains a valid OMB control number AUG 0 1 2001 & Under the Paperwork Reduction Act of 1995,

Substitute for Form 1449/A/PTO

Sheet | 8 of 17

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary

	Complete if Known
Application Number	09/545,139
Filing Date	April 7, 2000
First Named Inventor	D'Amato et al.
Group Art Unit	1614
Examiner Name	J. Goldberg
Attorney Docket Number	05213-0650 43170-219681

OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, Etc.) Grosshans, E., et al., "Thalidomide Therapy for Inflammatory Dermatoses", Int. J. Dermatol, Vol. 23, No. 9, pp. 598-602 (1984) HB Grosshans, E., et al., "Ricerche Sull' azione Immunodepressiva Della Talidomide ed Prednisolone in Ratti Portatori Di Neoplasie Sperimentalmente Indotte", Cancro, Vol. 22, pp. 503-512 (1969) Günzler, V., "Halidomide—in Human Immunodeficiency Virus (HIV) Patients. A Review of Safety Considerations", Drug Saf, Vol. 7, No. 2, pp. 116-134 (1992) Günzler, V., "Halidomide—A Therapy for the Immunological Consequences of HIV Intection?", Medical Hypotheses, Vol. 30, No. 2, pp. 105-109 (1989) HE Guiterez-Rodriguez, O. et al., "Treatment of Refractory Rheumatoid Arthritis—The Thalidomide Experience", The J. of Rheumatology, Vol. 16, No. 2, pp. 158-163 (1989) HF Guiterez-Rodriguez, O. et al., "Treatment of Refractory Rheumatoid Arthritis—Arthritis and Rheumatism, Vol. 27, No. 10, pp. 118-1121 (1984) HG Halmer, M.E. M.D., "Studies Involving Orphan Products for Treating/Diagnosing Women's Diseases", Food and Drug Law Journal, Vol. 48, pp. 205-211 (1992) HH Hamza, M. H., "Treatment of Behcer's Disease with Thalidomide", Clinical and Experimental Rheumatology, Vol. 3, No. 4, p. 427 (1990) Hamza, M. H., "Treatment of Behcer's Disease with Thalidomide", Clinical Rheumatol., Vol. 5, No. 3, pp. 365-371 (1986) HJ Handley, J. et al., "Chronic Bullous Disease of Childhood and Ulcerative Colitis", Pediatric Dermatol., Vol. 127, Supp. 40, pp. 67-68 (1992) HA Handley, J. et al., "Chronic Bullous Disease of Childhood and Ulcerative Colitis", Pediatric Dermatol., Vol. 127, Supp. 40, pp. 67-68 (1992) HA Handley, J. et al., "Chronic Bullous Disease of Childhood and Ulcerative Colitis", Pediatric Dermatol., Vol. 127, Supp. 40, pp. 67-68 (1992) HA Harindra, et al., "Papulo-Pruritic Eruption and Giant Ulceration of the Mouth: A Difficult Clinical Feature to Treate in the Patient Infected with Humanimmunodeficiency Virus(1)", Archi	U.S. PATENT DOCUMENTS			
Grosshans, E., et al., "Thalidomide Therapy for Inflammatory Dermatoses", Int. J. Dermatol., Vol. 23, No. 9, pp. 598-602 (1984) HB				
HA	OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, Etc.)			
HB Dartatori Di Neoplasie Sperimentalmente Indotte", Cancor, Vol. 22, pp. 503-512 (1969) HC Guinzier, V., "Thalidomide in Human Immunodefriency Virus (HIV) Patients. A Review of Safety Considerations", Drug Saf, Vol. 7, No. 2, pp. 116-134 (1992) HD Ginzier, V., "Thalidomide—A Therapy for the Immunological Consequences of HIV Infection?", Medical Hypotheses, Vol. 30, No. 2, pp. 105-109 (1989) HE Guiterrez, Rodriguez, O. et al., "Treatment of Kefractory Rheumatoid Arthritis—The Thalidomide Experience", The J. of Rheumatology, Vol. 16, No. 2, pp. 158-163 (1989) HF Guiterrez-Rodriguez, O. et al., "Thalidomide A Promising New Treatment for Rheumatoid Arthritis", Arthritis and Rheumatism, Vol. 27, No. 10, pp. 1118-1121 (1984) HG Haffner, M.E. M.D., "Studies Involving Orphan Products for Treating/Diagnosing Women's Diseases", Food and Drug Law Journal, Vol. 48, pp. 205-211 (1992) HH Hamza, M. M.D., "Beheet's Disease, Palmoplantar Pustulosis and HLA-B27 Treatment with Thalidomide", Clinical and Experimental Rheumatology, Vol. 8, No. 4, p. 427 (1990) Hamza, M.H., "Treatment of Beheet's Disease with Thalidomide", Clinical Rheumatol., Vol. 5, No. 3, pp. 365-371 (1986) HJ Hamdley, J. et al., "Chronic Bullous Disease of Childhood and Ulcerative Colitis", Pediatric Dermatol., Vol. 10, No. 3, pp. 256-288, (1993) HK Handley, J. et al., "Chronic Bullous Disease of Childhood and Ulcerative Colitis", Brit. J. of Dermatol., Vol. 127, Supp. 40, pp. 67-68 (1992) HH Harring, et al., "Papulo-Pruritic Eruption and Giant Ulceration of the Mouth: A Difficult Clinical Feature to Treat in the Patient Infected with Humanimmunodeficiency Virus(1)", Arch. Intern. Med., Vol. 152, No. 9, p. 1924 (1992) HA Harris, A., "Antiangiogenesis for Cancer Therapy", Lancet, Vol. 349 (Suppl. II), pp. 13-15 (1997) Hasper, M.F., et al., "Thalidomide in the Treatment of Erythema Nodosum Leprosum. With a Note on Selected Laboratory Abnormalities in Erythema Nodosum Leprosum.", Clin. Pharmacol. Ther., Vol. 11, No. 4, pp. 481-487 (1970) HG Hathill,			Grosshans, E., et al., "Thalidomide Therapy for Inflammatory Dermatoses", Int. J. Dermatol, Vol. 23, No. 9,	
HB Portatori Di Neoplasie Sperimentalmente Indotte", Cancro, Vol. 22, pp. 503-512 (1999) Günzler, V., "Thalidomide in Human Immunodeficiency Virus (HIV) Patients. A Review of Safety Considerations", Drug Saf, Vol. 7, No. 2, pp. 116-134 (1992) HC Considerations", Drug Saf, Vol. 7, No. 2, pp. 116-134 (1992) HB Günzler, V., "Thalidomide—A Therapy for the Immunological Consequences of HIV Infection?", Medical Hypotheses, Vol. 30, No. 2, pp. 105-109 (1989) HE Gutiérrez-Rodriguez, O. et al., "Treatment of Refractory Rheumatoid Arthritis—The Thalidomide Experience", The J. of Rheumatology, Vol. 16, No. 2, pp. 158-163 (1989) HF Gutiérrez-Rodriguez, O. et al., "Thalidomide A Promising New Treatment for Rheumatoid Arthritis", Arthritis and Rheumatism, Vol. 27, No. 10, pp. 1118-1121 (1984) HB Hattiner, M.E. M.D., "Studies Involving Orphan Products for Treating/Diagnosing Women's Diseases", Food and Drug Law Journal, Vol. 48, pp. 205-211 (1992) HH Harnza, M. M.D., "Behcet's Disease, Palmoplantar Pustulosis and HLA-B27 Treatment with Thalidomide", Clinical and Experimental Rheumatology, Vol. 8, No. 4, p. 427 (1990) Hamza, M.H., "Treatment of Behcet's Disease with Thalidomide", Clinical Rheumatol., Vol. 5, No. 3, pp. 365-371 (1986) HA Handley, J. et al., "Chronic Bullous Disease of Childhood and Ulcerative Colitis", Pediatric Dermatol., Vol. 10, No. 3, pp. 256-258, (1993) HK Handley, J. et al., "Chronic Bullous Disease of Childhood and Ulcerative Colitis", Pediatric Dermatol., Vol. 127, Supp. 40, pp. 67-68 (1992) HA Harnis, A., "Antinangiogenesis for Cancer Therapy", Lancet, Vol. 349 (Suppl. 11), pp. 13-15 (1997) Hasper, M.F., "Chronic Cutaneous Lupus Erythematosus. Thalidomide Treatment of 11 Patients", Arch. Dermatol., Vol. 19, No. 10, pp. 812-815 (1983) Hasper, M.F., "Chronic Cutaneous Lupus Erythematosus. Thalidomide Treatment of 11 Patients", Arch. Dermatol., Vol. 99, No. 11, pp. 2581-2587 (1997) HB Hayashi, S. et al., "Induction of Morphological Differentiation in the Human Leukemic Cell Line K562 by Exposure to Thali	()	HA	pp. 598-602 (1984)	
HB Portatori Di Neoplasie Sperimentalmente Indotte", Cancro, Vol. 22, pp. 503-512 (1999) Günzler, V., "Thalidomide in Human Immunodeficiency Virus (HIV) Patients. A Review of Safety Considerations", Drug Saf, Vol. 7, No. 2, pp. 116-134 (1992) HC Considerations", Drug Saf, Vol. 7, No. 2, pp. 116-134 (1992) HB Günzler, V., "Thalidomide—A Therapy for the Immunological Consequences of HIV Infection?", Medical Hypotheses, Vol. 30, No. 2, pp. 105-109 (1989) HE Gutiérrez-Rodriguez, O. et al., "Treatment of Refractory Rheumatoid Arthritis—The Thalidomide Experience", The J. of Rheumatology, Vol. 16, No. 2, pp. 158-163 (1989) HF Gutiérrez-Rodriguez, O. et al., "Thalidomide A Promising New Treatment for Rheumatoid Arthritis", Arthritis and Rheumatism, Vol. 27, No. 10, pp. 1118-1121 (1984) HB Hattiner, M.E. M.D., "Studies Involving Orphan Products for Treating/Diagnosing Women's Diseases", Food and Drug Law Journal, Vol. 48, pp. 205-211 (1992) HH Harnza, M. M.D., "Behcet's Disease, Palmoplantar Pustulosis and HLA-B27 Treatment with Thalidomide", Clinical and Experimental Rheumatology, Vol. 8, No. 4, p. 427 (1990) Hamza, M.H., "Treatment of Behcet's Disease with Thalidomide", Clinical Rheumatol., Vol. 5, No. 3, pp. 365-371 (1986) HA Handley, J. et al., "Chronic Bullous Disease of Childhood and Ulcerative Colitis", Pediatric Dermatol., Vol. 10, No. 3, pp. 256-258, (1993) HK Handley, J. et al., "Chronic Bullous Disease of Childhood and Ulcerative Colitis", Pediatric Dermatol., Vol. 127, Supp. 40, pp. 67-68 (1992) HA Harnis, A., "Antinangiogenesis for Cancer Therapy", Lancet, Vol. 349 (Suppl. 11), pp. 13-15 (1997) Hasper, M.F., "Chronic Cutaneous Lupus Erythematosus. Thalidomide Treatment of 11 Patients", Arch. Dermatol., Vol. 19, No. 10, pp. 812-815 (1983) Hasper, M.F., "Chronic Cutaneous Lupus Erythematosus. Thalidomide Treatment of 11 Patients", Arch. Dermatol., Vol. 99, No. 11, pp. 2581-2587 (1997) HB Hayashi, S. et al., "Induction of Morphological Differentiation in the Human Leukemic Cell Line K562 by Exposure to Thali		 	Guidetti, E., et al., "Ricerche Sull'azione Immunodepressiva Della Talidomide e del Prednisolone in Ratti	
HF Arthritis and Rheumatism, Vol. 27, No. 10, pp. 1118-1121 (1984) HG Haffner, M.E. M.D., "Studies Involving Orphan Products for Treating/Diagnosing Women's Diseases", Food and Drug Law Journal, Vol. 48, pp. 205-211 (1992) HH Hamza, M. M.D., "Beticet's Disease, Palmoplantar Pustulosis and HLA-B27 Treatment with Thalidomide", Clinical and Experimental Rheumatology, Vol. 8, No. 4, p. 427 (1990) HI Hamza, M.H., "Treatment of Behcet's Disease with Thalidomide", Clinical Rheumatol., Vol. 5, No. 3, pp. 365-371 (1986) HJ Handley, J. et al., "Chronic Bullous Disease of Childhood and Ulcerative Colitis", Pediatric Dermatol., Vol. 10, No. 3, pp. 256-258, (1993) HK Hamdley, J. et al., "Chronic Bullous Disease of Childhood and Ulcerative Colitis", Pediatric Dermatol., Vol. 127, Supp. 40, pp. 67-68 (1992) HL Harindra, et al., "Papulo-Pruritic Eruption and Giant Ulceration of the Mouth: A Difficult Clinical Feature to Treat in the Patient Infected with Humanimmunodeficiency Virus(1)", Arch. Intern. Med., Vol. 152, No. 9, p. 1924 (1992) HM Harris, A., "Antiangiogenesis for Cancer Therapy", Lancet, Vol. 349 (Suppl. II), pp. 13-15 (1997) Hasper, M.F., "Chronic Cutaneous Lupus Erythematosus. Thalidomide Treatment of 11 Patients", Arch. Dermatol., Vol. 19, No. 10, pp. 812-815 (1983) Hasper, M.F., et al., "Thalidomide in the Treatment of Chronic Discoid Lupus", Acta. Derm. Venereol, Vol. 62, No. 4, pp. 321-324 (1982) HASPER, M.F., et al., "Thalidomide in the Treatment of Erythema Nodosum Leprosum. With a Note on Selected Laboratory Abnormalities in Erythema Nodosum Leprosum", Clin. Pharmacol. Ther., Vol. 11, No. 4, pp. 481-487 (1970) HR Hayashi, S. et al., "A Synthetic Peptide for α Chemokines Inhibits the Growth of Melonoma Cell Lines", J. Clin. Invest., Vol. 99, No. 11, pp. 2581-2587 (1997) HS Heaton, et al., "Graft-versus-Host Disease Following Liver Transplantation", J. R. Soc. Med., Vol. 85, No. 6, pp. 313-314 (1992) HG Helm F. Ch. et al. "Comparative Teratological Investigation of Compounds Structurally and	l <i>Q</i>	HB	Portatori Di Neonlasie Sperimentalmente Indotte", Cancro, Vol. 22, pp. 503-512 (1969)	
HF Arthritis and Rheumatism, Vol. 27, No. 10, pp. 1118-1121 (1984) HG Haffner, M.E. M.D., "Studies Involving Orphan Products for Treating/Diagnosing Women's Diseases", Food and Drug Law Journal, Vol. 48, pp. 205-211 (1992) HH Hamza, M. M.D., "Beticet's Disease, Palmoplantar Pustulosis and HLA-B27 Treatment with Thalidomide", Clinical and Experimental Rheumatology, Vol. 8, No. 4, p. 427 (1990) HI Hamza, M.H., "Treatment of Behcet's Disease with Thalidomide", Clinical Rheumatol., Vol. 5, No. 3, pp. 365-371 (1986) HJ Handley, J. et al., "Chronic Bullous Disease of Childhood and Ulcerative Colitis", Pediatric Dermatol., Vol. 10, No. 3, pp. 256-258, (1993) HK Hamdley, J. et al., "Chronic Bullous Disease of Childhood and Ulcerative Colitis", Pediatric Dermatol., Vol. 127, Supp. 40, pp. 67-68 (1992) HL Harindra, et al., "Papulo-Pruritic Eruption and Giant Ulceration of the Mouth: A Difficult Clinical Feature to Treat in the Patient Infected with Humanimmunodeficiency Virus(1)", Arch. Intern. Med., Vol. 152, No. 9, p. 1924 (1992) HM Harris, A., "Antiangiogenesis for Cancer Therapy", Lancet, Vol. 349 (Suppl. II), pp. 13-15 (1997) Hasper, M.F., "Chronic Cutaneous Lupus Erythematosus. Thalidomide Treatment of 11 Patients", Arch. Dermatol., Vol. 19, No. 10, pp. 812-815 (1983) Hasper, M.F., et al., "Thalidomide in the Treatment of Chronic Discoid Lupus", Acta. Derm. Venereol, Vol. 62, No. 4, pp. 321-324 (1982) HASPER, M.F., et al., "Thalidomide in the Treatment of Erythema Nodosum Leprosum. With a Note on Selected Laboratory Abnormalities in Erythema Nodosum Leprosum", Clin. Pharmacol. Ther., Vol. 11, No. 4, pp. 481-487 (1970) HR Hayashi, S. et al., "A Synthetic Peptide for α Chemokines Inhibits the Growth of Melonoma Cell Lines", J. Clin. Invest., Vol. 99, No. 11, pp. 2581-2587 (1997) HS Heaton, et al., "Graft-versus-Host Disease Following Liver Transplantation", J. R. Soc. Med., Vol. 85, No. 6, pp. 313-314 (1992) HG Helm F. Ch. et al. "Comparative Teratological Investigation of Compounds Structurally and			Günzler, V., "Thalidomide in Human Immunodeficiency Virus (HIV) Patients. A Review of Safety	
HF Arthritis and Rheumatism, Vol. 27, No. 10, pp. 1118-1121 (1984) HG Haffner, M.E. M.D., "Studies Involving Orphan Products for Treating/Diagnosing Women's Diseases", Food and Drug Law Journal, Vol. 48, pp. 205-211 (1992) HH Hamza, M. M.D., "Beticet's Disease, Palmoplantar Pustulosis and HLA-B27 Treatment with Thalidomide", Clinical and Experimental Rheumatology, Vol. 8, No. 4, p. 427 (1990) HI Hamza, M.H., "Treatment of Behcet's Disease with Thalidomide", Clinical Rheumatol., Vol. 5, No. 3, pp. 365-371 (1986) HJ Handley, J. et al., "Chronic Bullous Disease of Childhood and Ulcerative Colitis", Pediatric Dermatol., Vol. 10, No. 3, pp. 256-258, (1993) HK Hamdley, J. et al., "Chronic Bullous Disease of Childhood and Ulcerative Colitis", Pediatric Dermatol., Vol. 127, Supp. 40, pp. 67-68 (1992) HL Harindra, et al., "Papulo-Pruritic Eruption and Giant Ulceration of the Mouth: A Difficult Clinical Feature to Treat in the Patient Infected with Humanimmunodeficiency Virus(1)", Arch. Intern. Med., Vol. 152, No. 9, p. 1924 (1992) HM Harris, A., "Antiangiogenesis for Cancer Therapy", Lancet, Vol. 349 (Suppl. II), pp. 13-15 (1997) Hasper, M.F., "Chronic Cutaneous Lupus Erythematosus. Thalidomide Treatment of 11 Patients", Arch. Dermatol., Vol. 19, No. 10, pp. 812-815 (1983) Hasper, M.F., et al., "Thalidomide in the Treatment of Chronic Discoid Lupus", Acta. Derm. Venereol, Vol. 62, No. 4, pp. 321-324 (1982) HASPER, M.F., et al., "Thalidomide in the Treatment of Erythema Nodosum Leprosum. With a Note on Selected Laboratory Abnormalities in Erythema Nodosum Leprosum", Clin. Pharmacol. Ther., Vol. 11, No. 4, pp. 481-487 (1970) HR Hayashi, S. et al., "A Synthetic Peptide for α Chemokines Inhibits the Growth of Melonoma Cell Lines", J. Clin. Invest., Vol. 99, No. 11, pp. 2581-2587 (1997) HS Heaton, et al., "Graft-versus-Host Disease Following Liver Transplantation", J. R. Soc. Med., Vol. 85, No. 6, pp. 313-314 (1992) HG Helm F. Ch. et al. "Comparative Teratological Investigation of Compounds Structurally and	19	HC	Considerations" Drug Saf Vol. 7, No. 2, pp. 116-134 (1992)	
HF Arthritis and Rheumatism, Vol. 27, No. 10, pp. 1118-1121 (1984) HG Haffner, M.E. M.D., "Studies Involving Orphan Products for Treating/Diagnosing Women's Diseases", Food and Drug Law Journal, Vol. 48, pp. 205-211 (1992) HH Hamza, M. M.D., "Beticet's Disease, Palmoplantar Pustulosis and HLA-B27 Treatment with Thalidomide", Clinical and Experimental Rheumatology, Vol. 8, No. 4, p. 427 (1990) HI Hamza, M.H., "Treatment of Behcet's Disease with Thalidomide", Clinical Rheumatol., Vol. 5, No. 3, pp. 365-371 (1986) HJ Handley, J. et al., "Chronic Bullous Disease of Childhood and Ulcerative Colitis", Pediatric Dermatol., Vol. 10, No. 3, pp. 256-258, (1993) HK Hamdley, J. et al., "Chronic Bullous Disease of Childhood and Ulcerative Colitis", Pediatric Dermatol., Vol. 127, Supp. 40, pp. 67-68 (1992) HL Harindra, et al., "Papulo-Pruritic Eruption and Giant Ulceration of the Mouth: A Difficult Clinical Feature to Treat in the Patient Infected with Humanimmunodeficiency Virus(1)", Arch. Intern. Med., Vol. 152, No. 9, p. 1924 (1992) HM Harris, A., "Antiangiogenesis for Cancer Therapy", Lancet, Vol. 349 (Suppl. II), pp. 13-15 (1997) Hasper, M.F., "Chronic Cutaneous Lupus Erythematosus. Thalidomide Treatment of 11 Patients", Arch. Dermatol., Vol. 19, No. 10, pp. 812-815 (1983) Hasper, M.F., et al., "Thalidomide in the Treatment of Chronic Discoid Lupus", Acta. Derm. Venereol, Vol. 62, No. 4, pp. 321-324 (1982) HASPER, M.F., et al., "Thalidomide in the Treatment of Erythema Nodosum Leprosum. With a Note on Selected Laboratory Abnormalities in Erythema Nodosum Leprosum", Clin. Pharmacol. Ther., Vol. 11, No. 4, pp. 481-487 (1970) HR Hayashi, S. et al., "A Synthetic Peptide for α Chemokines Inhibits the Growth of Melonoma Cell Lines", J. Clin. Invest., Vol. 99, No. 11, pp. 2581-2587 (1997) HS Heaton, et al., "Graft-versus-Host Disease Following Liver Transplantation", J. R. Soc. Med., Vol. 85, No. 6, pp. 313-314 (1992) HG Helm F. Ch. et al. "Comparative Teratological Investigation of Compounds Structurally and			Günzler, V., "Thalidomide—A Therapy for the Immunological Consequences of HIV Infection?", Medical	
HF Arthritis and Rheumatism, Vol. 27, No. 10, pp. 1118-1121 (1984) HG Haffner, M.E. M.D., "Studies Involving Orphan Products for Treating/Diagnosing Women's Diseases", Food and Drug Law Journal, Vol. 48, pp. 205-211 (1992) HH Hamza, M. M.D., "Beticet's Disease, Palmoplantar Pustulosis and HLA-B27 Treatment with Thalidomide", Clinical and Experimental Rheumatology, Vol. 8, No. 4, p. 427 (1990) HI Hamza, M.H., "Treatment of Behcet's Disease with Thalidomide", Clinical Rheumatol., Vol. 5, No. 3, pp. 365-371 (1986) HJ Handley, J. et al., "Chronic Bullous Disease of Childhood and Ulcerative Colitis", Pediatric Dermatol., Vol. 10, No. 3, pp. 256-258, (1993) HK Hamdley, J. et al., "Chronic Bullous Disease of Childhood and Ulcerative Colitis", Pediatric Dermatol., Vol. 127, Supp. 40, pp. 67-68 (1992) HL Harindra, et al., "Papulo-Pruritic Eruption and Giant Ulceration of the Mouth: A Difficult Clinical Feature to Treat in the Patient Infected with Humanimmunodeficiency Virus(1)", Arch. Intern. Med., Vol. 152, No. 9, p. 1924 (1992) HM Harris, A., "Antiangiogenesis for Cancer Therapy", Lancet, Vol. 349 (Suppl. II), pp. 13-15 (1997) Hasper, M.F., "Chronic Cutaneous Lupus Erythematosus. Thalidomide Treatment of 11 Patients", Arch. Dermatol., Vol. 19, No. 10, pp. 812-815 (1983) Hasper, M.F., et al., "Thalidomide in the Treatment of Chronic Discoid Lupus", Acta. Derm. Venereol, Vol. 62, No. 4, pp. 321-324 (1982) HASPER, M.F., et al., "Thalidomide in the Treatment of Erythema Nodosum Leprosum. With a Note on Selected Laboratory Abnormalities in Erythema Nodosum Leprosum", Clin. Pharmacol. Ther., Vol. 11, No. 4, pp. 481-487 (1970) HR Hayashi, S. et al., "A Synthetic Peptide for α Chemokines Inhibits the Growth of Melonoma Cell Lines", J. Clin. Invest., Vol. 99, No. 11, pp. 2581-2587 (1997) HS Heaton, et al., "Graft-versus-Host Disease Following Liver Transplantation", J. R. Soc. Med., Vol. 85, No. 6, pp. 313-314 (1992) HG Helm F. Ch. et al. "Comparative Teratological Investigation of Compounds Structurally and	1	1110	Hypotheses Vol 30 No 2 np 105-109 (1989)	
HF Arthritis and Rheumatism, Vol. 27, No. 10, pp. 1118-1121 (1984) HG Haffner, M.E. M.D., "Studies Involving Orphan Products for Treating/Diagnosing Women's Diseases", Food and Drug Law Journal, Vol. 48, pp. 205-211 (1992) HH Hamza, M. M.D., "Beticet's Disease, Palmoplantar Pustulosis and HLA-B27 Treatment with Thalidomide", Clinical and Experimental Rheumatology, Vol. 8, No. 4, p. 427 (1990) HI Hamza, M.H., "Treatment of Behcet's Disease with Thalidomide", Clinical Rheumatol., Vol. 5, No. 3, pp. 365-371 (1986) HJ Handley, J. et al., "Chronic Bullous Disease of Childhood and Ulcerative Colitis", Pediatric Dermatol., Vol. 10, No. 3, pp. 256-258, (1993) HK Hamdley, J. et al., "Chronic Bullous Disease of Childhood and Ulcerative Colitis", Pediatric Dermatol., Vol. 127, Supp. 40, pp. 67-68 (1992) HL Harindra, et al., "Papulo-Pruritic Eruption and Giant Ulceration of the Mouth: A Difficult Clinical Feature to Treat in the Patient Infected with Humanimmunodeficiency Virus(1)", Arch. Intern. Med., Vol. 152, No. 9, p. 1924 (1992) HM Harris, A., "Antiangiogenesis for Cancer Therapy", Lancet, Vol. 349 (Suppl. II), pp. 13-15 (1997) Hasper, M.F., "Chronic Cutaneous Lupus Erythematosus. Thalidomide Treatment of 11 Patients", Arch. Dermatol., Vol. 19, No. 10, pp. 812-815 (1983) Hasper, M.F., et al., "Thalidomide in the Treatment of Chronic Discoid Lupus", Acta. Derm. Venereol, Vol. 62, No. 4, pp. 321-324 (1982) HASPER, M.F., et al., "Thalidomide in the Treatment of Erythema Nodosum Leprosum. With a Note on Selected Laboratory Abnormalities in Erythema Nodosum Leprosum", Clin. Pharmacol. Ther., Vol. 11, No. 4, pp. 481-487 (1970) HR Hayashi, S. et al., "A Synthetic Peptide for α Chemokines Inhibits the Growth of Melonoma Cell Lines", J. Clin. Invest., Vol. 99, No. 11, pp. 2581-2587 (1997) HS Heaton, et al., "Graft-versus-Host Disease Following Liver Transplantation", J. R. Soc. Med., Vol. 85, No. 6, pp. 313-314 (1992) HG Helm F. Ch. et al. "Comparative Teratological Investigation of Compounds Structurally and	12	HE	Gutiérrez-Rodriguez, O. et al., "Treatment of Refractory Rheumatoid Arthritis—The Thalidomide	
HF Arthritis and Rheumatism, Vol. 27, No. 10, pp. 1118-1121 (1984) HG Haffner, M.E. M.D., "Studies Involving Orphan Products for Treating/Diagnosing Women's Diseases", Food and Drug Law Journal, Vol. 48, pp. 205-211 (1992) HH Hamza, M. M.D., "Beticet's Disease, Palmoplantar Pustulosis and HLA-B27 Treatment with Thalidomide", Clinical and Experimental Rheumatology, Vol. 8, No. 4, p. 427 (1990) HI Hamza, M.H., "Treatment of Behcet's Disease with Thalidomide", Clinical Rheumatol., Vol. 5, No. 3, pp. 365-371 (1986) HJ Handley, J. et al., "Chronic Bullous Disease of Childhood and Ulcerative Colitis", Pediatric Dermatol., Vol. 10, No. 3, pp. 256-258, (1993) HK Hamdley, J. et al., "Chronic Bullous Disease of Childhood and Ulcerative Colitis", Pediatric Dermatol., Vol. 127, Supp. 40, pp. 67-68 (1992) HL Harindra, et al., "Papulo-Pruritic Eruption and Giant Ulceration of the Mouth: A Difficult Clinical Feature to Treat in the Patient Infected with Humanimmunodeficiency Virus(1)", Arch. Intern. Med., Vol. 152, No. 9, p. 1924 (1992) HM Harris, A., "Antiangiogenesis for Cancer Therapy", Lancet, Vol. 349 (Suppl. II), pp. 13-15 (1997) Hasper, M.F., "Chronic Cutaneous Lupus Erythematosus. Thalidomide Treatment of 11 Patients", Arch. Dermatol., Vol. 19, No. 10, pp. 812-815 (1983) Hasper, M.F., et al., "Thalidomide in the Treatment of Chronic Discoid Lupus", Acta. Derm. Venereol, Vol. 62, No. 4, pp. 321-324 (1982) HASPER, M.F., et al., "Thalidomide in the Treatment of Erythema Nodosum Leprosum. With a Note on Selected Laboratory Abnormalities in Erythema Nodosum Leprosum", Clin. Pharmacol. Ther., Vol. 11, No. 4, pp. 481-487 (1970) HR Hayashi, S. et al., "A Synthetic Peptide for α Chemokines Inhibits the Growth of Melonoma Cell Lines", J. Clin. Invest., Vol. 99, No. 11, pp. 2581-2587 (1997) HS Heaton, et al., "Graft-versus-Host Disease Following Liver Transplantation", J. R. Soc. Med., Vol. 85, No. 6, pp. 313-314 (1992) HG Helm F. Ch. et al. "Comparative Teratological Investigation of Compounds Structurally and		1112	Experience". The J. of Rheumatology, Vol. 16, No. 2, pp. 158-163 (1989)	
Arthritis and Rheumatism, Vol. 27, No. 10, pp. 1118-1121 (1984) HG Haffner, M.E. M.D., "Studies Involving Orphan Products for Treating/Diagnosing Women's Diseases", Food and Drug Law Journal, Vol. 48, pp. 205-211 (1992) HH Hamza, M. M.D., "Behcet's Disease, Palmoplantar Pustulosis and HLA-B27 Treatment with Thalidomide", Clinical and Experimental Rheumatology, Vol. 8, No. 4, p. 427 (1990) Hamza, M.H., "Treatment of Behcet's Disease with Thalidomide", Clinical Rheumatol., Vol. 5, No. 3, pp. 365-371 (1986) Handley, J. et al., "Chronic Bullous Disease of Childhood and Ulcerative Colitis", Pediatric Dermatol., Vol. 10, No. 3, pp. 256-258, (1993) HK Handley, J. et al., "Chronic Bullous Disease of Childhood and Ulcerative Colitis", Pediatric Dermatol., Vol. 127, Supp. 40, pp. 67-68 (1992) HAI Hardley, J. et al., "Papulo-Pruritic Eruption and Giant Ulceration of the Mouth: A Difficult Clinical Feature to Treat in the Patient Infected with Humanimunodefficiency Virus(1)", Arch. Intern. Med., Vol. 152, No. 9, p. 1924 (1992) HM Harris, A., "Antiangiogenesis for Cancer Therapy", Lancet, Vol. 349 (Suppl. II), pp. 13-15 (1997) Hasper, M.F., "Chronic Cutaneous Lupus Erythematosus. Thalidomide Treatment of TI Patients", Arch. Dermatol., Vol. 19, No. 10, pp. 812-815 (1983) Hasper, M.F., et al., "Thalidomide in the Treatment of Chronic Discoid Lupus", Acta. Derm. Venereol, Vol. 62, No. 4, pp. 321-324 (1982) Hastings, R.C., et al., "Thalidomide in the Treatment of Erythema Nodosum Leprosum. With a Note on Selected Laboratory Abnormalities in Erythema Nodosum Leprosum. With a Note on Selected Laboratory Abnormalities in Erythema Nodosum Leprosum. With a Note on Selected Laboratory Abnormalities in Erythema Nodosum Leprosum. With a Note on Selected Laboratory Abnormalities in Erythema Nodosum Leprosum with a Note on Selected Laboratory Abnormalities in Erythema Nodosum Leprosum of Melonoma Cell Line K562 by Exposure to Thalidomide Metabolites", Leukemia Ress., Vol. 15, No. 2/3, pp. 129-136 (1991) HR Hayashi, S. et al.,		HE	Gutiérrez-Rodriguez O et al "Thalidomide A Promising New Treatment for Rheumatoid Arthritis",	
HG Haffner, M.E. M.D., "Studies Involving Orphan Products for Treating/Diagnosing Women's Diseases", Pood and Drug Law Journal, Vol. 48, pp. 205-211 (1992) HH Hamza, M. M.D., "Behcer's Disease, Palmoplantar Pustulosis and HLA-B27 Treatment with Thalidomide", Clinical and Experimental Rheumatology, Vol. 8, No. 4, p. 427 (1990) HI Hamza, M.H., "Treatment of Behcet's Disease with Thalidomide", Clinical Rheumatol., Vol. 5, No. 3, pp. 365-371 (1986) HJ Handley, J. et al., "Chronic Bullous Disease of Childhood and Ulcerative Colitis", Pediatric Dermatol., Vol. 10, No. 3, pp. 256-258, (1993) HK Handley, J. et al., "Chronic Bullous Disease of Childhood and Ulcerative Colitis", Brit. J. of Dermatol., Vol. 127, Supp. 40, pp. 67-68 (1992) HK Handley, J. et al., "Chronic Bullous Disease of Childhood and Ulcerative Colitis", Brit. J. of Dermatol., Vol. 127, Supp. 40, pp. 67-68 (1992) HA Harndra, et al., "Papulo-Pruritic Eruption and Giant Ulceration of the Mouth: A Difficult Clinical Feature to Treat in the Patient Infected with Humanimmunodeficiency Virus(1)", Arch. Intern. Med., Vol. 152, No. 9, p. 1924 (1992) HA Harris, A., "Antiangiogenesis for Cancer Therapy", Lancet, Vol. 349 (Suppl. II), pp. 13-15 (1997) Hasper, M.F., "Chronic Cutaneous Lupus Erythematosus. Thalidomide Treatment of 11 Patients", Arch. Dermatol., Vol. 19, No. 10, pp. 812-815 (1983) Hasper, M.F., et al., "Thalidomide in the Treatment of Chronic Discoid Lupus", Acta. Derm. Venereol, Vol. 62, No. 4, pp. 321-324 (1982) Hastings, R.C., et al., "Thalidomide in the Treatment of Erythema Nodosum Leprosum. With a Note on Selected Laboratory Abnormalities in Erythema Nodosum Leprosum", Clin. Pharmacol. Ther., Vol. 11, No. 4, pp. 481-487 (1970) HO Hattill, S.J. et al., "Induction of Morphological Differentiation in the Human Leukemic Cell Line K562 by Exposure to Thalidomide Metabolites", Leukemia Res., Vol. 15, No. 2/3, pp. 129-136 (1991) HR Hayashi, S. et al., "Graft-versus-Host Disease Following Liver Transplantation", J. R. Soc. Med., Vol. 85, No	2	111	Arthritis and Rheumatism Vol 27 No 10, pp. 1118-1121 (1984)	
### HAMPIZA, M. M.D., "Behcet's Disease, Palmoplantar Pustulosis and HLA-B27 Treatment with Thalidomide", Clinical and Experimental Rheumatology, Vol. 8, No. 4, p. 427 (1990) ### HI Hamza, M. H., "Treatment of Behcet's Disease with Thalidomide", Clinical Rheumatol., Vol. 5, No. 3, pp. 365-371 (1986) ### HJ Hamdley, J. et al., "Chronic Bullous Disease of Childhood and Ulcerative Colitis", Pediatric Dermatol., Vol. 10, No. 3, pp. 256-258, (1993) ### HAMDLEY, J. et al., "Chronic Bullous Disease of Childhood and Ulcerative Colitis", Brit. J. of Dermatol., Vol. 127, Supp. 40, pp. 67-68 (1992) ### HL Harindra, et al., "Papulo-Pruritic Eruption and Giant Ulceration of the Mouth: A Difficult Clinical Feature to Treat in the Patient Infected with Humanimmunodeficiency Virus(1)", Arch. Intern. Med., Vol. 152, No. 9, p. 1924 (1992) ### HAMDLEY, "Chronic Cutaneous Lupus Erythematosus. Thalidomide Treatment of 11 Patients", Arch. Dermatol., Vol. 19, No. 10, pp. 812-815 (1983) ### HN HAMDLEY, "Chronic Cutaneous Lupus Erythematosus. Thalidomide Treatment of 11 Patients", Arch. Dermatol., Vol. 19, No. 10, pp. 812-815 (1983) ### HAMDLEY, "Chronic Cutaneous Lupus Erythematosus. Thalidomide Treatment of 11 Patients", Arch. Dermatol., Vol. 19, No. 10, pp. 812-815 (1983) ### HAMDLEY, "Chronic Cutaneous Lupus Erythematosus. Thalidomide Treatment of 11 Patients", Arch. Dermatol., Vol. 62, No. 4, pp. 321-324 (1982) ### HAMDLEY, "Chronic Cutaneous Lupus Erythema Nodosum Leprosum. With a Note on Selected Laboratory Abnormalities in Erythema Nodosum Leprosum." Clin. Pharmacol. Ther., Vol. 11, No. 4, pp. 481-487 (1970) ### HAMDLEY, "Chronic Cutaneous Lupus Erythema Nodosum Leprosum." Clin. Pharmacol. Ther., Vol. 11, No. 4, pp. 481-487 (1970) ### HAMDLEY, "Chronic Cutaneous Lupus Erythema Nodosum Leprosum." Clin. Pharmacol. Ther., Vol. 11, No. 4, pp. 313-314 (1992) ### HAMDLEY, "Chronic Cutaneous Lupus Erythema Nodosum Leprosum." Clin. Pharmacol. Ther., Vol. 11, No. 4, pp. 313-314 (1992) ### HAMDLEY, "Chronic Cutaneous Lupus		LIC:	Hattner M.E. M.D. "Studies Involving Orphan Products for Treating/Diagnosing Women's Diseases", Food	
HH Hamza, M. M.D., "Behcet's Disease, Palmoplantar Pustulosis and HLA-B27 Treatment with Thalidomide", Clinical and Experimental Rheumatology, Vol. 8, No. 4, p. 427 (1990) HI Hamza, M. H., "Treatment of Behcet's Disease with Thalidomide", Clinical Rheumatol., Vol. 5, No. 3, pp. 365-371 (1986) HJ Hamdley, J. et al., "Chronic Bullous Disease of Childhood and Ulcerative Colitis", Pediatric Dermatol., Vol. 10, No. 3, pp. 256-258, (1993) HK Handley, J. et al., "Chronic Bullous Disease of Childhood and Ulcerative Colitis", Brit. J. of Dermatol., Vol. 127, Supp. 40, pp. 67-68 (1992) HL Harindra, et al., "Papulo-Pruritic Eruption and Giant Ulceration of the Mouth: A Difficult Clinical Feature to Treat in the Patient Infected with Humanimmunodeficiency Virus(1)", Arch. Intern. Med., Vol. 152, No. 9, p. 1924 (1992) HM Harris, A., "Antiangiogenesis for Cancer Therapy", Lancet, Vol. 349 (Suppl. II), pp. 13-15 (1997) Hasper, M.F., "Chronic Cutaneous Lupus Erythematosus. Thalidomide Treatment of 11 Patients", Arch. Dermatol, Vol. 19, No. 10, pp. 812-815 (1983) HASPER, M.F., et al., "Thalidomide in the Treatment of Chronic Discoid Lupus", Acta. Derm. Venereol, Vol. 62, No. 4, pp. 321-324 (1982) Hastings, R.C., et al., "Thalidomide in the Treatment of Erythema Nodosum Leprosum. With a Note on Selected Laboratory Abnormalities in Erythema Nodosum Leprosum", Clin. Pharmacol. Ther., Vol. 11, No. 4, pp. 481-487 (1970) HQ Hatfill, S.J. et al., "Induction of Morphological Differentiation in the Human Leukemic Cell Line K562 by Exposure to Thalidomide Metabolites", Leukemia Res., Vol. 15, No. 2/3, pp. 129-136 (1991) HR Hayashi, S. et al., "A Synthetic Peptide for α Chemokines Inhibits the Growth of Melonoma Cell Lines", J. Clin. Invest., Vol. 99, No. 11, pp. 2581-2587 (1997) Heaton, et al., "Graft-versus-Host Disease Following Liver Transplantation", J. R. Soc. Med., Vol. 85, No. 6, pp. 313-314 (1992) Helm F. Ch. et al. "Comparative Teratological Investigation of Compounds Structurally and);==	no	and Drug Law Journal Vol 48 nn 205-211 (1992)	
HI Hamza, M.H., "Treatment of Behcet's Disease with Thalidomide", Clinical Rheumatol., Vol. 5, No. 3, pp. 365-371 (1986) HJ Handley, J. et al., "Chronic Bullous Disease of Childhood and Ulcerative Colitis", Pediatric Dermatol., Vol. 10, No. 3, pp. 256-258, (1993) HAMILEY, J. et al., "Chronic Bullous Disease of Childhood and Ulcerative Colitis", Pediatric Dermatol., Vol. 127, Supp. 40, pp. 67-68 (1992) HA Harindra, et al., "Papulo-Pruritic Eruption and Giant Ulceration of the Mouth: A Difficult Clinical Feature to Treat in the Patient Infected with Humanimmunodeficiency Virus(1)", Arch. Intern. Med., Vol. 152, No. 9, p. 1924 (1992) HM Harris, A., "Antiangiogenesis for Cancer Therapy", Lancet, Vol. 349 (Suppl. II), pp. 13-15 (1997) Hasper, M.F., "Chronic Cutaneous Lupus Erythematosus. Thalidomide Treatment of T1 Patients", Arch. Dermatol, Vol. 19, No. 10, pp. 812-815 (1983) HO Hasper, M.F., et al., "Thalidomide in the Treatment of Chronic Discoid Lupus", Acta. Derm. Venereol, Vol. 62, No. 4, pp. 321-324 (1982) HABSINGS, R.C., et al., "Thalidomide in the Treatment of Erythema Nodosum Leprosum. With a Note on Selected Laboratory Abnormalities in Erythema Nodosum Leprosum", Clin. Pharmacol. Ther., Vol. 11, No. 4, pp. 481-487 (1970) HQ Hatfill, S.J. et al., "Induction of Morphological Differentiation in the Human Leukemic Cell Line K562 by Exposure to Thalidomide Metabolites", Leukemia Res., Vol. 15, No. 2/3, pp. 129-136 (1991) HR Hayashi, S. et al., "A Synthetic Peptide for α Chemokines Inhibits the Growth of Melonoma Cell Lines", J. Clin. Invest., Vol. 99, No. 11, pp. 2581-2587 (1997) HB Heaton, et al., "Graft-versus-Host Disease Following Liver Transplantation", J. R. Soc. Med., Vol. 85, No. 6, pp. 313-314 (1992) HCH Harris Andrews Marchines Produced Investigation of Compounds Structurally and	1/2		Hamza M. M.D. "Behcet's Disease, Palmonlantar Pustulosis and HLA-B27 Treatment with Thalidomide",	
HI Hamza, M.H., "Treatment of Behcet's Disease with Thalidomide", Clinical Rheumatol., Vol. 5, No. 3, pp. 365-371 (1986) HI Handley, J. et al., "Chronic Bullous Disease of Childhood and Ulcerative Colitis", Pediatric Dermatol., Vol. 10, No. 3, pp. 256-258, (1993) HK Handley, J. et al., "Chronic Bullous Disease of Childhood and Ulcerative Colitis", Brit. J. of Dermatol., Vol. 127, Supp. 40, pp. 67-68 (1992) HA Handley, J. et al., "Chronic Bullous Disease of Childhood and Ulcerative Colitis", Brit. J. of Dermatol., Vol. 127, Supp. 40, pp. 67-68 (1992) HA Harria, at al., "Papulo-Pruritic Eruption and Giant Ulceration of the Mouth: A Difficult Clinical Feature to Treat in the Patient Infected with Humanimmunodeficiency Virus(1)", Arch. Intern. Med., Vol. 152, No. 9, p. 1924 (1992) HATTIS, A., "Antiangiogenesis for Cancer Therapy", Lancet, Vol. 349 (Suppl. II), pp. 13-15 (1997) Hasper, M.F., "Chronic Cutaneous Lupus Erythematosus. Thalidomide Treatment of 11 Patients", Arch. Dermatol, Vol. 19, No. 10, pp. 812-815 (1983) Hasper, M.F., et al., "Thalidomide in the Treatment of Chronic Discoid Lupus", Acta. Derm. Venereol, Vol. 62, No. 4, pp. 321-324 (1982) Hasper, M.F., et al., "Indiadomide in the Treatment of Erythema Nodosum Leprosum. With a Note on Selected Laboratory Abnormalities in Erythema Nodosum Leprosum", Clin. Pharmacol. Ther., Vol. 11, No. 4, pp. 481-487 (1970) HQ Hattill, S.J. et al., "Induction of Morphological Differentiation in the Human Leukemic Cell Line K562 by Exposure to Thalidomide Metabolites", Leukemia Res., Vol. 15, No. 2/3, pp. 129-136 (1991) HR Hayashi, S. et al., "A Synthetic Peptide for α Chemokines Inhibits the Growth of Melonoma Cell Lines", J. Clin. Invest., Vol. 99, No. 11, pp. 2581-2587 (1997) Heaton, et al., "Graft-versus-Host Disease Following Liver Transplantation", J. R. Soc. Med., Vol. 25, pp. 687-689 (1965) HCH Hasper, C. et al., "Comparative Teratological Investigation of Compounds Structurally and		1111	Clinical and Experimental Rheymatology, Vol. 8, No. 4, p. 427 (1990)	
pp. 365-371 (1986) HJ Handley, J. et al., "Chronic Bullous Disease of Childhood and Ulcerative Colitis", <i>Pediatric Dermatol.</i> , Vol. 10, No. 3, pp. 256-258, (1993) HK Handley, J. et al., "Chronic Bullous Disease of Childhood and Ulcerative Colitis", <i>Brit. J. of Dermatol.</i> , Vol. 127, Supp. 40, pp. 67-68 (1992) Harindra, et al., "Papulo-Pruritic Eruption and Giant Ulceration of the Mouth: A Difficult Clinical Feature to Treat in the Patient Infected with Humanimmunodeficiency Virus(1)", <i>Arch. Intern. Med.</i> , Vol. 152, No. 9, p. 1924 (1992) HM Harris, A., "Antiangiogenesis for Cancer Therapy", <i>Lancet</i> , Vol. 349 (Suppl. II), pp. 13-15 (1997) Hasper, M.F., "Chronic Cutaneous Lupus Erythematosus. Thalidomide Treatment of 11 Patients", <i>Arch. Dermatol.</i> , Vol. 19, No. 10, pp. 812-815 (1983) Hasper, M.F., et al., "Thalidomide in the Treatment of Chronic Discoid Lupus", <i>Acta. Derm. Venereol.</i> , Vol. 62, No. 4, pp. 321-324 (1982) Hastings, R.C., et al., "Thalidomide in the Treatment of Erythema Nodosum Leprosum. With a Note on Selected Laboratory Abnormalities in Erythema Nodosum Leprosum", <i>Clin. Pharmacol. Ther.</i> , Vol. 11, No. 4, pp. 481-487 (1970) Hatfill, S.J. et al., "Induction of Morphological Differentiation in the Human Leukemic Cell Line K562 by Exposure to Thalidomide Metabolites", <i>Leukemia Res.</i> , Vol. 15, No. 2/3, pp. 129-136 (1991) HR Hayashi, S. et al., "A Synthetic Peptide for α Chemokines Inhibits the Growth of Melonoma Cell Lines", <i>J. Clin. Invest.</i> , Vol. 99, No. 11, pp. 2581-2587 (1997) HB Heaton, et al., "Graft-versus-Host Disease Following Liver Transplantation", <i>J. R. Soc. Med.</i> , Vol. 85, No. 6, pp. 313-314 (1992) HFI Hellman, K. et al., Prolongation of Skin Homograft Survival by Thalidomide", <i>Brit. Med. J.</i> , Vol. 2, pp. 687-689 (1965)		-	Homes M. H. "Treatment of Rehoet's Disease with Thaildomide". Clinical Rheumatol., Vol. 5, No. 3,	
HJ Handley, J. et al., "Chronic Bullous Disease of Childhood and Ulcerative Colitis", Pediatric Dermatol., Vol. 10, No. 3, pp. 256-258, (1993) HK Handley, J. et al., "Chronic Bullous Disease of Childhood and Ulcerative Colitis", Brit. J. of Dermatol., Vol. 127, Supp. 40, pp. 67-68 (1992) HL Harindra, et al., "Papulo-Pruritic Eruption and Giant Ulceration of the Mouth: A Difficult Clinical Feature to Treat in the Patient Infected with Humanimmunodeficiency Virus(1)", Arch. Intern. Med., Vol. 152, No. 9, p. 1924 (1992) HM Harris, A., "Antiangiogenesis for Cancer Therapy", Lancet, Vol. 349 (Suppl. II), pp. 13-15 (1997) Hasper, M.F., "Chronic Cutaneous Lupus Erythematosus. Thalidomide Treatment of 11 Patients", Arch. Dermatol, Vol. 19, No. 10, pp. 812-815 (1983) Hasper, M.F., et al., "Thalidomide in the Treatment of Chronic Discoid Lupus", Acta. Derm. Venereol, Vol. 62, No. 4, pp. 321-324 (1982) Hastings, R.C., et al., "Thalidomide in the Treatment of Erythema Nodosum Leprosum. With a Note on Selected Laboratory Abnormalities in Erythema Nodosum Leprosum", Clin. Pharmacol. Ther., Vol. 11, No. 4, pp. 481-487 (1970) HG Hatfill, S.J. et al., "Induction of Morphological Differentiation in the Human Leukemic Cell Line K562 by Exposure to Thalidomide Metabolites", Leukemia Res., Vol. 15, No. 2/3, pp. 129-136 (1991) HR Hayashi, S. et al., "A Synthetic Peptide for α Chemokines Inhibits the Growth of Melonoma Cell Lines", J. Clin. Invest., Vol. 99, No. 11, pp. 2581-2587 (1997) Heaton, et al., "Graft-versus-Host Disease Following Liver Transplantation", J. R. Soc. Med., Vol. 85, No. 6, pp. 313-314 (1992) Hellman, K. et al., Prolongation of Skin Homograft Survival by Thalidomide", Brit. Med. J., Vol. 2, pp. 687-689 (1965)		п		
10, No. 3, pp. 256-258, (1993) Handley, J. et al., "Chronic Bullous Disease of Childhood and Ulcerative Colitis", Brit. J. of Dermatol., Vol. 127, Supp. 40, pp. 67-68 (1992) Harindra, et al., "Papulo-Pruritic Eruption and Giant Ulceration of the Mouth: A Difficult Clinical Feature to Treat in the Patient Infected with Humanimmunodeficiency Virus(1)", Arch. Intern. Med., Vol. 152, No. 9, p. 1924 (1992) HM Harris, A., "Antiangiogenesis for Cancer Therapy", Lancet, Vol. 349 (Suppl. II), pp. 13-15 (1997) Hasper, M.F., "Chronic Cutaneous Lupus Erythematosus. Thalidomide Treatment of 11 Patients", Arch. Dermatol, Vol. 19, No. 10, pp. 812-815 (1983) Hasper, M.F., et al., "Thalidomide in the Treatment of Chronic Discoid Lupus", Acta. Derm. Venereol, Vol. 62, No. 4, pp. 321-324 (1982) Hastings, R.C., et al., "Thalidomide in the Treatment of Erythema Nodosum Leprosum. With a Note on Selected Laboratory Abnormalities in Erythema Nodosum Leprosum", Clin. Pharmacol. Ther., Vol. 11, No. 4, pp. 481-487 (1970) HQ Hatfill, S.J. et al., "Induction of Morphological Differentiation in the Human Leukemic Cell Line K562 by Exposure to Thalidomide Metabolites", Leukemia Res., Vol. 15, No. 2/3, pp. 129-136 (1991) HR Hayashi, S. et al., "A Synthetic Peptide for α Chemokines Inhibits the Growth of Melonoma Cell Lines", J. Clin. Invest., Vol. 99, No. 11, pp. 2581-2587 (1997) Hellman, K. et al., "Graft-versus-Host Disease Following Liver Transplantation", J. R. Soc. Med., Vol. 85, No. 6, pp. 313-314 (1992) Hellman, K. et al., "Comparative Teratological Investigation of Compounds Structurally and		111	Headley Let al. "Chronic Bullous Disease of Childhood and Ulcerative Colitis". Pediatric Dermatol., Vol.	
HK Handley, J. et al., "Chronic Bullous Disease of Childhood and Ulcerative Colitis", Brit. J. of Dermatol., Vol. 127, Supp. 40, pp. 67-68 (1992) HL Harindra, et al., "Papulo-Pruritic Eruption and Giant Ulceration of the Mouth: A Difficult Clinical Feature to Treat in the Patient Infected with Humanimmunodeficiency Virus(1)", Arch. Intern. Med., Vol. 152, No. 9, p. 1924 (1992) HM Harris, A., "Antiangiogenesis for Cancer Therapy", Lancet, Vol. 349 (Suppl. II), pp. 13-15 (1997) Hasper, M.F., "Chronic Cutaneous Lupus Erythematosus. Thalidomide Treatment of 11 Patients", Arch. Dermatol, Vol. 19, No. 10, pp. 812-815 (1983) Hasper, M.F., et al., "Thalidomide in the Treatment of Chronic Discoid Lupus", Acta. Derm. Venereol, Vol. 62, No. 4, pp. 321-324 (1982) Hastings, R.C., et al., "Thalidomide in the Treatment of Erythema Nodosum Leprosum. With a Note on Selected Laboratory Abnormalities in Erythema Nodosum Leprosum", Clin. Pharmacol. Ther., Vol. 11, No. 4, pp. 481-487 (1970) HQ Hatfill, S.J. et al., "Induction of Morphological Differentiation in the Human Leukemic Cell Line K562 by Exposure to Thalidomide Metabolites", Leukemia Res., Vol. 15, No. 2/3, pp. 129-136 (1991) HR Hayashi, S. et al., "A Synthetic Peptide for α Chemokines Inhibits the Growth of Melonoma Cell Lines", J. Clin. Invest., Vol. 99, No. 11, pp. 2581-2587 (1997) Haton, et al., "Graft-versus-Host Disease Following Liver Transplantation", J. R. Soc. Med., Vol. 85, No. 6, pp. 313-314 (1992) HT Hellman, K. et al., Prolongation of Skin Homograft Survival by Thalidomide", Brit. Med. J., Vol. 2, pp. 687-689 (1965)		П	10 No. 2 no. 256-258 (1993)	
127, Supp. 40, pp. 67-68 (1992) Harindra, et al., "Papulo-Pruritic Eruption and Giant Ulceration of the Mouth: A Difficult Clinical Feature to Treat in the Patient Infected with Humanimmunodeficiency Virus(1)", Arch. Intern. Med., Vol. 152, No. 9, p. 1924 (1992) HM Harris, A., "Antiangiogenesis for Cancer Therapy", Lancet, Vol. 349 (Suppl. II), pp. 13-15 (1997) Hasper, M.F., "Chronic Cutaneous Lupus Erythematosus. Thalidomide Treatment of 11 Patients", Arch. Dermatol, Vol. 19, No. 10, pp. 812-815 (1983) Hasper, M.F., et al., "Thalidomide in the Treatment of Chronic Discoid Lupus", Acta. Derm. Venereol, Vol. 62, No. 4, pp. 321-324 (1982) Hastings, R.C., et al., "Thalidomide in the Treatment of Erythema Nodosum Leprosum. With a Note on Selected Laboratory Abnormalities in Erythema Nodosum Leprosum", Clin. Pharmacol. Ther., Vol. 11, No. 4, pp. 481-487 (1970) HQ Hatfill, S.J. et al., "Induction of Morphological Differentiation in the Human Leukemic Cell Line K562 by Exposure to Thalidomide Metabolites", Leukemia Res., Vol. 15, No. 2/3, pp. 129-136 (1991) HR Hayashi, S. et al., "A Synthetic Peptide for α Chemokines Inhibits the Growth of Melonoma Cell Lines", J. Clin. Invest., Vol. 99, No. 11, pp. 2581-2587 (1997) HS Heaton, et al., "Graft-versus-Host Disease Following Liver Transplantation", J. R. Soc. Med., Vol. 85, No. 6, pp. 313-314 (1992) Hellman, K. et al., Prolongation of Skin Homograft Survival by Thalidomide", Brit. Med. J., Vol. 2, pp. 687-689 (1965) Helm FCh. et al. "Comparative Teratological Investigation of Compounds Structurally and		1112	10, No. 3, pp. 250-250, (1797). Use a see of Childhood and Ulcerative Colitis". Brit. J. of Dermatol., Vol.	
HL Harindra, et al., "Papulo-Pruritic Eruption and Glant Olceration of the Mouth. A Difficult Clinical Feature to Treat in the Patient Infected with Humanimmunodeficiency Virus(1)", Arch. Intern. Med., Vol. 152, No. 9, p. 1924 (1992) HM Harris, A., "Antiangiogenesis for Cancer Therapy", Lancet, Vol. 349 (Suppl. II), pp. 13-15 (1997) Hasper, M.F., "Chronic Cutaneous Lupus Erythematosus. Thalidomide Treatment of 11 Patients", Arch. Dermatol, Vol. 19, No. 10, pp. 812-815 (1983) Hasper, M.F., et al., "Thalidomide in the Treatment of Chronic Discoid Lupus", Acta. Derm. Venereol, Vol. 62, No. 4, pp. 321-324 (1982) Hastings, R.C., et al., "Thalidomide in the Treatment of Erythema Nodosum Leprosum. With a Note on Selected Laboratory Abnormalities in Erythema Nodosum Leprosum", Clin. Pharmacol. Ther., Vol. 11, No. 4, pp. 481-487 (1970) HQ Hatfill, S.J. et al., "Induction of Morphological Differentiation in the Human Leukemic Cell Line K562 by Exposure to Thalidomide Metabolites", Leukemia Res., Vol. 15, No. 2/3, pp. 129-136 (1991) HR Haris, S. et al., "A Synthetic Peptide for α Chemokines Inhibits the Growth of Melonoma Cell Lines", J. Clin. Invest., Vol. 99, No. 11, pp. 2581-2587 (1997) Heaton, et al., "Graft-versus-Host Disease Following Liver Transplantation", J. R. Soc. Med., Vol. 85, No. 6, pp. 313-314 (1992) Hellman, K. et al., Prolongation of Skin Homograft Survival by Thalidomide", Brit. Med. J., Vol. 2, pp. 687-689 (1965) Hellm F. Ch. et al., "Comparative Teratological Investigation of Compounds Structurally and	191	пк	127 Supp. 40 pp. 67.68 (1907)	
Treat in the Patient Infected with Humanimmunodeficiency Virus(1)", Arch. Intern. Med., Vol. 152, No. 9, p. 1924 (1992) HM Harris, A., "Antiangiogenesis for Cancer Therapy", Lancet, Vol. 349 (Suppl. II), pp. 13-15 (1997) Hasper, M.F., "Chronic Cutaneous Lupus Erythematosus. Thalidomide Treatment of 11 Patients", Arch. Dermatol, Vol. 19, No. 10, pp. 812-815 (1983) Hasper, M.F., et al., "Thalidomide in the Treatment of Chronic Discoid Lupus", Acta. Derm. Venereol, Vol. 62, No. 4, pp. 321-324 (1982) Hastings, R.C., et al., "Thalidomide in the Treatment of Erythema Nodosum Leprosum. With a Note on Selected Laboratory Abnormalities in Erythema Nodosum Leprosum", Clin. Pharmacol. Ther., Vol. 11, No. 4, pp. 481-487 (1970) HQ Hatfill, S.J. et al., "Induction of Morphological Differentiation in the Human Leukemic Cell Line K562 by Exposure to Thalidomide Metabolites", Leukemia Res., Vol. 15, No. 2/3, pp. 129-136 (1991) HR Hayashi, S. et al., "A Synthetic Peptide for α Chemokines Inhibits the Growth of Melonoma Cell Lines", J. Clin. Invest., Vol. 99, No. 11, pp. 2581-2587 (1997) Heaton, et al., "Graft-versus-Host Disease Following Liver Transplantation", J. R. Soc. Med., Vol. 85, No. 6, pp. 313-314 (1992) Hellman, K. et al., Prolongation of Skin Homograft Survival by Thalidomide", Brit. Med. J., Vol. 2, pp. 687-689 (1965) Hellm FCh et al. "Comparative Teratological Investigation of Compounds Structurally and			127, Supp. 40, pp. 07-08 (1972)	
No. 9, p. 1924 (1992) HM Harris, A., "Antiangiogenesis for Cancer Therapy", Lancet, Vol. 349 (Suppl. II), pp. 13-15 (1997) Hasper, M.F., "Chronic Cutaneous Lupus Erythematosus. Thalidomide Treatment of 11 Patients", Arch. Dermatol, Vol. 19, No. 10, pp. 812-815 (1983) Hasper, M.F., et al., "Thalidomide in the Treatment of Chronic Discoid Lupus", Acta. Derm. Venereol, Vol. 62, No. 4, pp. 321-324 (1982) Ho Hastings, R.C., et al., "Thalidomide in the Treatment of Erythema Nodosum Leprosum. With a Note on Selected Laboratory Abnormalities in Erythema Nodosum Leprosum", Clin. Pharmacol. Ther., Vol. 11, No. 4, pp. 481-487 (1970) HQ Hatfill, S.J. et al., "Induction of Morphological Differentiation in the Human Leukemic Cell Line K562 by Exposure to Thalidomide Metabolites", Leukemia Res., Vol. 15, No. 2/3, pp. 129-136 (1991) HR Hayashi, S. et al., "A Synthetic Peptide for α Chemokines Inhibits the Growth of Melonoma Cell Lines", J. Clin. Invest., Vol. 99, No. 11, pp. 2581-2587 (1997) Heaton, et al., "Graft-versus-Host Disease Following Liver Transplantation", J. R. Soc. Med., Vol. 85, No. 6, pp. 313-314 (1992) Hellm, F., Ch. et al., "Comparative Teratological Investigation of Compounds Structurally and	0	HL	Tract in the Decient Infected with Humanimmundeficiency Virus(1)" Arch Intern Med. Vol. 152.	
HM Harris, A., "Antiangiogenesis for Cancer Therapy", Lancet, Vol. 349 (Suppl. II), pp. 13-15 (1997) Hasper, M.F., "Chronic Cutaneous Lupus Erythematosus. Thalidomide Treatment of 11 Patients", Arch. Dermatol, Vol. 19, No. 10, pp. 812-815 (1983) Hasper, M.F., et al., "Thalidomide in the Treatment of Chronic Discoid Lupus", Acta. Derm. Venereol, Vol. 62, No. 4, pp. 321-324 (1982) Hastings, R.C., et al., "Thalidomide in the Treatment of Erythema Nodosum Leprosum. With a Note on Selected Laboratory Abnormalities in Erythema Nodosum Leprosum", Clin. Pharmacol. Ther., Vol. 11, No. 4, pp. 481-487 (1970) HQ Hatfill, S.J. et al., "Induction of Morphological Differentiation in the Human Leukemic Cell Line K562 by Exposure to Thalidomide Metabolites", Leukemia Res., Vol. 15, No. 2/3, pp. 129-136 (1991) HR Hayashi, S. et al., "A Synthetic Peptide for α Chemokines Inhibits the Growth of Melonoma Cell Lines", J. Clin. Invest., Vol. 99, No. 11, pp. 2581-2587 (1997) HS Heaton, et al., "Graft-versus-Host Disease Following Liver Transplantation", J. R. Soc. Med., Vol. 85, No. 6, pp. 313-314 (1992) HT Hellm FCh et al., "Comparative Teratological Investigation of Compounds Structurally and	, E 155		No. 0 = 1024 (1002)	
HN Hasper, M.F., "Chronic Cutaneous Lupus Erythematosus. Thalidomide Treatment of 11 Patients", Arch. Dermatol, Vol. 19, No. 10, pp. 812-815 (1983) Hasper, M.F., et al., "Thalidomide in the Treatment of Chronic Discoid Lupus", Acta. Derm. Venereol, Vol. 62, No. 4, pp. 321-324 (1982) Hastings, R.C., et al., "Thalidomide in the Treatment of Erythema Nodosum Leprosum. With a Note on Selected Laboratory Abnormalities in Erythema Nodosum Leprosum", Clin. Pharmacol. Ther., Vol. 11, No. 4, pp. 481-487 (1970) HQ Hatfill, S.J. et al., "Induction of Morphological Differentiation in the Human Leukemic Cell Line K562 by Exposure to Thalidomide Metabolites", Leukemia Res., Vol. 15, No. 2/3, pp. 129-136 (1991) HR Hayashi, S. et al., "A Synthetic Peptide for α Chemokines Inhibits the Growth of Melonoma Cell Lines", J. Clin. Invest., Vol. 99, No. 11, pp. 2581-2587 (1997) Heaton, et al., "Graft-versus-Host Disease Following Liver Transplantation", J. R. Soc. Med., Vol. 85, No. 6, pp. 313-314 (1992) Hellman, K. et al., Prolongation of Skin Homograft Survival by Thalidomide", Brit. Med. J., Vol. 2, pp. 687-689 (1965) Helm FCh et al., "Comparative Teratological Investigation of Compounds Structurally and	العالم	LINA	No. 9, p. 1924 (1992)	
HN Arch. Dermatol, Vol. 19, No. 10, pp. 812-815 (1983) Hasper, M.F., et al., "Thalidomide in the Treatment of Chronic Discoid Lupus", Acta. Derm. Venereol, Vol. 62, No. 4, pp. 321-324 (1982) Hastings, R.C., et al., "Thalidomide in the Treatment of Erythema Nodosum Leprosum. With a Note on Selected Laboratory Abnormalities in Erythema Nodosum Leprosum", Clin. Pharmacol. Ther., Vol. 11, No. 4, pp. 481-487 (1970) HQ Hatfill, S.J. et al., "Induction of Morphological Differentiation in the Human Leukemic Cell Line K562 by Exposure to Thalidomide Metabolites", Leukemia Res., Vol. 15, No. 2/3, pp. 129-136 (1991) HR Hayashi, S. et al., "A Synthetic Peptide for α Chemokines Inhibits the Growth of Melonoma Cell Lines", J. Clin. Invest., Vol. 99, No. 11, pp. 2581-2587 (1997) Heaton, et al., "Graft-versus-Host Disease Following Liver Transplantation", J. R. Soc. Med., Vol. 85, No. 6, pp. 313-314 (1992) Hellman, K. et al., Prolongation of Skin Homograft Survival by Thalidomide", Brit. Med. J., Vol. 2, pp. 687-689 (1965) Helm FCh et al., "Comparative Teratological Investigation of Compounds Structurally and		HIVI	Harris, A., Antiangiogenesis for Cancer Therapy, Luricei, vol. 347 (Suppl. 11), pp. 13-13 (1997)	
Hasper, M.F., et al., "Thalidomide in the Treatment of Chronic Discoid Lupus", Acta. Derm. Venereol, Vol. 62, No. 4, pp. 321-324 (1982) Hastings, R.C., et al., "Thalidomide in the Treatment of Erythema Nodosum Leprosum. With a Note on Selected Laboratory Abnormalities in Erythema Nodosum Leprosum", Clin. Pharmacol. Ther., Vol. 11, No. 4, pp. 481-487 (1970) HQ Hatfill, S.J. et al., "Induction of Morphological Differentiation in the Human Leukemic Cell Line K562 by Exposure to Thalidomide Metabolites", Leukemia Res., Vol. 15, No. 2/3, pp. 129-136 (1991) HR Hayashi, S. et al., "A Synthetic Peptide for α Chemokines Inhibits the Growth of Melonoma Cell Lines", J. Clin. Invest., Vol. 99, No. 11, pp. 2581-2587 (1997) Heaton, et al., "Graft-versus-Host Disease Following Liver Transplantation", J. R. Soc. Med., Vol. 85, No. 6, pp. 313-314 (1992) Hellman, K. et al., Prolongation of Skin Homograft Survival by Thalidomide", Brit. Med. J., Vol. 2, pp. 687-689 (1965) Helm FCh et al., "Comparative Teratological Investigation of Compounds Structurally and		Hasper, M.F., "Chronic Cutaneous Lupus Erythematosus. Thandonnue Treatment of 11 Fatients,		
HO Vol. 62, No. 4, pp. 321-324 (1982) Hastings, R.C., et al., "Thalidomide in the Treatment of Erythema Nodosum Leprosum. With a Note on Selected Laboratory Abnormalities in Erythema Nodosum Leprosum", Clin. Pharmacol. Ther., Vol. 11, No. 4, pp. 481-487 (1970) HQ Hatfill, S.J. et al., "Induction of Morphological Differentiation in the Human Leukemic Cell Line K562 by Exposure to Thalidomide Metabolites", Leukemia Res., Vol. 15, No. 2/3, pp. 129-136 (1991) HR Hayashi, S. et al., "A Synthetic Peptide for α Chemokines Inhibits the Growth of Melonoma Cell Lines", J. Clin. Invest., Vol. 99, No. 11, pp. 2581-2587 (1997) Heaton, et al., "Graft-versus-Host Disease Following Liver Transplantation", J. R. Soc. Med., Vol. 85, No. 6, pp. 313-314 (1992) Hellman, K. et al., Prolongation of Skin Homograft Survival by Thalidomide", Brit. Med. J., Vol. 2, pp. 687-689 (1965) Hellm FCh et al., "Comparative Teratological Investigation of Compounds Structurally and	HN Arch. Dermatol, Vol. 19, No. 10, pp. 012-013 (1903) Horar M.E. et al. "The lideraide in the Treatment of Chronic Discoid Lunus" Acta Derm Venereal			
Hastings, R.C., et al., "Thalidomide in the Treatment of Erythema Nodosum Leprosum. With a Note on Selected Laboratory Abnormalities in Erythema Nodosum Leprosum", Clin. Pharmacol. Ther., Vol. 11, No. 4, pp. 481-487 (1970) Hatfill, S.J. et al., "Induction of Morphological Differentiation in the Human Leukemic Cell Line K562 by Exposure to Thalidomide Metabolites", Leukemia Res., Vol. 15, No. 2/3, pp. 129-136 (1991) HR Hayashi, S. et al., "A Synthetic Peptide for α Chemokines Inhibits the Growth of Melonoma Cell Lines", J. Clin. Invest., Vol. 99, No. 11, pp. 2581-2587 (1997) Heaton, et al., "Graft-versus-Host Disease Following Liver Transplantation", J. R. Soc. Med., Vol. 85, No. 6, pp. 313-314 (1992) Helman, K. et al., Prolongation of Skin Homograft Survival by Thalidomide", Brit. Med. J., Vol. 2, pp. 687-689 (1965) Helm FCh et al., "Comparative Teratological Investigation of Compounds Structurally and		Hasper, M.F., et al., "Inaligomide in the Treatment of Chronic Discoid Lupus", Acta. Del m. Venereot,		
HP Selected Laboratory Abnormalities in Erythema Nodosum Leprosum", Clin. Pharmacol. Ther., Vol. 11, No. 4, pp. 481-487 (1970) HQ Hatfill, S.J. et al., "Induction of Morphological Differentiation in the Human Leukemic Cell Line K562 by Exposure to Thalidomide Metabolites", Leukemia Res., Vol. 15, No. 2/3, pp. 129-136 (1991) HR Hayashi, S. et al., "A Synthetic Peptide for α Chemokines Inhibits the Growth of Melonoma Cell Lines", J. Clin. Invest., Vol. 99, No. 11, pp. 2581-2587 (1997) HS Heaton, et al., "Graft-versus-Host Disease Following Liver Transplantation", J. R. Soc. Med., Vol. 85, No. 6, pp. 313-314 (1992) Hellman, K. et al., Prolongation of Skin Homograft Survival by Thalidomide", Brit. Med. J., Vol. 2, pp. 687-689 (1965) Hellm FCh et al., "Comparative Teratological Investigation of Compounds Structurally and		но	Vol. 62, No. 4, pp. 521-524 (1962) With a Note on	
No. 4, pp. 481-487 (1970) Hatfill, S.J. et al., "Induction of Morphological Differentiation in the Human Leukemic Cell Line K562 by Exposure to Thalidomide Metabolites", <i>Leukemia Res.</i> , Vol. 15, No. 2/3, pp. 129-136 (1991) HR Hayashi, S. et al., "A Synthetic Peptide for α Chemokines Inhibits the Growth of Melonoma Cell Lines", <i>J. Clin. Invest.</i> , Vol. 99, No. 11, pp. 2581-2587 (1997) HS Heaton, et al., "Graft-versus-Host Disease Following Liver Transplantation", <i>J. R. Soc. Med.</i> , Vol. 85, No. 6, pp. 313-314 (1992) Helman, K. et al., Prolongation of Skin Homograft Survival by Thalidomide", <i>Brit. Med. J.</i> , Vol. 2, pp. 687-689 (1965) Helm FCh et al., "Comparative Teratological Investigation of Compounds Structurally and		TID	Hastings, R.C., et al., A mandolinder in the Treatment of Edynderia Processin, Walter and There Vol 11.	
HQ Hatfill, S.J. et al., "Induction of Morphological Differentiation in the Human Leukemic Cell Line K562 by Exposure to Thalidomide Metabolites", Leukemia Res., Vol. 15, No. 2/3, pp. 129-136 (1991) HR Hayashi, S. et al., "A Synthetic Peptide for α Chemokines Inhibits the Growth of Melonoma Cell Lines", J. Clin. Invest., Vol. 99, No. 11, pp. 2581-2587 (1997) HS Heaton, et al., "Graft-versus-Host Disease Following Liver Transplantation", J. R. Soc. Med., Vol. 85, No. 6, pp. 313-314 (1992) Helman, K. et al., Prolongation of Skin Homograft Survival by Thalidomide", Brit. Med. J., Vol. 2, pp. 687-689 (1965) Helm FCh et al., "Comparative Teratological Investigation of Compounds Structurally and	1	HP	Selected Laboratory Abhoritanties in Erythema Nouosum Echrosum , Carl. 1 Marinteen. 2001, 457 (1970)	
Exposure to Thalidomide Metabolites", Leukemia Res., Vol. 15, No. 2/3, pp. 129-136 (1991) HR Hayashi, S. et al., "A Synthetic Peptide for α Chemokines Inhibits the Growth of Melonoma Cell Lines", J. Clin. Invest., Vol. 99, No. 11, pp. 2581-2587 (1997) HS Heaton, et al., "Graft-versus-Host Disease Following Liver Transplantation", J. R. Soc. Med., Vol. 85, No. 6, pp. 313-314 (1992) Helman, K. et al., Prolongation of Skin Homograft Survival by Thalidomide", Brit. Med. J., Vol. 2, pp. 687-689 (1965) Helm FCh et al., "Comparative Teratological Investigation of Compounds Structurally and	<u> </u>		No. 4, pp. 481-487 (1970)	
HR Hayashi, S. et al., "A Synthetic Peptide for α Chemokines Inhibits the Growth of Melonoma Cell Lines", J. Clin. Invest., Vol. 99, No. 11, pp. 2581-2587 (1997) HS Heaton, et al., "Graft-versus-Host Disease Following Liver Transplantation", J. R. Soc. Med., Vol. 85, No. 6, pp. 313-314 (1992) HT Hellman, K. et al., Prolongation of Skin Homograft Survival by Thalidomide", Brit. Med. J., Vol. 2, pp. 687-689 (1965) Helm FCh et al., "Comparative Teratological Investigation of Compounds Structurally and	10	HQ	Hatfill, S.J. et al., Induction of Morphological Differentiation in the Hatfill Beakenite Con Ellie R502 by	
Clin. Invest., Vol. 99, No. 11, pp. 2581-2587 (1997) Heaton, et al., "Graft-versus-Host Disease Following Liver Transplantation", J. R. Soc. Med., Vol. 85, No. 6, pp. 313-314 (1992) Hellman, K. et al., Prolongation of Skin Homograft Survival by Thalidomide", Brit. Med. J., Vol. 2, pp. 687-689 (1965) Helm FCh et al., "Comparative Teratological Investigation of Compounds Structurally and	0			
Clin. Invest., Vol. 99, No. 11, pp. 2581-2587 (1997) Heaton, et al., "Graft-versus-Host Disease Following Liver Transplantation", J. R. Soc. Med., Vol. 85, No. 6, pp. 313-314 (1992) Hellman, K. et al., Prolongation of Skin Homograft Survival by Thalidomide", Brit. Med. J., Vol. 2, pp. 687-689 (1965) Helm FCh et al., "Comparative Teratological Investigation of Compounds Structurally and		HR	Hayashi, S. et al., "A Synthetic Peptide for α Chemokines Inhibits the Growth of Melonoma Cell Lines", J.	
No. 6, pp. 313-314 (1992) Hellman, K. et al., Prolongation of Skin Homograft Survival by Thalidomide", Brit. Med. J., Vol. 2, pp. 687-689 (1965) Helm FCh et al., "Comparative Teratological Investigation of Compounds Structurally and			Clin. Invest., Vol. 99, No. 11, pp. 2581-2587 (1997)	
No. 6, pp. 313-314 (1992) Hellman, K. et al., Prolongation of Skin Homograft Survival by Thalidomide", Brit. Med. J., Vol. 2, pp. 687-689 (1965) Helm FCh et al., "Comparative Teratological Investigation of Compounds Structurally and		HS	Heaton, et al., "Graft-versus-Host Disease Following Liver Transplantation", J. R. Soc. Med., Vol. 85,	
HT Hellman, K. et al., Prolongation of Skin Homograft Survival by Thalidomide", Brit. Med. J., Vol. 2, pp. 687-689 (1965) Helm FCh et al., "Comparative Teratological Investigation of Compounds Structurally and	10		No. 6, np. 313-314 (1992)	
pp. 687-689 (1965) Helm F -Ch et al. "Comparative Teratological Investigation of Compounds Structurally and	100	HT	Hellman, K. et al., Prolongation of Skin Homograft Survival by Thalidomide", Brit. Med. J., Vol. 2,	
Helm F -Ch et al. "Comparative Teratological Investigation of Compounds Structurally and			pp. 687-689 (1965)	
		+-+	Helm F -Ch et al. "Comparative Teratological Investigation of Compounds Structurally and	
HU Pharmacologically Related to Thalidomide", ArzneimForsch./Drug Res., Vol. 31 (I), No. 6, pp. 941-949		HU	Pharmacologically Related to Thalidomide", ArzneimForsch./Drug Res., Vol. 31 (I), No. 6, pp. 941-949	
(1981)			(1981)	
EXAMINER DATE CONSIDERED 8/23/2/	EXAMIN	ER	DATE CONSIDERED 8/23/2/	
	1			
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in	EXAMIN	VER: Init	tial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in	

conformance and not considered. Include copy of this form with next communication to applicant.

AUG 0 3 2001 TECH CENTER 1600/2900

Approved for use through 10/31/2002 OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

1.5. no persons are required to respond to a collection of information unless it contains a valid OMB control number

Under the Paper of Reduction Act of

Substitute for Form 1449/A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

AUS 0 1 2001

(use as many sheets as necessary

Sheet 9 of 17

	Complete if Known
Application Number	09/545,139
Filing Date	April 7, 2000
First Named Inventor	D'Amato et al.
Group Art Unit	1614
Examiner Name	J. Goldberg
Attorney Docket Number	05213-0650 43170-219681

		U.S. PATENT DOCUMENTS	
		OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, Etc.)	
	IA	Hendler, S. S. et al., "Thalidomide for Autoimmune Disease", Medical Hypotheses, Vol. 10, pp. 437-443 (1983)	
	-IB	Hendler S.S. "Immune Modulators Thalidomide". The Oxygen Breakthrough pp. 217-219 no clave	
à	IC	Heney, D. et al., "Thalidomide Treatment for Chronic Graft-Versus-Host Disease", Brit. J. of Haematol. Vol. 78, pp. 23-27 (1991)	
9		Heney, D., et al., "Thalidomide in the Treatment of Graft-versus-Host Disease", Biomed. Pharmacother, Vol. 44, No. 4, pp. 199-204 (1990)	
	ID IE	Heney, D., et al., "Thalidomide for Chronic Graft-versus-Host Disease in Children", Lancet, Vol. 2,	
	112	No. 8623, p. 1317 (1988) Hojyo, et al., "Actinic Prurigo (9)", Int. J. Dermatol., Vol. 31, No. 5, pp. 372-373 (1992)	
	IF	Holyo, et al., 'Chronic Cutaneous Lupus Erythematosus Treated with Thalidomide', Arch. Dermatol.,	
2	IG	Vol. 129 No. 12 nn. 1548-1550 (1993)	
95	IH	Hori, A. et al., "Suppression of Solid Tumor Growth by Immunoneutralizing Monoclonal Antibody against Human Basic Fibroblast Growth Factor", Canc. Res., Vol. 51, pp. 6180-6184 (1991)	
91	II	Hu, D.E., "Inhibition of Angiogenesis in Rats by IL-1 Receptor Antagonist and Selected Cytokine Antibodies", <i>Inflammation</i> , Vol. 18, pp. 45-58 (1994)	
	IJ	Hu, J. et al., "A Novel Regulatory Function of Proteolytically Cleaved VEGF-2 for Vascular Endothelial and Smooth Muscle Cells", <i>The FASEB Journal</i> , Vol. 11, pp. 498-504 (1997)	
9		Ingber, D. et al., "Synthetic Analogues of Fumagillin that Inhibit Angiogenesis and Suppress Tumor Growth", Ltrs. to Nat., Vol. 348, pp. 555-557 (1990)	
	IK	Ingber, D., "Drug News and Trial Developments", AIDS Patient Care, Vol. 6, No. 6, p. 288 (1992)	
	IL	Jacobson, J. et al., "Thalidomide for the Treatment of Oral Aphthous Ulcers in Patients with Human	
	IM	Immunodeficiency Virus Infection", <i>The New England Journal of Medicine</i> , Vol. 336, No. 21, pp. 1487-1493 (1997)	
QZ	IN	Jacobson, et al., "The Diagnosis and Treatment of Leprosy", South Med., J., Vol. 69, No. 8, pp. 979-985 (1976)	
92	Ю	Jager, et al., "Clinical Observations in the Treatment of Leprosy Reaction with Cyclic Imides", Int. J. Lepr. Other Mycobact Dis., Vol. 39, No. 2, p. 589 (1971)	
	IP	Jeltsch, M. et al., "Hypeplasia of Lymphatic Vessels in VEGF-C Transgenic Mice", Science, Vol. 276, pp. 1423-1426 (1997)	
9	IQ	Jenkins, et al., "Thalidomide, Orogenital Ulcers, and Risk of Teratogenicity", <i>The Lancet</i> , Vol. 1, No. 8417-18, p. 511 (1985)	
9	IR	Jenkins, et al., "Thalidomide in Severe Orogenital Ulceration", <i>The Lancet</i> , Vol. 2, No. 8417-18, pp. 1424-1426 (1984)	
	IS	Jennings, et al., "Effect of Actinomycin D on the Production of Acute Phase Protein in the Rabbit", Experienta, Vol. 25, pp. 305-306 (1969)	
1	IT	Jew, et al., "Thalidomide in Erythema Nodosum Leprosum", <i>DICP</i> , Vol. 24, No. 5, pp. 482-483 (1990)	
100	IU	Johnke, et al., "Thalidomide Treatment of Prurigo Nodularis", Ugeskr Laeger, Vol. 155, No. 38,	
8		nn 3028-3030 (1993) (Abstract Only)	
0	IV	Jönsson, N., "Chemical Structure and Teratogenic Propeties IV. An Outline of a Chemical Hypothesis for the Teratogenic Action of Thalidomide", <i>Acia Pharm. Succica</i> , Vol. 9, pp. 543-562 (1972)	
3	IW	Jönsson, N., "Chemical Structure and Teratogenic Properties I. Synthesis and Teratogenic Activity in Rabbits of some Derivatives of Phthalidmide, Isoindoine-1-one, 1.2-Benzisothiazoline-3-one-1, 1-Dioxide and 4(3II)-Quinazolinone", Acia Pharm Succica, Vol. 9, pp. 431-436 (1972)	
0	IX	Jönsson, N., "Chemical Structure and Teratogenic Properties III a Review of Available Data on Structure-Activity Relationships and Mechanism of Action of Thalidomide Analogues", <i>Acia Pharm. Succia</i> , Vol. 9, pp. 521-542 (1972)	
EXAMINI	R	DATE CONSIDERED P/82/07	
EXAMIN	ER:	nitial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in not considered. Include copy of this form with next communication to applicant.	

RECEIVED

AUG 0 3 2001

PTO/SB/08A (08-00)
Approved for use through 10/31/2002 OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
to persons are required to respond to a collection of information unless it contains a valid OMB control number AUG 0 1 2001 Under the Paperwork Reduction Act of 1995

Substitute for Form 1449/A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary

Sheet | 10 of 17

	Complete if Known
Application Number	09/545,139
Filing Date	April 7, 2000
First Named Inventor	D'Amato et al.
Group Art Unit	1614
Examiner Name	J. Goldberg
Attorney Docket Number	05213-0650 43170-219681

U.S. PATENT DOCUMENTS			
		The state of the s	
OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, Etc.)			
\mathcal{L}		Jorizzo, et al., "Thalidomide Effects in Behcet's Syndrome and Pustular Vasculitis", Arch. Intern. Med.,	
	JA	Vol. 146, No. 5, pp. 878-881 (1986) Juret, et al., "Absence d'effet Carcino-Frénateur du Talidomide vis-á-vis de deux Tumerus Greffées", Société	
Q	JB	Juret, et al., "Absence d'erret Carcino-Frenateur du Tandonnue Vis-a-vis de deux Tamerus Grences, boeiere	
		de Biologie, Vol. 23, pp. 246-249 (1963) Kaitin, K.I., "Graft-versus-Host Disease", N. Engl. J. Med., Vol. 325, No. 5, pp. 357-358 (1991)	
	JC	Kaitin, K.I., "Grant-versus-Host Disease", N. Engl. J. Med., Vol. 323, No. 3, pp. 337-336 (37)	
2	JD	Kaplan, G. et al., "TNFα regulation of HIV1: Biology and Therapy", Res. in Immunology, Vol. 145, No. 8-9, pp. 685-690 (1994)	
Q	JE	Katsuta, et al., "Carcinogenesis in Tissue Culture. 3. Effects of the Second Treatments on DAB-Induced Proliferating Liver Cells of Normal Rats in Culture", <i>Jpn. J. Exp. Med.</i> , Vol. 35, No. 4, pp. 231-248 (1965)	
X	JF	Keenan, R.J. et al., "Immunosuppressive Properties of Thalidomide", Transplantation, Vol. 52, No. 5, pp. 908-910 (1991)	
F	JG	Kenyon, et al., "The Discovery of New Inhibitors of Angiogenesis Using an Improved Mouse Corneal.	
		Neovascularization Model" No. 459-367, p. S94 (Abstract only) no date	
	JH	Kim, K. J. et al., "Inhibition of Vascular Endothelial Growth Factor-Induced Angiogenesis Suppresses Tumor Growth in vivo" Ltrs. to Nat. Vol. 362, pp. 841-844 (1993)	
	 JI 	Kitamoto V et al. "Vascular Endothelial Growth Factor is an Essential Molecule for Mouse Kidney	
		Development: Glomerulogenesis and Nephrogenesis", J. Clin. Invest., Vol. 99, No. 10, pp. 2351-2357	
73	11	Klug, S. et al., "Embryotoxic Effects of Thalidomide Derivatives in the Non-Human Primate Callithrix	
		Jacchus" Arch Toxicol Vol. 68 pp. 203-205 (1994)	
9	JK	Knighton, D. et al., "Avascular and Vascular Phases of Tumor Growth in the Chick Embryo", Br. J. Canc.,	
	JL	Knop, et al., "Thalidomide in the Treatment of Sixty Cases of Chronic Discoid Lupus Erythematosus", Br. J. Dermatol. Vol. 108, No. 4, pp. 461-466 (1983)	
	JM	Koch, H.P. et al., "4 Thalidomide and Congeners as Anti-inflammatory Agents", Progress in Medicinal	
	JN	Korn, et al., "The Second International Workshop on Scleroderma Research", Matrix, Vol. 13, No. 5, pp. 427-429 (1993)	
0	JO Kroger, et al., "Synergistic Effects of Thalidomide and Poly (ADP-ribose) Polymerase Inhibition on Type II Collagen-Induced Arthritis in Mice", Inflammation, Vol. 20, No. 2, pp. 203-215 (1996)		
	JP	Kundu, et al., "Prurigo Nodularis in an HIV Positive Man (2)", Genitourinary Medicine, Vol. 71, No. 2,	
1	JF	nn 129-130 (1995)	
	JQ	Kürkcüoglu, N. et al., "Thalidomide in the treatment of Recurrent Necrotic Mucocutaneous Aphthae", Brit. J.	
S	1.4	of Dermatol, Vol. 112, No. 5, pp. 632 (1985)	
	JR	Lane et al. "Treatment of Actinic Prurigo with Intermittent Short-Course Topical 0.05% Clobetasol	
0	310	17-Propionate A Preliminary Report". Arch. Dermatol. Vol. 126, No. 9, pp. 1211-1213 (1990)	
	JS	Languillon, J., "The Effects of Thalidomide on Leprosy Reaction", Int. J. Lepr. Other Mycobact. Dis.,	
	100	Vol. 39, No. 2, pp. 590-592 (1971)	
	JT	Larsson, H., "Treatment of Severe Colitis in Behcet's Syndrome with Thalidomide (CG-217)", J. of Intern.	
		Med Vol 228 pp 405-407 (1990)	
Ledo, E., "Photodermatosis. Part I: Photobiology, Photoimmunology, and Idiopathicphotodermatoses", Int.			
	JU	I Dermatol, Vol. 32, No. 6, pp. 387-396 (1993)	
	Lehner, T., et al., "Thalidomide, Orogenital Ulcers, and the Risk of Teratogenesis", <i>The Lancet</i> , Vol. 8423,		
19_	JV	pp. 288-289 (1985)	
EXAMIN		DATE CONSIDERED // - /	
EXAMINER DATE CONSIDERED 8/23/0/			
EYAM	AEB:	Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in	
LEVANIA	ALIX.	milital in reference considered, whether or not obtained a communication to applicant.	

conformance and not considered. Include copy of this form with next communication to applicant.

RECEIVED

AUG 0 3 2001
TECH CENTER 1600/2900

PTO/SB/08A (08-00)
Approved for use through 10/31/2002 OMB 0651-0031
U.S. Patent and Trademark Office U.S. DEPARTMENT OF COMMERCE
to a collection of information unless it contains a valid OMB control with

Under the Paper 5, no persons are required

Substitute for Form 1449/A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

AUG 0 1 2001

(use as many sheets as necessary

Sheet | 11 of 17

mod to respond to a conscitor of time	innation unless it contains a valid ONB control number
	Complete if Known
Application Number	09/545,139
Filing Date	April 7, 2000
First Named Inventor	D'Amato et al.
Group Art Unit	1614
Examiner Name	J. Goldberg
Attorney Docket Number	05213-0650 43170-219681

A		OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, Etc.)
A		OTHER REFERENCES (Including Author, Title, Dale, Fertinent Pages, Fig.)
4		Lenicque, "Action of Thalidomide on the Induction of Tentacles in Regenerating Hydra Littoralis",
	KA	Acta. Zool., pp. 127-139 (1967)
Õ	KB	Levy, et al., "Treatment of Erythema Nodosum Leprosum with Thalidomide", <i>The Lancet</i> , Vol. 2, No. 824, pp. 324-325 (1973)
	КС	Lien, W. M. et al., "The Blood Supply of Experimental Liver Metastases. II. A microcirculatory Study of the Normal and Tumor Vessels of the Liver with the Use of Perfused Silicone Rubber", Surgery, Vol. 68, No. 2, pp. 334-340 (1970)
	KD	Lo, et al., "Treatment of Discoid Lupus Erythematosus", Int. J. Dermatol., Vol. 28, No. 8, pp. 497-507 (1989)
2	KE	Londono, F., "Thalidomide in the Treatment of Actinic Prurigo", Int. J. Dermatol., Vol. 12, No. 5, pp. 326-328 (1973)
	KF	Lovell, et al., "Thalidomide in Actinic Prurigo", Br. J. Dermatol, Vol. 108, No. 4, pp. 467-471 (1983)
R	KG	Lopez, J. et al., "Thalidomide as Therapy for Intestinal Chronic GVHD", <i>Bone Marrow Transplantation</i> , Vol. 11, No. 3, pp. 251-252 (1993)
	кн	Louzir, B. et al., "Erythroleucemie chez un patient ayant une maladie de Behcet et traite au long cours par thalidomide", <i>Annales de Medecine Interne</i> , Vol. 143, pp. 479-480 (1992)
		Lueprasitsakul, W. et al., "Effect of Thalidomide on the Incidence of Iodine-Induced and Spontaneous KI Lymphocytic Thyroiditis and Spontaneous Diabetes Mellitus in the BB/Wor Rat", <i>Acta Endocrino Logica</i> ", Vol. 123, pp. 79-83 (1990)
	KJ	Lüers, H., "Failure of Mutagenic Action of Thalidomide in Drosophila", <i>The Lancet</i> , Vol. II, No. 7258, p. 1332 (1962)
	KK	Magana-Garcia, M., "Antimalarials for Children", J. Am. Acad. Dermatol, Vol. 30, No. 3, p. 510 (1994)
	KL	Maione, T. E. et al., "Inhibition of Angiogenesis by Recombinant Human Platelet Factor-4 and Related Peptides", Science, Vol. 2, pp. 77-78 (1990)
	КМ	Makonkawkeyoon, S. et al., "Thalidomide Inhibits the Replication of Human Immunodeficiency virus type 1", <i>Proc. Natl. Acad. Sci.</i> , Vol. 90, pp. 5974-5978 (1993)
	KN	Marin-Padilla, M. et al. "Thalidomide Induced alterations in the Blastocyst and Placenta of the Armadillo, Dasypus Novemcinctus Mexicanus, Including a Choriocarcinoma", <i>The Am. J. of Pathol.</i> , Vol. 43, No. 6, pp. 999-1016 (1963)
	ко	Mascaro, et al., "Thalidomide in the Treatment of Recurrent, Necrotic, and Giant Mucocutaneous Aphthae and Aphthosis", Arch. Dermt., Vol. 115, pp. 636-637 (1979)
	KP	Matsubara, et al., "Inhibition of Human Endothelial Cell Proliferation by Gold Compounds", J. Clin. Invest., Vol. 79, pp. 1440-1446 (1987)
	KQ	Matsuyama, T. et al., "Cytokines and HIV Infection: is AIDS a Tumor Necrosis Factor Disease?", AIDS, Vol. 5, No. 12, pp. 1405-1417 (1991)
3	KR	Mauád, "Melhoras Clínicas Obtidas em Doentes Cancerosos Avançados com Tratamento Pela Talidomida Associada a Hormônios", <i>Anais Paulistas Medicina e Cirurgia</i> , pp. 15-39 (1963)
	KS	Maurice, et al., "The Effect of Thalidomide on Arachidonic Acid Metabolism in Human Polymorphonuclear Leukocytes and Platelets", Br. J. Dermatol., Vol. 115, No. 6, pp. 677-680 (1986)
0	ζT .	McCarthy, et al., "Thalidomide for the Therapy of Graft-versus-Host Disease Following Allogeneic Bone Marrow Transplantation", <i>Biomed. Pharmacother</i> , Vol. 43, No. 9, pp. 693-697 (1989)
EXAMINER	1	DATE CONSIDERED 6/23/0/
EXAMINEI conformance	R: Initia and not o	l if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in considered. Include copy of this form with next communication to applicant.

RECEIVED'

AIIG 0 3 2001

Under the Paper

PTO/SB/08A (08-00)
Approved for use through 10/31/2002 OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
5, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for Form 1449/A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary

Sheet | 12 of 17 |

The state of the s	which driess it contains a valid ONB control number	
Complete if Known		
Application Number	09/545,139	
Filing Date	April 7, 2000	
First Named Inventor	D'Amato et al.	
Group Art Unit	1614	
Examiner Name	J. Goldberg	
Attorney Docket Number	05213-0650 43170-219681	

U.S. PATENT DOCUMENTS				
OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, Etc.)				
· (-)	McKenna, et al., "Linear IgA Disease, Oral Ulceration and Crohn's Disease", Br. J. Dermatol, Vol. 127,			
4	LA	pp. 67-68 (1992)		
Q	LB	Meza, D. et al., "Managing the Gastrointestinal Complications of AIDS", <i>Drug Therapy</i> , Vol. 23, No. 11, pp. 74-83 (1993)		
9	LC	Miller, et al., "Zusammentreffen Einer Thalidomid-Induzierten Fehlbildung mit Einem Malignen Lymphom Hohen Malignitätsgrades", Monatsschr. Kinderheilkd., Vol. 128, pp. 27-29 (1980)		
2	LD	Miller, et al., "Treatment of Chronic Erythema Nodosum Leprosum with Cyclosporine A Produces Clinical and Immunohistologic Remission", Int. J. Lepr. Other Mycobact. Dis., Vol. 55, No. 3, pp. 441-449 (1987)		
2	LE	Misery, L. et al., "Remission of Langerhans Cell Histiocytosis with Thalidomide Treatment", Clinical and Experimental Dermatol., Vol. 18, No. 5, p. 487 (1993)		
2	LF	Miura, M. et al., "Potentiating Effect of Thalidomide on Methylcholanthrene Oncogenesis in Mice", Experieentia, Vol. 26, Fasc. 3, pp. 305-306 (1970)		
	LG	Miyachi, Y., "A Possible Mechanism of Action of Thalidomide on Rheumatoid Arthritis", Arthritis and Rheuma, Vol. 28, No. 7, p. 836 (1985)		
2	LH	Miyachi, et al., "Effects of Thalidomide on the Generation of Oxygen Intermediates by Zymosan-Stimulated Normal Polymorphonuclear Leukocytes", Arch. Dermatol. Res., Vol. 274, Nos. 3-4, pp. 363-367 (1982)		
	LI	Chem. Pharm. Bull., Vol. 16, pp. 2289-2292 (1968)		
9	LJ	Moncada, et al., "Thalidomide – Effect on T Cell Subsets as a Possible Mechanism of Action", Int. J. Lepr. Other Mycobact. Dis., Vol. 53, No. 2, pp. 201-205 (1985)		
	LK	Montrucchio, et al., "Tumor Necrosis Factor α-Induced Angiogenesis Depends on In Situ Platelet-Activating Factor Biosynthesis", J. Exp. Med., Vol. 180, pp. 377-382 (1994)		
	LL	Moulin, et al., "Treatment of Jessner-Kanof Disease with Thalidomide", Ann. Dermatol Venereol, Vol. 10, No. 8, pp. 611-614 (1983)		
	LM	Mshana, et al., "Thymus-Dependent Lymphocytes in Leprosy. II. Effect of Chemotherapy on T-Lymphocyte Subpopulations", J. Clin. Immunol., Vol. 2, No. 2, pp. 69-74 (1982)		
2	LN	Mückter, et al., "Thalidomide and Tumor", Antimicrobial Agents and Chemotherapy, pp. 531-538 (1965)		
2	LO	on the Presence of Serum", Toxicology Letters, Vol. 18, pp. 201-209 (1983)		
	LP	Munro, et al., "Pyoderma Gangrenosum Associated with Behcet's Syndrome-Response to Thalidomide", Clin. Exp. Dermatol., Vol. 13, No. 6, pp. 408-410 (1988)		
	LQ	Muthukkaruppan, Vr. et al., "Angiogenesis in the Mouse Cornea", Science, Vol. 205, No. 28, pp.1416-1418 (1979)		
R	Naafs, B. et al., "Thalidomide Therapy An Open Trial", Intl. J. of Dermatol., Vol. 24, No. 2, pp. 131-134 (1985)			
2	LS Naafs, B., "Bangkok Workshop on Leprosy Research. Treatment of Reactions and Nerve Damage. Int. J. Lepr. Other Mycobact. Dis., Vol. 64, No. 4, Suppl. S21-28 (1996)			
	Neubert, "Teratogenicity: Any Relationship to Careinogenicity?", Institute for Toxicology and LT Embryopharmacology, Free University of Berlin, Berlin, Federal Rep. Of Germany, pp. 169-178			
2	Nguyen, M. et al., "Elevated Levels of the Angiogenic Peptide Basic Fibroblast Growth Factor in Urine of Bladder Cancer Patients", J. of the Natl. Canc. Inst., Vol. 85, No. 3, pp. 241-242 (1993)			
\bigcirc	LV Reguyeri, M. et al., Elevated Levels of the Angiogenic Peptide Basic Fibroblast Growth Factor in Urine of Patients with a Wide Spectrum of Cancers", J. of the Natl. Canc. Inst., Vol. 86, No. 5, pp. 356-361 (1994) (Abstract only)			
EVANOR	Nicolas, J., et al., "Interferon Alfa Therapy in Severe Unresponsive Subacute Cutaneous Lupus Erythematosus", New Engl. J. Med., Vol. 321, No. 22, pp. 1550-1551 (1989)			
EXAMIN	///	DATE CONSIDERED 8/23/01		
conformar	nce and not	If reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in considered. Include copy of this form with next communication to applicant.		

AUG 0 1 2001 3

PTO/SB/08A (08-00)

Approved for use through 10/31/2002 OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE to persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for Form 1449/A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary

Sheet | 13 of 17 |

Under the Paperwork Reduction Act of 199

Complete if Known		
Application Number	09/545,139	
Filing Date	April 7, 2000	
First Named Inventor	D'Amato et al.	
Group Art Unit	1614	
Examiner Name	J. Goldberg	
Attorney Docket Number	05213-0650 43170-219681	

		U.S. PATENT DOCUMENTS
		OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, Etc.)
L	MA	Nicolau, et al., "Thalidomide: Treatment of Severe Recurrent Aphthous Stomatitis in Patients with AIDS", DICP, Vol. 24, No. 11, pp. 1054-1056 (1990)
9	МВ	Nielsen, et al., "Thalidomide Enhances Superoxide Anion Release from Human Polymorphonuclear and Leukocytes", Acta. Pathol. Microbiol. Immunol. Scand. [C], Vol. 94, No. 6, pp. 233-237 (1986)
9	MC	Obeso, J. et al., "Methods in Laboratory Investigation A Hemangioendothelioma-Derived Cell Line: Its Use as a Model for the Study of Endothelial Cell Biology", <i>Laboratory Investigation</i> , Vol. 63, No. 2, pp. 259-269
	MD	(1990)
2		Oikawa, T. et al., "Eponemycin, A Novel Antibiotic is a Highly Powerful Angiogenesis Inhibitor", Biochem. and Biophy. Res. Comm., Vol. 181, No. 3, pp. 1070-1077 (1991)
2	ME	Olson, et al., "Thalidomide (N-phthaloylglutamimide) in the Treatment of Advanced Cancer", Clin. Pharmacol. Therap., Vol. 6, No. 3, pp. 292-297 (1965)
5	MF	Orzalesi, M., ""Il Danno latrogeno in Neonatologica", Ped. Med. Chir., Vol. 14, pp. 105-112 (1992)
	MG	Ostraat, et al., "Thalidomide Prolongs Graft Survival in Rat Cardiac Transplants", Transplant Proc., Vol. 24, No. 6, pp. 2624-2625 (1992)
	МН	Otsuka, et al., "A New Potent Angiogenesis Inhibitor, FR-118487", J. of Microbiol. and Biotechno., Vol. 1, No. 3, pp. 163-168 (1991)
	MI	Paller, et al., "Proceedings of the Concurrent Sessions", Pediatr. Dermatol, Vol. 9, No. 4, pp. 397-406 (1992)
	MJ	Passaniti, A. et al., "Methods in Laboratory Investigation A Simple, Quantitative Method for Assessing Angiogenesis and Antiangiogenic Agents Using Reconstituted Basement Membrane, Heparin, and Fibroblast Growth Factor", <i>Laboratory Investigation</i> , Vol. 67, No. 4, pp. 519-528 (1992)
	MK	Patey, O. et al., "Thalidomide et colite ulcereuse dans la maladie de Behcet", Gastroenterol. Clin. Biol., Vol. 13, pp. 104-110 (1989)
	ML	Pearson, et al., "Treatment of Moderately Severe Erythema Nodosum Leprosum with Thalidomide – A Double-Blind Controlled Trial", Lepr. Rev., Vol. 40, No. 2, pp. 111-116 (1969)
	MM	Peyron, et al., "The Pharmacological Basis for the Treatment of Photodermatoses", Biochimie, Vol. 68
	MN	No. 0, pp. 899-904.
\mathcal{Q}		Pfordte, "Über die Beeinflussung des Serumproperdinsystems Durch Verschiedene Arzneimittel", Pharmazie, Vol. 26, pp. 301-302 (1971)
	МО	Phillips, et al., "Tumor Necrosis Factor Alpha (rhTNF) Fails to Stimulate Angiogenesis in the Rabbit Cornea", Anatomical Rec., Vol. 245, pp. 53-56 (1996)
9	MP	Powell, R.J. et al., "Investigation and Treatment of Orogenital Ulceration; studies on a Possible Mode of Action of Thalidomide", <i>Brit. J. of Dermatol.</i> , Vol. 113, Supp. 28, pp. 141-144 (1985)
Q	MQ	Prigent, F. et al., "Sarcoidose cutanee Traitement par la Thalidomide", <i>La Presse Medicale</i> , Vol. 12, No. 47, p. 3007 (1983)
9	MR	Proenca, N.G., "Thalidomide: An Eclectic Medication in Dermatology", Rev. Paul. Med., Vol. 107, No. 1, pp. 41-46. (Abstract Only)
9	MS	Radeff, et al., "Recurrent Aphthous Ulcer in Patient Infected with Human Immunodeficiency Virus: Successful Treatment with Thalidomide", J. Am. Acad. Dermatol, Vol. 23, No. 3, Pt. 1, pp. 523-525 (1990)
<u>Q</u>	MT	Rainsford, K.D., "Disease-Modifying Antirheumatic and Immunoregulatory Agents" Railliere's Clinical
D	MU	Rheumatology, Vol. 4, No. 3, pp. 405-432 (1990) Rajan, et al., "A Clinical Study of Thalidomide Comparing Pre-Treatment and Post-Treatment Reactional
	MV	Episodes and Corticosteroid Requirements", <i>Lepr. India</i> , Vol. 55, No. 1, 111-116 (1983) Randall, T., "Investigational New Drug (US) 'Orphan' Trials now Use Thalidomide from two Sources",
	272 7	JAMA, Vol. 263, No. 11, p. 1474 (1990)
Dy.		Randall, T., "Thalidomide's Back in the News, but in more Favorable Circumstances", <i>JAMA</i> , Vol. 263, No. 11, pp. 1467-1468 (1990)
91	MW	Revuz, J., "Actualite Du Thalidomide", Ann. Dermatol. Venereol., Vol. 117, pp. 313-321 (1990)
XAMINE	R	DATE CONSIDERED 8/23/0/
EXAMIN	ER: Init	ial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in
conformanc	re and no	to considered. Include converte the form with not communication to entire the converted to the form with not converted to th

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

RECEIVED

PTO/SB/08A (08-00)
Approved for use through 10/31/2002 OMB 0651-0031
U.S. Patent and Trademark Office: U.S DEPARTMENT OF COMMERCE
ons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for Form 1449/A/PTO

Under the Paperwork Redi

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary

Sheet | 14 of 17 |

Complete if Known
09/545,139
April 7, 2000
D'Amato et al.
1614
J. Goldberg
05213-0650 43170-219681

in Cyst Fluid of Enlarging and Recurrent Thyroid Nodules", Journal of Clinical Endocrinology and Metabolism, Vol. 82, No. 6, pp. 1968-1972 (1997) NO Schweigerer, L. et al., "Angiogenesis and Angiogenesis Inhibitors in Paediatric Diseases", European J. of Pediatric, Vol. 151, pp. 472-476 (1992) NP Shannon, et al., "Inhibition of de Novo IgM Antibody Synthesis by Thalidomide as a Relevant Mechanism of Action in Leprosy", Scand. J. Immunol., Vol. 13, No. 6, pp. 553-562 (1981) NO Shannon, et al., "Thalidomide's Effectiveness in Erythema Nodosum Leprosum is Associated with a Decrease in CD4+ Cells in the Peripheral Blood", Lepr. Rev., Vol. 63, No. 1, pp. 5-11 (1992) NR Shealy, Y.F. et al., "D-and L-Thalidomide", Chemistry and Industry, pp. 1030-1031 (1965) Sheehan, N.J., "Thalidomide Neurotoxicity and Rheumatoid Arthritis", Arthritis and Rheuma., Vol. 29, No. 10, p. 1296 (1986) NS No. 10, p. 1296 (1986) Sherman, M. et al., "Thalidomide: A Twenty-Five Year Perspective", Food Drug Cosmetic Law J., Vol. 41, pp. 458-466 (1986) Sheskin, J., "The Treatment of Lepra Reaction in Lepromatous Leprosy. Fifteen Years' Experience with Thalidomide", Int. J. Dermatol., Vol. 19, No. 6, pp. 318-322 (1980) Sheskin, et al., "In Vivo Measurements of Iron, Copper and Zinc in the Skin of Prurigo Nodularis Patients Treated with Thalidomide", Dermatologica, Vol. 162, No. 2, pp. 86-90 (1981) Shi, G. et al., "Kringle Domains and Plasmin Denaturation", Biochem. and Biophy. Res. Comm., Vol. 178, No. 1, pp. 360-368 (1991)	U.S. PATENT DOCUMENTS		
NA Revuz, J. et al., "Crossover Sudy of Thalidomide vs. Placebo in Severe Recurrent Aphthous Stomatitis", Arch Dermatol, Vol. 126, pp. 923-927 (1990)			
Arch. Dermatol., Vol. 126, pp. 923-927 (1990) NB Rhoton, A. J., P86 (1993) NC Robelns, K. C., The Plasming explaining Enzyme System.", Albiniolysis, pp. 740-357-(27) ND Roe, F.J.C., "Pathology Thaildomide and Neoplasia", Nature, Vol. 200, pp. 1016-1017 (1983) NE Roe, et al., "Tumour-incidence in Progeny of Thaildomide-Treated Mice", British J. Cancer, pp. 331-333, (1965) NF Ruggenini, et al., "Pyoderma Gangrenosum Associated with Beheet's Disease: Treatment with Thaildomide", J. Am. Acad Dermatol, Vol. 23, No. 5, Pt. 1, pp. 941-944 (1990) Ryan, et al., "Thaildomide to Treat Esophageal Ulcer in AIDS (6)", New Engl. J. Med., Vol. 327, No. 3, pp. 208-209 (1992) Salven, P. et al., "Serum Vascular Endothelial Growth Factor is Often Elevated in Disseminated Cancer", Clinical Cancer Research, Vol. 3, pp. 647-651 (1997) Sampaio, et al., "Thaildomide to Treat Esophageal Ulcer in AIDS (6)", New Engl. J. Med., Vol. 327, No. 3, pp. 208-209 (1992) Salven, P. et al., "Serum Vascular Endothelial Growth Factor is Often Elevated in Disseminated Cancer", Clinical Cancer Research, Vol. 3, pp. 647-651 (1997) Sampaio, et al., "Thaildomide Sciectively Inhibits Tumor Necrosis Factor Alpha Production by Stimulated Human Monocytes", J. Exp. Med., Vol. 173, No. 6, pp. 1729-1737 (1992) NN Santis, H.R., "Aphilmous Stomatitis and its Management", Curr. Opin. Dent., Vol. 1, No. 6, pp. 763-768 (1991) (Abstract Only) NN Salo, K. et al., "Increased Concentration of Vascular Endothelial Growth Factor Vascular Permeability Factor in Cyst Fluid of Enlarging and Recurrent Thyroid Nodules", Journal of Clinical Endocrinology and Metabolism, Vol. 82, No. 6, pp. 1968-1972 (1992) NN Salo, K. et al., "United Tumor Necrosis Factor Production by Mononuclear Cells from Lepromatous Leprosy Patients and from Patients with Erythema Nodosumleprosum", Clin. Immunol. Immunopathol., Vol. 67, No. 31, pp. 199-203 (1996) NN Salo, K. et al., "United Tumor Necrosis Factor Production by Mononuclear Cells from Lepropean J. of Pedicaric, Vol. 151,	1	NA	
No. 3, p. 956 (1993) NC Robbins, K. C., "The Plasminogers Plasmin Enzyme System", Fibrinochysis, pp. 340-357(27) 10. J. C. Robbins, K. C., "The Plasminogers Plasmin Enzyme System", Fibrinochysis, pp. 340-357(27) 10. J. C. Robbins, K. C., "The Plasminogers Plasmin Enzyme System", Nature, Vol. 200, pp. 1016-1017 (1963) NE Rustin, et al., "Tallodomide or Tumori Sperimental", Concro, Vol. 20, pp. 39-55 (1967) NF Rustin, et al., "Tallodomide or Tumori Sperimental", Concro, Vol. 20, pp. 39-55 (1967) Rustin, et al., "Tallodomide or Tumori Sperimental", Concro, Vol. 20, pp. 39-55 (1967) Rustin, et al., "Tallodomide or Tumori Sperimental", Concro, Vol. 20, pp. 39-55 (1967) Rustin, et al., "Tallodomide or Tumori Sperimental", Concro, Vol. 20, pp. 39-55 (1967) Rustin, et al., "Tallodomide or Tumori Sperimental", Concro, Vol. 20, pp. 39-55 (1967) Rustin, et al., "Tallodomide or Tumori Sperimental", Concro, Vol. 20, pp. 39-55 (1967) Ryan, et al., "Tallodomide or Tumori Sperimental", Concro, Vol. 60, pp. 1729-1737 (1992) Salven, P. et al., "Serum Vascular Endothelial Growth Factor Is Often Elevated in Disseminated Cancer", Clinical Concer Research, Vol. 3, pp. 647-651 (1997) Sampajo, et al., "Thallodomide Selectively Inhibits Timori Necrosis Factor Apha Production by Stimulated Human Monocytes", J. Exp. Med., Vol. 173, No. 3, pp. 699-703 (1991) Santis, H.R., "Aphithous Stomatius and its Management", Curr. Opin. Denit, Vol. 1, No. 6, pp. 763-768 (1991) (Abstract Only) Santos, et al., "In Vitro Tumor Necrosis Factor Production by Mononuclear Cells from Lepromatous Leprosy Patients and from Patients with Erythema Nodosumleprosum", Clin. Immunol, Vol. 67, No. 31, pp. 199-203 (1993) NN Sato, S. et al., "Apidense of Selectively Inhibits and its Management", Curr. Opin. Denit, Vol. 1, No. 6, pp. 1968-1972 (1997) NO Schweigerer, L. et al., "Angiogenesis and Angiogenesis Inhibitors in Paediatric Diseases", European J. of Pediatric, Vol. 151, pp. 472-476 (1992) NN Shanon, et al., "Thallodomide Selectively Inhibits in P			Arch. Dermatol, Vol. 126, pp. 923-927 (1990)
Roe, F.J.C., "Pathology Thalidomide and Neoplasia", <i>Nature</i> , Vol. 200, pp. 1016-1017 (1963) NE (1965) NE (1965) NE (1965) NE Rustin, et al., "Talidomide e Tumori Sperimental", <i>Camero</i> , Vol. 20, pp. 39-55 (1967) Rustin, et al., "Pyoderma Gangrenosum Associated with Behcet's Disease: Treatment with Thalidomide", <i>J. Am. Acad Dermatolo</i> , Vol. 23, No. 5, Pt. 1, pp. 941-944 (1990) NG Rustin, et al., "Serum Vascular Endothelial Growth Factor Is Oliten Elevated in Disseminated Cancer", Pp. 208-209 (1992) NH Ryan, et al., "Serum Vascular Endothelial Growth Factor Is Oliten Elevated in Disseminated Cancer", <i>Clinical Cameer Research</i> , Vol. 3, pp. 647-651 (1997) Salven, P. et al., "Serum Vascular Endothelial Growth Factor Is Oliten Elevated in Disseminated Cancer", <i>Clinical Cameer Research</i> , Vol. 3, pp. 647-651 (1997) Sampano, et al., "Finalidomide Selectively Inhibits Tumor Necrosis Factor Alpha Production by Stimulated Human Monocytes", <i>J. Exp. Med.</i> , Vol. 173, No. 3, pp. 699-703 (1991) Sanis, H.R. "Aphthous Stomatics and its Management", <i>Curr. Opin. Dent.</i> , Vol. 1, No. 6, pp. 763-768 (1991) (Abstract Only) Sanis, H.R. "Aphthous Stomatics and its Management", <i>Curr. Opin. Dent.</i> , Vol. 1, No. 6, pp. 763-768 (1991) (Abstract Only) NN Salos, K. et al., "Intercased Concentration of Vascular Endothelial Growth Factor/Vascular Permeability Factor in Cyst Fluid of Enlarging and Recurrent Thyroid Nodules", <i>Journal of Clinical Endocrinology and Metabolism</i> , Vol. 82, No. 6, pp. 1968-1972 (1997) NO Schweigerer, L. et al., "Angiogenesis and Angiogenesis Inhibitors in Paediatric Diseases", <i>European J. of Pediatric</i> , Vol. 151, pp. 472-476 (1992) NR Shannon, et al., "Thalidomide's Effectiveness in Erythema Nodosum Leprosum is Associated with a Decrease in CD4+ Cells in the Peripheral Blood", <i>Lepr. Rev.</i> , Vol. 63, No. 1, pp. 511 (1992) NR Shannon, et al., "Thalidomide's Effectiveness in Erythema Nodosum Leprosum is Associated with Thalidomide's Jumunol., Vol. 1, No. 6, pp. 318-322 (1980) NN Sheshan, N.J., "Thal	2	NB	No. 3, p. 956 (1993)
Roe, et al., "Tumour-incidence in Progeny of Thalidomide-Treated Mice", British J. Cancer, pp. 331-333, (1965) NF Ruggenini, et al., "Talidomide e Tumori Sperimentali", Cancro, Vol. 20, pp. 39-55 (1967) Rustin, et al., "Pyoderma Gangrenosum Associated with Behcet's Disease: Treatment with Thalidomide", J. Am. Acad. Dermatol, Vol. 23, No. 5, Pt. 1, pp. 941-944 (1990) Ryan, et al., "Thalidomide to Treat Esophageal Ulcer in AIDS (6)", New Engl. J. Med., Vol. 327, No. 3, pp. 208-209 (1992) Salven, P. et al., "Serum Vascular Endothelial Growth Factor Is Often Elevated in Disseminated Cancer", Clinical Cancer Research, Vol. 3, pp. 647-651 (1997) Sampaio, et al., "Thalidomide Selectively Inhibits Tumor Necrosis Factor Alpha Production by Stimulated Human Monocytes", J. Exp. Med., Vol. 173, No. 6, pp. 1729-1737 (1992) Santis, H.R., "Aphthous Stomatitis and its Management", Curr. Opin. Dent., Vol. 1, No. 6, pp. 763-768 (1991) (Abstract Only) Santos, et al., "In Vitro Tumor Necrosis Factor Production by Mononuclear Cells from Lepromatous Leprosy Patients and from Patients with Erythema Nodosumeprosum", Clin. Immunol. Immunopathol., Vol. 67, No. 31, pp. 199-203 (1993) NN Sato, K. et al., "Increased Concentration of Vascular Endothelial Growth Factor/Vascular Permeability Factor in Cyst Fluid of Enlarging and Recurrent Thyroid Nodules", Journal of Clinical Endocrinology and Metabolism, Vol. 82, No. 6, pp. 1968-1972 (1997) NO Schweigerer, L. et al., "Angiogenesis and Angiogenesis Inhibitors in Paediatric Diseases", European J. of Pediatric, Vol. 151, pp. 472-476 (1992) Shannon, et al., "Inhibition of de Novo IgM Antibody Synthesis by Thalidomide as a Relevant Mechanism of Action in Leprosy", Scand. J. Immunol., Vol. 13, No. 6, pp. 535-562 (1981) NR Sheahy, Y.F. et al., "Panal CInalidomide", Ericetivenes in Erythema Nodosum Leprosum is Associated with a Decrease in CD4+ Cells in the Peripheral Blood", Lepr. Rev., Vol. 63, No. 1, pp. 511 (1992) NR Sheaha, N.J., "Thalidomide", Vol. 19, No. 6, pp. 318-322 (1980)			Robbins, K. C., "The Plasminogen-Plasmin Enzyme System", Fibrinolysis, pp. 340-357 (??) no late
NE (1965) NF Ruggenini, et al., "Talidomide e Tumori Sperimeniali", Cancro, Vol. 20, pp. 39-55 (1967) Rustin, et al., "Pyoderma Gangrenosum Associated with Behcet's Disease: Treatment with Thalidomide", J. Am. Acad. Dermatol, Vol. 23, No. 5, Pt. 1, pp. 941-944 (1990) Ryan, et al., "Thalidomide to Treat Esophageal Ulcer in AIDS (6)", New Engl. J. Med., Vol. 327, No. 3, pp. 208-209 (1992) Salven, P. et al., "Serum Vascular Endothelial Growth Factor Is Often Elevated in Disseminated Cancer", Clinical Cancer Research, Vol. 3, pp. 647-651 (1997) Sampaio, et al., "Frolonged Treatment with Recombinant Interferon Gamma Induces Erythema Nodosum Lepromatous Leprosy Patients", J. Exp. Med., Vol. 175, No. 6, pp. 1729-1737 (1992) Sampaio, et al., "Thalidomide Selectively Inhibits Tumor Necrosis Factor Alpha Production by Stimulated Human Monocytes", J. Exp. Med., Vol. 173, No. 3, pp. 699-703 (1991) Santis, H.R., "Aphithous Stomatitis and its Management", Curr. Opin. Dent., Vol. 1, No. 6, pp. 763-768 (1991) (Abstract Only) Santos, et al., "In Vitro Tumor Necrosis Factor Production by Mononuclear Cells from Lepromatous Leprosy Patients and from Patients with Erythema Nodosumleprosum", Clin. Immunopathol., Vol. 67, No. 3, pp. 199-203 (1993) NO Schweigerer, L. et al., "Angiogenesis and Angiogenesis Inhibitors in Paediatric Diseases", European J. of Pediatric, Vol. 15, pp. 472-476 (1992) NO Schweigerer, L. et al., "Angiogenesis and Angiogenesis Inhibitors in Paediatric Diseases", European J. of Pediatric, Vol. 15, pp. 472-476 (1992) NO Shannon, et al., "Inhibition of de Novo [gM Antibody Synthesis by Thalidomide as a Relevant Mechanism of Action in Leprosy", Scand. J. Immunol., Vol. 13, No. 6, pp. 553-562 (1981) NO Shannon, et al., "Thalidomide's Effectiveness in Erythema Nodosum Leprosum is Associated with a Decrease in CD4+ Cells in the Peripheral Blood", Lepr. Rev., Vol. 63, No. 1, pp. 5-11 (1992) NR Sheahan, N.J., "Thalidomide's Effectiveness in Erythema Nodosum Leprosum is Associated with a Decrease in CD4+ Cel	2	ND	
NH pp. 208-209 (1992) NI pp. 208-209 (1992) NI pp. 208-209 (1992) NI Salven, P. et al., "Serum Vascular Endothelial Growth Factor Is Often Elevated in Disseminated Cancer", Clinical Cancer Research, Vol. 3, pp. 647-651 (1997) Sampaio, et al., "Prolonged Treatment with Recombinant Interferon Gamma Induces Erythema Nodosum Lepromatous Leprosy Patients", J. Exp. Med., Vol. 175, No. 6, pp. 1729-1737 (1992) Sampaio, et al., "Thalidomide Selectively Inhibits Tumor Necrosis Factor Alpha Production by Stimulated Human Monocytes", J. Exp. Med., Vol. 173, No. 3, pp. 699-703 (1991) Santis, H.R., "Aphthous Stomatitis and its Management", Curr. Opin. Dent, Vol. 1, No. 6, pp. 763-768 (1991) (Abstract Only) Santis, et al., "In Vitro Tumor Necrosis Factor Production by Mononuclear Cells from Lepromatous Leprosy Patients and from Patients with Erythema Nodosumleprosum", Clin. Immunol. Immunopathol., Vol. 67, No. 31, pp. 199-203 (1993) Sato, K. et al., "Increased Concentration of Vascular Endothelial Growth Factor/Vascular Permeability Factor in Cyst Fluid of Enlarging and Recurrent Thyroid Nodules", Journal of Clinical Endocrinology and Metabolism, Vol. 82, No. 6, pp. 1968-1972 (1997) NO Schweigerer, L. et al., "Angiogenesis and Angiogenesis Inhibitors in Paediatric Diseases", European J. of Pediatric, Vol. 151, pp. 472-476 (1992) NP Shanon, et al., "Inhibition of de Novo IgM Antibody Synthesis by Thalidomide as a Relevant Mechanism of Action in Leprosy", Scand. J. Immunol., Vol. 13, No. 6, pp. 553-562 (1981) NR Sheahan, N.J., "Thalidomide's Effectiveness in Erythema Nodosum Leprosum is Associated with a Decrease in CD4+ Cells in the Peripheral Blood", Lepr. Rev., Vol. 63, No. 1, pp. 5-11 (1992) NR Sheahan, N.J., "Thalidomide's Effectiveness in Erythema Nodosum Leprosum is Associated with a Decrease in CD4+ Cells in the Peripheral Blood", Lepr. Rev., Vol. 63, No. 1, pp. 5-10 (1986) NS Sheehan, N.J., "Thalidomide Neurotoxicity and Rheumatold Arthritis", Arthritis and Rheuma., Vol. 29, No. 10, p. 268-66 (1986) NS Sh	0		(1965)
NH pp. 208-209 (1992) NI pp. 208-209 (1992) NI pp. 208-209 (1992) NI Salven, P. et al., "Serum Vascular Endothelial Growth Factor Is Often Elevated in Disseminated Cancer", Clinical Cancer Research, Vol. 3, pp. 647-651 (1997) Sampaio, et al., "Prolonged Treatment with Recombinant Interferon Gamma Induces Erythema Nodosum Lepromatous Leprosy Patients", J. Exp. Med., Vol. 175, No. 6, pp. 1729-1737 (1992) Sampaio, et al., "Thalidomide Selectively Inhibits Tumor Necrosis Factor Alpha Production by Stimulated Human Monocytes", J. Exp. Med., Vol. 173, No. 3, pp. 699-703 (1991) Santis, H.R., "Aphthous Stomatitis and its Management", Curr. Opin. Dent, Vol. 1, No. 6, pp. 763-768 (1991) (Abstract Only) Santis, et al., "In Vitro Tumor Necrosis Factor Production by Mononuclear Cells from Lepromatous Leprosy Patients and from Patients with Erythema Nodosumleprosum", Clin. Immunol. Immunopathol., Vol. 67, No. 31, pp. 199-203 (1993) Sato, K. et al., "Increased Concentration of Vascular Endothelial Growth Factor/Vascular Permeability Factor in Cyst Fluid of Enlarging and Recurrent Thyroid Nodules", Journal of Clinical Endocrinology and Metabolism, Vol. 82, No. 6, pp. 1968-1972 (1997) NO Schweigerer, L. et al., "Angiogenesis and Angiogenesis Inhibitors in Paediatric Diseases", European J. of Pediatric, Vol. 151, pp. 472-476 (1992) NP Shanon, et al., "Inhibition of de Novo IgM Antibody Synthesis by Thalidomide as a Relevant Mechanism of Action in Leprosy", Scand. J. Immunol., Vol. 13, No. 6, pp. 553-562 (1981) NR Sheahan, N.J., "Thalidomide's Effectiveness in Erythema Nodosum Leprosum is Associated with a Decrease in CD4+ Cells in the Peripheral Blood", Lepr. Rev., Vol. 63, No. 1, pp. 5-11 (1992) NR Sheahan, N.J., "Thalidomide's Effectiveness in Erythema Nodosum Leprosum is Associated with a Decrease in CD4+ Cells in the Peripheral Blood", Lepr. Rev., Vol. 63, No. 1, pp. 5-10 (1986) NS Sheehan, N.J., "Thalidomide Neurotoxicity and Rheumatold Arthritis", Arthritis and Rheuma., Vol. 29, No. 10, p. 268-66 (1986) NS Sh	2	NF	
NH pp. 208-209 (1992) Salven, P. et al., "Serum Vascular Endothelial Growth Factor Is Often Elevated in Disseminated Cancer", Clinical Cancer Research, Vol. 3, pp. 647-651 (1997) NJ Sampaio, et al., "Prolonged Treatment with Recombinant Interferon Gamma Induces Erythema Nodosum Lepromatous Leprosy Patients", J. Exp. Med., Vol. 175, No. 6, pp. 1729-1737 (1992) NK Human Monocytes", J. Exp. Med., Vol. 173, No. 3, pp. 699-703 (1992) NK Human Monocytes", J. Exp. Med., Vol. 173, No. 3, pp. 699-703 (1994) Santis, H.R., "Aphthous Stomatitis and its Management", Curr. Opin. Dent, Vol. 1, No. 6, pp. 763-768 (1991) (Abstract Only) Santis, H.R., "Aphthous Stomatitis and its Management", Curr. Opin. Dent, Vol. 1, No. 6, pp. 763-768 (1991) (Abstract Only) Santis, H.R., "Aphthous Stomatitis and its Management", Curr. Opin. Dent, Vol. 1, No. 6, pp. 763-768 (1991) (Abstract Only) Santis, E., in Vitro Tumor Necrosis Factor Production by Mononuclear Cells from Lepromatous Leprosy Patients and from Patients with Erythema Nodosumleprosum", Clin. Immunopathol., Vol. 67, No. 3, pp. 199-203 (1993) Sato, K. et al., "Increased Concentration of Vascular Endothelial Growth Factor/Vascular Permeability Factor in Cyst Fluid of Enlarging and Recurrent Thyroid Nodules", Journal of Clinical Endocrinology and Metabolism, Vol. 82, No. 6, pp. 1968-1972 (1997) NO Schweigerer, L. et al., "Angiogenesis and Angiogenesis Inhibitors in Paediatric Diseases", European J. of Pediatric, Vol. 151, pp. 472-476 (1992) NP Shannon, et al., "Thalidomide's Effectiveness in Erythema Nodosum Leprosum is Associated with a Decrease in CD4+ Cells in the Peripheral Blood", Lepr. Rev., Vol. 63, No. 1, pp. 5-11 (1992) NS Shannon, et al., "Thalidomide's Effectiveness in Erythema Nodosum Leprosum is Associated with a Decrease in CD4+ Cells in the Peripheral Blood", Lepr. Rev., Vol. 63, No. 1, pp. 5-11 (1992) NS Shehan, NJ., "Thalidomide Neurotoxicity and Rheumatoid Arthritis", Arthritis and Rheuma., Vol. 29, No. 10, p. 126-6 (1986) NS Shehan, M. et al., "Thalidomide Neurot	2	NG	J. Am. Acad. Dermatol, Vol. 23, No. 5, Pt. 1, pp. 941-944 (1990)
Clinical Cancer Research, Vol. 3, pp. 647-651 (1997) Sampaio, et al., "Prolonged Treatment with Recombinant Interferon Gamma Induces Erythema Nodosum Lepromatous Leprosy Patients", J. Exp. Med., Vol. 175, No. 6, pp. 1729-1737 (1992) Sampaio, et al., "Inalidomide Selectively Inhibits Tumor Necrosis Factor Alpha Production by Stimulated Human Monocytes", J. Exp. Med., Vol. 173, No. 3, pp. 699-703 (1991) Santis, H.R., "Aphthous Stomatitis and its Management", Curr. Opin. Dent., Vol. 1, No. 6, pp. 763-768 (1991) (Abstract Only) Santos, et al., "In Vitro Tumor Necrosis Factor Production by Mononuclear Cells from Lepromatous Leprosy Patients and from Patients with Erythema Nodosumleprosum", Clin. Immunol. Immunopathol., Vol. 67, No. 3, pp. 199-203 (1993) No. 6, pp. 1968-1972 (1997) Sato, K. et al., "Increased Concentration of Vascular Endothelial Growth Factor/Vascular Permeability Factor in Cyst Fluid of Enlarging and Recurrent Thyroid Nodules", Journal of Clinical Endocrinology and Metabolism, Vol. 82, No. 6, pp. 1968-1972 (1997) No. 6, pp. 504-86, pp. 1968-1972 (1997) Schweigerer, L. et al., "Angiogenesis and Angiogenesis Inhibitors in Paediatric Diseases", European J. of Pediatric, Vol. 151, pp. 472-476 (1992) No. 6, pp. 535-562 (1981) Shannon, et al., "Inhibition of de Novo IgM Antibody Synthesis by Thalidomide as a Relevant Mechanism of Action in Leprosy", Scand. J. Immunol., Vol. 13, No. 6, pp. 553-562 (1981) Shannon, et al., "Thalidomide's Effectiveness in Erythema Nodosum Leprosum is Associated with a Decrease in CD4+ Cells in the Peripheral Blood", Lepr. Rev., Vol. 63, No. 1, pp. 511 (1992) Sheehan, N.J., "Inalidomide's Effectiveness in Erythema Nodosum Leprosum is Associated with a Decrease in CD4+ Cells in the Peripheral Blood", Lepr. Rev., Vol. 63, No. 1, pp. 510 (1992) Sheehan, N.J., "Inalidomide's Effectiveness in Erythema Nodosum Leprosum is Associated with a Decrease in CD4+ Cells in the Peripheral Blood", Lepr. Rev., Vol. 63, No. 1, pp. 510 (1992) Sheehan, N.J., "Inalid	2	NH	
NK Human Monocytes", J. Exp. Med., Vol. 173, No. 3, pp. 699-703 (1991) Santis, H.R., "Aphthous Stomatitis and its Management", Curr. Opin. Dent, Vol. 1, No. 6, pp. 763-768 (1991) (Abstract Only) Santis, H.R., "Aphthous Stomatitis and its Management", Curr. Opin. Dent, Vol. 1, No. 6, pp. 763-768 (1991) (Abstract Only) Santos, et al., "In Vitro Tumor Necrosis Factor Production by Mononuclear Cells from Lepromatous Leprosy Patients and from Patients with Erythema Nodosumleprosum", Clin. Immunol. Immunopathol., Vol. 67, No. 31, pp. 199-203 (1993) NN Sato, K. et al., "Increased Concentration of Vascular Endothelial Growth Factor/Vascular Permeability Factor in Cyst Fluid of Enlarging and Recurrent Thyroid Nodules", Journal of Clinical Endocrinology and Metabolism, Vol. 82, No. 6, pp. 1968-1972 (1997) NO Schweigerer, L. et al., "Angiogenesis and Angiogenesis Inhibitors in Paediatric Diseases", European J. of Pediatric, Vol. 151, pp. 472-476 (1992) NO Shannon, et al., "Inhibition of de Novo IgM Antibody Synthesis by Thalidomide as a Relevant Mechanism of Action in Leprosy", Scand. J. Immunol., Vol. 13, No. 6, pp. 553-562 (1981) NO Shannon, et al., "Thalidomide's Effectiveness in Erythema Nodosum Leprosum is Associated with a Decrease in CD4+ Cells in the Peripheral Blood", Lepr. Rev., Vol. 63, No. 1, pp. 5-11 (1992) NR Shealy, Y.F. et al., "D-and L-Thalidomide", Chemistry and Industry, pp. 1030-1031 (1965) NS Sheehan, N.J., "Thalidomide Neurotoxicity and Rheumatoid Arthritis", Arthritis and Rheuma., Vol. 29, No. 10, p. 1296 (1986) NS Sheshin, J., "Thalidomide", Dermatol, Vol. 19, No. 6, pp. 318-322 (1980) NS Sheshin, J., "The Treatment of Lepra Reaction in Lepromatous Leprosy. Fifteen Years' Experience with Thalidomide", Int. J. Dermatol, Vol. 19, No. 6, pp. 318-322 (1980) Sheskin, et al., "In Vivo Measurements of Iron, Copper and Zinc in the Skin of Prurigo Nodularis Patients Treated with Thalidomide", Dermatologica, Vol. 162, No. 2, pp. 86-90 (1981) Sheskin, et al., "The Metabolism of Thalidomide: The F	2	NI	
NK Human Monocytes", J. Exp. Med., Vol. 173, No. 3, pp. 699-703 (1991) Santis, H.R., "Aphthous Stomatitis and its Management", Curr. Opin. Dent, Vol. 1, No. 6, pp. 763-768 (1991) (Abstract Only) Santis, H.R., "Aphthous Stomatitis and its Management", Curr. Opin. Dent, Vol. 1, No. 6, pp. 763-768 (1991) (Abstract Only) Santos, et al., "In Vitro Tumor Necrosis Factor Production by Mononuclear Cells from Lepromatous Leprosy Patients and from Patients with Erythema Nodosumleprosum", Clin. Immunol. Immunopathol., Vol. 67, No. 31, pp. 199-203 (1993) NN Sato, K. et al., "Increased Concentration of Vascular Endothelial Growth Factor/Vascular Permeability Factor in Cyst Fluid of Enlarging and Recurrent Thyroid Nodules", Journal of Clinical Endocrinology and Metabolism, Vol. 82, No. 6, pp. 1968-1972 (1997) NO Schweigerer, L. et al., "Angiogenesis and Angiogenesis Inhibitors in Paediatric Diseases", European J. of Pediatric, Vol. 151, pp. 472-476 (1992) NO Shannon, et al., "Inhibition of de Novo IgM Antibody Synthesis by Thalidomide as a Relevant Mechanism of Action in Leprosy", Scand. J. Immunol., Vol. 13, No. 6, pp. 553-562 (1981) NO Shannon, et al., "Thalidomide's Effectiveness in Erythema Nodosum Leprosum is Associated with a Decrease in CD4+ Cells in the Peripheral Blood", Lepr. Rev., Vol. 63, No. 1, pp. 5-11 (1992) NR Shealy, Y.F. et al., "D-and L-Thalidomide", Chemistry and Industry, pp. 1030-1031 (1965) NS Sheehan, N.J., "Thalidomide Neurotoxicity and Rheumatoid Arthritis", Arthritis and Rheuma., Vol. 29, No. 10, p. 1296 (1986) NS Sheshin, J., "Thalidomide", Dermatol, Vol. 19, No. 6, pp. 318-322 (1980) NS Sheshin, J., "The Treatment of Lepra Reaction in Lepromatous Leprosy. Fifteen Years' Experience with Thalidomide", Int. J. Dermatol, Vol. 19, No. 6, pp. 318-322 (1980) Sheskin, et al., "In Vivo Measurements of Iron, Copper and Zinc in the Skin of Prurigo Nodularis Patients Treated with Thalidomide", Dermatologica, Vol. 162, No. 2, pp. 86-90 (1981) Sheskin, et al., "The Metabolism of Thalidomide: The F	9	NJ	Sampaio, et al., "Prolonged Treatment with Recombinant Interferon Gamma Induces Erythema Nodosum Lepromatous Leprosy Patients", <i>J. Exp. Med.</i> , Vol. 175, No. 6, pp. 1729-1737 (1992)
Santos, et al., "In Vitro Tumor Necrosis Factor Production by Mononuclear Cells from Leprosy Patients and from Patients with Erythema Nodosumleprosum", Clin. Immunol. Immunopathol., Vol. 67, No. 3 l, pp. 199-203 (1993) NN Sato, K. et al., "Increased Concentration of Vascular Endothelial Growth Factor/Vascular Permeability Factor in Cyst Fluid of Enlarging and Recurrent Thyroid Nodules", Journal of Clinical Endocrinology and Metabolism, Vol. 82, No. 6, pp. 1968-1972 (1997) NO Schweigerer, L. et al., "Angiogenesis and Angiogenesis Inhibitors in Paediatric Diseases", European J. of Pediatric, Vol. 151, pp. 472-476 (1992) NP Shannon, et al., "Inhibition of de Novo IgM Antibody Synthesis by Thalidomide as a Relevant Mechanism of Action in Leprosy", Scand. J. Immunol., Vol. 13, No. 6, pp. 553-562 (1981) Shannon, et al., "Inhibition of de Novo IgM Antibody Synthesis by Thalidomide as a Relevant Mechanism of Action in Leprosy", Scand. J. Immunol., Vol. 13, No. 6, pp. 553-562 (1981) NR Shannon, et al., "Phalidomide Effectiveness in Erythema Nodosum Leprosum is Associated with a Decrease in CD4+ Cells in the Peripheral Blood", Lepr. Rev., Vol. 63, No. 1, pp. 5-11 (1992) NR Shealy, Y.F. et al., "D-and L-Thalidomide", Chemistry and Industry, pp. 1030-1031 (1965) NS Sheehan, N.J., "Thalidomide Neurotoxicity and Rheumatoid Arthritis", Arthritis and Rheuma., Vol. 29, No. 10, p. 1296 (1986) NS No. 10, p. 1296 (1986) Sherman, M. et al., "Thalidomide: A Twenty-Five Year Perspective", Food Drug Cosmetic Law J., Vol. 41, pp. 458-466 (1986) Sheskin, J., "The Treatment of Lepra Reaction in Lepromatous Leprosy. Fifteen Years' Experience with Thalidomide", Int. J. Dermatol., Vol. 19, No. 6, pp. 318-322 (1980) Sheskin, et al., "In Vivo Measurements of Iron, Copper and Zinc in the Skin of Prurigo Nodularis Patients Treated with Thalidomide", Dermatologica, Vol. 162, No. 2, pp. 86-90 (1981) Shi, G. et al., "Kringle Domains and Plasmin Denaturation", Biochem. and Biophy. Res. Comm., Vol. 178, No. 1, pp. 360-368 (1991) Schumac	9	NK	
Santos, et al., "In Vitro Tumor Necrosis Factor Production by Mononuclear Cells from Leprosy Patients and from Patients with Erythema Nodosumleprosum", Clin. Immunol. Immunopathol., Vol. 67, No. 3 l, pp. 199-203 (1993) NN Sato, K. et al., "Increased Concentration of Vascular Endothelial Growth Factor/Vascular Permeability Factor in Cyst Fluid of Enlarging and Recurrent Thyroid Nodules", Journal of Clinical Endocrinology and Metabolism, Vol. 82, No. 6, pp. 1968-1972 (1997) NO Schweigerer, L. et al., "Angiogenesis and Angiogenesis Inhibitors in Paediatric Diseases", European J. of Pediatric, Vol. 151, pp. 472-476 (1992) NP Shannon, et al., "Inhibition of de Novo IgM Antibody Synthesis by Thalidomide as a Relevant Mechanism of Action in Leprosy", Scand. J. Immunol., Vol. 13, No. 6, pp. 553-562 (1981) Shannon, et al., "Inhibition of de Novo IgM Antibody Synthesis by Thalidomide as a Relevant Mechanism of Action in Leprosy", Scand. J. Immunol., Vol. 13, No. 6, pp. 553-562 (1981) NR Shannon, et al., "Phalidomide Effectiveness in Erythema Nodosum Leprosum is Associated with a Decrease in CD4+ Cells in the Peripheral Blood", Lepr. Rev., Vol. 63, No. 1, pp. 5-11 (1992) NR Shealy, Y.F. et al., "D-and L-Thalidomide", Chemistry and Industry, pp. 1030-1031 (1965) NS Sheehan, N.J., "Thalidomide Neurotoxicity and Rheumatoid Arthritis", Arthritis and Rheuma., Vol. 29, No. 10, p. 1296 (1986) NS No. 10, p. 1296 (1986) Sherman, M. et al., "Thalidomide: A Twenty-Five Year Perspective", Food Drug Cosmetic Law J., Vol. 41, pp. 458-466 (1986) Sheskin, J., "The Treatment of Lepra Reaction in Lepromatous Leprosy. Fifteen Years' Experience with Thalidomide", Int. J. Dermatol., Vol. 19, No. 6, pp. 318-322 (1980) Sheskin, et al., "In Vivo Measurements of Iron, Copper and Zinc in the Skin of Prurigo Nodularis Patients Treated with Thalidomide", Dermatologica, Vol. 162, No. 2, pp. 86-90 (1981) Shi, G. et al., "Kringle Domains and Plasmin Denaturation", Biochem. and Biophy. Res. Comm., Vol. 178, No. 1, pp. 360-368 (1991) Schumac	2	NL	Santis, H.R., "Aphthous Stomatitis and its Management", Curr. Opin. Dent, Vol. 1, No. 6, pp. 763-768 (1991) (Abstract Only)
in Cyst Fluid of Enlarging and Recurrent Thyroid Nodules", Journal of Clinical Endocrinology and Metabolism, Vol. 82, No. 6, pp. 1968-1972 (1997) NO Schweigerer, L. et al., "Angiogenesis and Angiogenesis Inhibitors in Paediatric Diseases", European J. of Pediatric, Vol. 151, pp. 472-476 (1992) NP Shannon, et al., "Inhibition of de Novo IgM Antibody Synthesis by Thalidomide as a Relevant Mechanism of Action in Leprosy", Scand. J. Immunol., Vol. 13, No. 6, pp. 553-562 (1981) NO Shannon, et al., "Thalidomide's Effectiveness in Erythema Nodosum Leprosum is Associated with a Decrease in CD4+ Cells in the Peripheral Blood", Lepr. Rev., Vol. 63, No. 1, pp. 5-11 (1992) NR Shealy, Y.F. et al., "D-and L-Thalidomide", Chemistry and Industry, pp. 1030-1031 (1965) Sheehan, N.J., "Thalidomide Neurotoxicity and Rheumatoid Arthritis", Arthritis and Rheuma., Vol. 29, No. 10, pp. 1296 (1986) NS No. 10, pp. 1296 (1986) Sherman, M. et al., "Thalidomide: A Twenty-Five Year Perspective", Food Drug Cosmetic Law J., Vol. 41, pp. 458-466 (1986) Sheskin, J., "The Treatment of Lepra Reaction in Lepromatous Leprosy. Fifteen Years' Experience with Thalidomide", Int. J. Dermatol., Vol. 19, No. 6, pp. 318-322 (1980) Sheskin, et al., "In Vivo Measurements of Iron, Copper and Zinc in the Skin of Prurigo Nodularis Patients Treated with Thalidomide", Dermatologica, Vol. 162, No. 2, pp. 86-90 (1981) NN Shi, G. et al., "Kringle Domains and Plasmin Denaturation", Biochem. and Biophy. Res. Comm., Vol. 178, No. 1, pp. 360-368 (1991) Schumacher, H. et al., "The Metabolism of Thalidomide: The Fate of Thalidomide and Some of its Hydrolysis Products in Various Species", Brit. J. Pharmacol., Vol. 25, pp. 338-351 (1965) NY Sidky, Y. et al., "Inhibition of Angiogenesis by Interferons: Effects on Tumor-and Lymphocyte-induced Vascular Responses", Canc. Res., Vol. 47, pp. 5155-5161 (1987) EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw Invented Citation if not in	2	NM	Leprosy Patients and from Patients with Erythema Nodosumleprosum", Clin. Immunol. Immunopathol.
NR Shealy, Y.F. et al., "D-and L-Thalidomide", Chemistry and Industry, pp. 1030-1031 (1965) Sheehan, N.J., "Thalidomide Neurotoxicity and Rheumatoid Arthritis", Arthritis and Rheuma., Vol. 29, No. 10, p. 1296 (1986) Sheeman, M. et al., "Thalidomide: A Twenty-Five Year Perspective", Food Drug Cosmetic Law J., Vol. 41, pp. 458-466 (1986) Sheskin, J., "The Treatment of Lepra Reaction in Lepromatous Leprosy. Fifteen Years' Experience with Thalidomide", Int. J. Dermatol., Vol. 19, No. 6, pp. 318-322 (1980) Sheskin, et al., "In Vivo Measurements of Iron, Copper and Zinc in the Skin of Prurigo Nodularis Patients Treated with Thalidomide", Dermatologica, Vol. 162, No. 2, pp. 86-90 (1981) Shi, G. et al., "Kringle Domains and Plasmin Denaturation", Biochem. and Biophy. Res. Comm., Vol. 178, No. 1, pp. 360-368 (1991) Schumacher, H. et al., "The Metabolism of Thalidomide: The Fate of Thalidomide and Some of its Hydrolysis Products in Various Species", Brit. J. Pharmacol., Vol. 25, pp. 338-351 (1965) Sidky, Y. et al., "Inhibition of Angiogenesis by Interferons: Effects on Tumor-and Lymphocyte-induced Vascular Responses", Canc. Res., Vol. 47, pp. 5155-5161 (1987) EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw limitation if not in		NN	Metabolism, Vol. 82, No. 6, pp. 1968-1972 (1997)
NR Shealy, Y.F. et al., "D-and L-Thalidomide", Chemistry and Industry, pp. 1030-1031 (1965) Sheehan, N.J., "Thalidomide Neurotoxicity and Rheumatoid Arthritis", Arthritis and Rheuma., Vol. 29, No. 10, p. 1296 (1986) Sheeman, M. et al., "Thalidomide: A Twenty-Five Year Perspective", Food Drug Cosmetic Law J., Vol. 41, pp. 458-466 (1986) Sheskin, J., "The Treatment of Lepra Reaction in Lepromatous Leprosy. Fifteen Years' Experience with Thalidomide", Int. J. Dermatol., Vol. 19, No. 6, pp. 318-322 (1980) Sheskin, et al., "In Vivo Measurements of Iron, Copper and Zinc in the Skin of Prurigo Nodularis Patients Treated with Thalidomide", Dermatologica, Vol. 162, No. 2, pp. 86-90 (1981) Shi, G. et al., "Kringle Domains and Plasmin Denaturation", Biochem. and Biophy. Res. Comm., Vol. 178, No. 1, pp. 360-368 (1991) Schumacher, H. et al., "The Metabolism of Thalidomide: The Fate of Thalidomide and Some of its Hydrolysis Products in Various Species", Brit. J. Pharmacol., Vol. 25, pp. 338-351 (1965) Sidky, Y. et al., "Inhibition of Angiogenesis by Interferons: Effects on Tumor-and Lymphocyte-induced Vascular Responses", Canc. Res., Vol. 47, pp. 5155-5161 (1987) EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw limitation if not in	0		Pediatric, Vol. 151, pp. 472-476 (1992)
NR Shealy, Y.F. et al., "D-and L-Thalidomide", Chemistry and Industry, pp. 1030-1031 (1965) Sheehan, N.J., "Thalidomide Neurotoxicity and Rheumatoid Arthritis", Arthritis and Rheuma., Vol. 29, No. 10, p. 1296 (1986) Sheeman, M. et al., "Thalidomide: A Twenty-Five Year Perspective", Food Drug Cosmetic Law J., Vol. 41, pp. 458-466 (1986) Sheskin, J., "The Treatment of Lepra Reaction in Lepromatous Leprosy. Fifteen Years' Experience with Thalidomide", Int. J. Dermatol., Vol. 19, No. 6, pp. 318-322 (1980) Sheskin, et al., "In Vivo Measurements of Iron, Copper and Zinc in the Skin of Prurigo Nodularis Patients Treated with Thalidomide", Dermatologica, Vol. 162, No. 2, pp. 86-90 (1981) Shi, G. et al., "Kringle Domains and Plasmin Denaturation", Biochem. and Biophy. Res. Comm., Vol. 178, No. 1, pp. 360-368 (1991) Schumacher, H. et al., "The Metabolism of Thalidomide: The Fate of Thalidomide and Some of its Hydrolysis Products in Various Species", Brit. J. Pharmacol., Vol. 25, pp. 338-351 (1965) Sidky, Y. et al., "Inhibition of Angiogenesis by Interferons: Effects on Tumor-and Lymphocyte-induced Vascular Responses", Canc. Res., Vol. 47, pp. 5155-5161 (1987) EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw limitation if not in	Q	NP	
Sheehan, N.J., "Thalidomide Neurotoxicity and Rheumatoid Arthritis", Arthritis and Rheuma., Vol. 29, No. 10, p. 1296 (1986) Sherman, M. et al., "Thalidomide: A Twenty-Five Year Perspective", Food Drug Cosmetic Law J., Vol. 41, pp. 458-466 (1986) NU Sheskin, J., "The Treatment of Lepra Reaction in Lepromatous Leprosy. Fifteen Years' Experience with Thalidomide", Int. J. Dermatol., Vol. 19, No. 6, pp. 318-322 (1980) Sheskin, et al., "In Vivo Measurements of Iron, Copper and Zinc in the Skin of Prurigo Nodularis Patients Treated with Thalidomide", Dermatologica, Vol. 162, No. 2, pp. 86-90 (1981) Shi, G. et al., "Kringle Domains and Plasmin Denaturation", Biochem. and Biophy. Res. Comm., Vol. 178, No. 1, pp. 360-368 (1991) Schumacher, H. et al., "The Metabolism of Thalidomide: The Fate of Thalidomide and Some of its Hydrolysis Products in Various Species", Brit. J. Pharmacol., Vol. 25, pp. 338-351 (1965) Sidky, Y. et al., "Inhibition of Angiogenesis by Interferons: Effects on Tumor-and Lymphocyte-induced Vascular Responses", Canc. Res., Vol. 47, pp. 5155-5161 (1987) EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in	i	1	Decrease in CD4+ Cells in the Peripheral Blood", Lepr. Rev., Vol. 63, No. 1, pp. 5-11 (1992)
NS No. 10, p. 1296 (1986) Sherman, M. et al., "Thalidomide: A Twenty-Five Year Perspective", Food Drug Cosmetic Law J., Vol. 41, pp. 458-466 (1986) Sheskin, J., "The Treatment of Lepra Reaction in Lepromatous Leprosy. Fifteen Years' Experience with Thalidomide", Int. J. Dermatol., Vol. 19, No. 6, pp. 318-322 (1980) Sheskin, et al., "In Vivo Measurements of Iron, Copper and Zinc in the Skin of Prurigo Nodularis Patients Treated with Thalidomide", Dermatologica, Vol. 162, No. 2, pp. 86-90 (1981) Shi, G. et al., "Kringle Domains and Plasmin Denaturation", Biochem. and Biophy. Res. Comm., Vol. 178, No. 1, pp. 360-368 (1991) NX Schumacher, H. et al., "The Metabolism of Thalidomide: The Fate of Thalidomide and Some of its Hydrolysis Products in Various Species", Brit. J. Pharmacol., Vol. 25, pp. 338-351 (1965) NY Sidky, Y. et al., "Inhibition of Angiogenesis by Interferons: Effects on Tumor-and Lymphocyte-induced Vascular Responses", Canc. Res., Vol. 47, pp. 5155-5161 (1987) EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw linestheough citation if not in	2	NR	
NT pp. 458-466 (1986) Sheskin, J., "The Treatment of Lepra Reaction in Lepromatous Leprosy. Fifteen Years' Experience with Thalidomide", Int. J. Dermatol., Vol. 19, No. 6, pp. 318-322 (1980) Sheskin, et al., "In Vivo Measurements of Iron, Copper and Zinc in the Skin of Prurigo Nodularis Patients Treated with Thalidomide", Dermatologica, Vol. 162, No. 2, pp. 86-90 (1981) Shi, G. et al., "Kringle Domains and Plasmin Denaturation", Biochem. and Biophy. Res. Comm., Vol. 178, No. 1, pp. 360-368 (1991) Schumacher, H. et al., "The Metabolism of Thalidomide: The Fate of Thalidomide and Some of its Hydrolysis Products in Various Species", Brit. J. Pharmacol., Vol. 25, pp. 338-351 (1965) Sidky, Y. et al., "Inhibition of Angiogenesis by Interferons: Effects on Tumor-and Lymphocyte-induced Vascular Responses", Canc. Res., Vol. 47, pp. 5155-5161 (1987) EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in		NS	
Sheskin, J., "The Treatment of Lepra Reaction in Lepromatous Leprosy. Fifteen Years' Experience with Thalidomide", Int. J. Dermatol., Vol. 19, No. 6, pp. 318-322 (1980) Sheskin, et al., "In Vivo Measurements of Iron, Copper and Zinc in the Skin of Prurigo Nodularis Patients Treated with Thalidomide", Dermatologica, Vol. 162, No. 2, pp. 86-90 (1981) Shi, G. et al., "Kringle Domains and Plasmin Denaturation", Biochem. and Biophy. Res. Comm., Vol. 178, No. 1, pp. 360-368 (1991) Schumacher, H. et al., "The Metabolism of Thalidomide: The Fate of Thalidomide and Some of its Hydrolysis Products in Various Species", Brit. J. Pharmacol., Vol. 25, pp. 338-351 (1965) Sidky, Y. et al., "Inhibition of Angiogenesis by Interferons: Effects on Tumor-and Lymphocyte-induced Vascular Responses", Canc. Res., Vol. 47, pp. 5155-5161 (1987) EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in	0	NT	pp. 458-466 (1986)
Sheskin, et al., "In Vivo Measurements of Iron, Copper and Zinc in the Skin of Prurigo Nodularis Patients Treated with Thalidomide", Dermatologica, Vol. 162, No. 2, pp. 86-90 (1981) Shi, G. et al., "Kringle Domains and Plasmin Denaturation", Biochem. and Biophy. Res. Comm., Vol. 178, No. 1, pp. 360-368 (1991) Schumacher, H. et al., "The Metabolism of Thalidomide: The Fate of Thalidomide and Some of its Hydrolysis Products in Various Species", Brit. J. Pharmacol., Vol. 25, pp. 338-351 (1965) Sidky, Y. et al., "Inhibition of Angiogenesis by Interferons: Effects on Tumor-and Lymphocyte-induced Vascular Responses", Canc. Res., Vol. 47, pp. 5155-5161 (1987) EXAMINER DATE CONSIDERED EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in	Q	NU	Sheskin, J., "The Treatment of Lepra Reaction in Lepromatous Leprosy. Fifteen Years' Experience with Thalidomide", <i>Int. J. Dermatol.</i> , Vol. 19, No. 6, pp. 318-322 (1980)
Shi, G. et al., "Kringle Domains and Plasmin Denaturation", Biochem. and Biophy. Res. Comm., Vol. 178, No. 1, pp. 360-368 (1991) Schumacher, H. et al., "The Metabolism of Thalidomide: The Fate of Thalidomide and Some of its Hydrolysis Products in Various Species", Brit. J. Pharmacol., Vol. 25, pp. 338-351 (1965) Sidky, Y. et al., "Inhibition of Angiogenesis by Interferons: Effects on Tumor-and Lymphocyte-induced Vascular Responses", Canc. Res., Vol. 47, pp. 5155-5161 (1987) EXAMINER DATE CONSIDERED EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in	9	NV	Sheskin, et al., "In Vivo Measurements of Iron, Copper and Zinc in the Skin of Prurigo Nodularis Patients Treated with Thalidomide", <i>Dermatologica</i> , Vol. 162, No. 2, pp. 86-90 (1981)
NX Products in Various Species", Brit. J. Pharmacol., Vol. 25, pp. 338-351 (1965) Sidky, Y. et al., "Inhibition of Angiogenesis by Interferons: Effects on Tumor-and Lymphocyte-induced Vascular Responses", Canc. Res., Vol. 47, pp. 5155-5161 (1987) EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in	2	NW	Shi, G. et al., "Kringle Domains and Plasmin Denaturation", Biochem. and Biophy. Res. Comm., Vol. 178, No. 1, pp. 360-368 (1991)
Sidky, Y. et al., "Inhibition of Angiogenesis by Interferons: Effects on Tumor-and Lymphocyte-induced Vascular Responses", Canc. Res., Vol. 47, pp. 5155-5161 (1987) EXAMINER DATE CONSIDERED EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in	9	NX	Schumacher, H. et al., "The Metabolism of Thalidomide: The Fate of Thalidomide and Some of its Hydrolysis
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line, through citation if not in	a	NY	Sidky, Y. et al., "Inhibition of Angiogenesis by Interferons: Effects on Tumor-and Lymphocyte-induced
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw light through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.			DATE CONSIDERED 8/23/0/
	EXAMINE conformance	R: Init	ial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in the considered. Include copy of this form with next communication to applicant.

PTO/SB/08A (08-00)
Approved for use through 10/31/2002 OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE from a required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for Form 1449/A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary

Sheet | 15 of 17

	Complete if Known
Application Number	09/545,139
Filing Date	April 7, 2000
First Named Inventor	D'Amato et al.
Group Art Unit	1614
Examiner Name	J. Goldberg
Attorney Docket Number	05213-0650 43170-219681

OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, Etc.) OA Silverman, W.A., "Medical Inflation", Persp. Biol. Med., pp. 617-637 (1980) DB Smith, et al., "Studies on the Relationship Between the Chemical Structure and Embryotoxic Activity of Theiridomide and Related Compounds", Chemical Structure and Embryotoxic Programs, pp. 194-299. Delation of Sirvastava, A. et al., "The Prognostic Significance of Tumor Vascularity in Intermediate-Thickness Skin Melanoma", Am. J. Pathol., Vol. 133, pp. 419-423 (1988) (abstract from MEDLINE: Accession no. 06745734) OC 06745734) Style, A., "Early Diagnosis and Treatment of Leprosy in the United States", American Family Physician, Vol. 52, No. 1, 172-178 (1995) Sugiura, et al., "Effect of Thaildomide on Transplantable Mouse, Rat, and Hamster Tumors", CANN, Vol. 55, pp. 57-60 (1964) OF Surak, H. "The History of latrogemic Diseases in Japan", First Department of Internal Medicinie, University of Emvir. And Occup. Health, Kitakyushu, Japan, pp. 35-40- OG Swift, T.R. "Thaildomide in Erythema Nodosum Leprosum", Lancet, Vol. 2, No. 835, p. 966 (1973) Szydlowska, et al., "On the Application of Thaildomide as a Block of Functional Groups of Proteins in Histochemical Investigations", Folia Histo. Cytochem., Vol. 16, No. 3, pp. 233-240 (1978) Tamura, et al., "Combination Thaildomide and Cyclosporine for Cardiac Allograft Rejection. Comparison with Combination Methylprodnisolone and Cyclosporine", Transplantation, Vol. 49, No. 1, p. 20-25 (1990) Tanaka, Y. et al., "Protamine is an Inhibitor of Angiogenesis", Nature, Vol. 297, pp. 307-312 (1982) Taplor, S. et al., "Protamine is an Inhibitor of Angiogenesis", Nature, Vol. 297, pp. 307-312 (1982) Teppo, L. et al., "Inhaildomide-Type Malformations and Subsequent Osteosarcoma", The Lancet, Vol. II, No. 8034, p. 405 (1977) "Thaildomide", The Merck Index, 11th ed., p. 1458 (1989) Thomas, et al., "Effect of Thaildomide in Steroid Dependency and Neuritis", Lepr. India, Vol. 52, No. 3, pp. 423-428 (1980) Thomas, et al			U.S. PATENT DOCUMENTS
OA Silverman, W.A., "Medical Inflation", Persp. Biol. Med., pp. 617-637 (1980) OB Smith, et al., "Studieso on the Retainoship Between the Chemical Structure and Embryotoxic Activity of Thalidomide and Related Compounds", Chemical Structure and Embryopathy, pp. 194-299 Srivastava, A. et al., "The Prognostic Significance of Tumor Vascularity in Intermediate-Intickness Skin Melanoma", Am. J. Pathol., Vol. 133, pp. 419-423 (1988) (abstract from BULINE: Accession no. 06745734) OC 06745734) OD Vol. 52, No. 1, 172-178 (1995) Sugura, et al., "Effect of Thalidomide on Transplantable Mouse, Rat, and Hamster Tumors", GANN, Vol. 55, pp. 57-60 (1964) OF Suzuki, H. 'The History of Tatrogenic Diseases in Japan", First Department of Internal Medicinie, University of Emrit and Occupie Health, Kitakyushu, Japan, pp. 35-40 OG Switt, T.R., "Thalidomide in Erythema Nodosum Leprosum", Lancet, Vol. 2, No. 835, p. 966 (1973) Szydlowska, et al., "On the Application of Thalidomide as a Block of Funcional Groups of Proteins in Histochemical Investigations", Folia Histo. Cytochem., Vol. 16, No. 3, pp. 233-240 (1978) OI Sanaka, Y. et al., "Von the Application of Thalidomide as a Block of Funcional Groups of Proteins in Histochemical Investigations", Folia Histo. Cytochem., Vol. 16, No. 3, pp. 233-240 (1978) OI Tanaka, Y. et al., "Vascular Endothelial Growth Factor in Diabetic Retinopathy", The Lancet, Vol. 349, p. 1520 (1997) Tanaka, Y. et al., "Protamine is an Inhibitor of Angiogenesis", Nature, Vol. 297, pp. 307-312 (1982) Teppo, L. et al., "Thalidomide-Type Malformations and Subsequent Osteosarcoma", The Lancet, Vol. 11, No. 3034, p. 405 (1977) "Thalidomide 20 Years On", The Lancet, Vol. II, No. 8245, pp. 510-511 (1981) "Thomas, et al., "Effect of Thalidomide in Steroid Dependency and Neuritis", Lept. India, Vol. 52, No. 3, pp. 423-428 (1980) Thomas, L. et al., "Successful Treatment of Adult's Langerhans Cell Histiocytosis with Thalidomide", Archives of Jearnach, Vol. 129, pp. 316-317 (1972) Thomas, L. et al., "Successfu			OTHER REFERENCES (Including Author Title, Date, Pertinent Pages, Etc.)
OB Smith, et al., "Studies on the Relationship Between the Chemical Structure and Embryotoxic Activity of Thalidomide and Related Compountsh", Chemical Structure and Embryotoxic Activity of Thalidomide and Related Compountship of the Chemical Structure and Embryotoxic Activity of Strivastava, A. et al., "The Prognostic Significance of Tumor Vascularity in Intermediate Thickness Skin Melanoma", Am. J. Pathol., Vol. 133, pp. 419-423 (1988) (abstract from MEDLINE: Accession no. 06745734) OC Style, A., "Early Diagnosis and Treatment of Leprosy in the United States", American Family Physician, Vol. 52, No. 1, 172-178 (1995) Sugiura, et al., "Effect of Thalidomide on Transplantable Mouse, Rat, and Hamster Tumors", GANN, Vol. 53, pp. 57-60 (1964) OF Suziki, H., The History of Tarrogenic Diseases in Japan", First Department of Internal Medicinie, University of Emvir. And Occup. Health, Kitakyusin, Japan, pp. 35-40 OH Szydlowska, et al., "On the Application of Thalidomide as a Block of Functional Groups of Proteins in Histochemical Investigations", Folia Histo. Cytochem., Vol. 16, No. 3, pp. 233-240 (1978) OH Szydlowska, et al., "Combination Thalidomide and Cyclosporine for Cardiac Allograft Rejection. Comparison with Combination Methylprodnisolone and Cyclosporine", Transplantation, Vol. 49, No. 1, p. 20-25 (1990) OT Tanawa, et al., "Yoscular Endothelial Growth Factor in Diabetic Retinally", The Lancet, Vol. 349, p. 1520 (1997) Taylor, S. et al., "Protamine is an Inhibitor of Angiogenesis", Nature, Vol. 297, pp. 307-312 (1982) Teppo, L. et al., "Thalidomide-Type Malformations and Subsequent Osteosarcoma", The Lancet, Vol. 11, No. 8034, p. 405 (1977) "Thalidomide 20 Years On", The Lancet, Vol. 11, No. 8245, pp. 510-511 (1981) "Thomas, et al., "Effect of Thalidomide in Steroid Dependency and Neuritis", Lepr. India, Vol. 52, No. 3, pp. 423-428 (1980) Thomas, et al., "Lack of Thalidomide on Liver Regeneration in Rat", Indian J. Exp. Biol., Vol. 10, pp. 316-317 (1972) Thomas, t. et al., "Successful Treatment of		TOAT	
Theidomtide and Related Compounds, "Chemical Structure and Embryopathy, pp. 194-299. — John Medanoma", Am. J. Pathol., Vol. 133, pp. 419-423 (1988) (abstract from MEDLINE: Accession no. 06745734) OC 06745734) OD Vol. 52, No. 1, 172-178 (1995) Sugura, et al., "Effect of Thalidomide on Transplantable Mouse, Rat, and Hamster Tumors", GANN, Vol. 55, pp. 57-60 (1964) OF Suzuki, H. The History of Tarogenic Diseases in Japan", First Department of Internal Medicinie, University of Emir, Ind Occup. Health, Kitakyushu, Japan, pp. 35-40- OH Switt, T.R. "Thalidomide in Erythema Nodosum Leprosum", Lancet, Vol. 2, No. 835, p. 966 (1973) Sydlowska, et al., "On the Application of Thalidomide as a Block of Functional Groups of Proteins in Histochemical Investigations", Folia Histo. Cytochem., Vol. 16, No. 3, pp. 233-240 (1978) OI Tamura, et al., "Combination Thalidomide and Cyclosporine: Fransplantation, Vol. 49, No. 19, 20-25 (1990) Taylor, S. et al., "Vascular Endothelial Growth Factor in Diabetic Retinopathy", The Lancet, Vol. 11, No. 8034, p. 405 (1977) Taylor, S. et al., "Protamine is an Inhibitor of Angiogenesis", Nature, Vol. 297, pp. 307-312 (1982) Teppo, L. et al., "Thalidomide-Type Malformations and Subsequent Osteosarcoma", The Lancet, Vol. 11, No. 8034, p. 405 (1977) Thalidomide", The Merck Index, 11th ed., p. 1458 (1989) Thomas, et al., "Effect of Thalidomide on Liver Regeneration in Rat", Indian J. Exp. Biol., Vol. 10, pp. 314-315 (1972) Thomas, et al., "Lack of Thalidomide on Liver Regeneration and Relation to Tumor Angiogenesis", Am. J. of Reproductive Immunology, Vol. 27, pp. 171-179 (1992) Thomas, et al., "Lack of Thalidomide on Liver Regeneration and Relation to Tumor Angiogenesis", Am. J. of Reproductive Immunology, Vol. 27, pp. 171-179 (1992) Thomas, L. et al., "Naccessful Treatment of Adult's Langerhans Cell Histocytosis with Thalidomide", Archives of Dermadol, Vol. 129, pp. 1261-1264 (1993) Torry, R. J. et al., "Nagiogenesis in the Uterus: Potential Regulation and Relation to Tumor Angioge	<u> </u>	1 - 1	
Srivastava, A. et al., "The Prognostic Significance of Tumor Vascularity in Infermediate-Thickness Skin Melanoma", Am. J. Pathol., Vol. 133, pp. 419-423 (1988) (abstract from MEDLINE: Accession no. 06745734) OC 0745734) Style, A., "Early Diagnosis and Treatment of Leprosy in the United States", American Family Physician, Vol. 52, No. 1, 172-178 (1995) Sugiura, et al., "Effect of Thalidomide on Transplantable Mouse, Rat, and Hamster Tumors", GANN, Vol. 55, pp. 57-60 (1964) OF Suzuki, H., "The History of Tatrogenic Diseases in Japan", Fust Department of Internal Medicinie, University of Envir. And Occup. Health, Kitakyashu. Japan, pp. 35-40 OG Swift, T.R., "Thalidomide in Erythema Nodosum Leprosum", Lancet, Vol. 2, No. 353, p. 966 (1973) OH Szydlowska, et al., "On the Application of Thalidomide as a Block of Functional Groups of Proteins in Histochemical Investigations", Folia Histo. Cytochem., Vol. 16, No. 3, 233-240 (1978) OI Tamura, et al., "Combination Thalidomide and Cyclosporine for Cardiac Allograft Rejection. Comparison with Combination Methylprodnisolone and Cyclosporine", Transplantation, Vol. 49, No. 1, p. 20-25 (1990) Tamura, et al., "Combination Thalidomide and Cyclosporine", Transplantation, Vol. 49, No. 1, p. 20-25 (1990) Tamura, et al., "Treatment is an Inhibitor of Angiogenesis", Nature, Vol. 297, pp. 307-312 (1982) Teppo, L. et al., "Thalidomide-Type Malformations and Subsequent Osteosarcoma", The Lancet, Vol. II, No. 8245, pp. 510-511 (1981) ON Thalidomide 20 Years On", The Lancet, Vol. II, No. 8245, pp. 510-511 (1981) "Thalidomide", The Merck Index, 11th ed., p. 1458 (1989) ON Thomas, et al., "Elect of Thalidomide in Steroid Dependency and Neuritis", Lepr. India, Vol. 52, No. 3, pp. 423-428 (1980) Thomas, et al., "Elect of Thalidomide in Steroid Dependency and Neuritis", Lepr. India, Vol. 10, pp. 314-315 (1972) Thomas, et al., "Lack of Thalidomide in Induced Aplasia in Regenerating Tail of Lizard, Hemidactylus Flavidis", Indian J. Exp. Biol., Vol. 10, pp. 316-317 (1972) Thomas,		UD	
Melanoma", Am. J. Pathol., Vol. 133, pp. 419-423 (1988) (abstract from MEDLINE: Accession no. 06745734) OC 0745734) Style, A., "Early Diagnosis and Treatment of Leprosy in the United States", American Family Physician, Vol. 52, No. 1, 172-178 (1995) OE Vol. 52, No. 1, 172-178 (1995) Suguira, et al., "Effect of Thalidomide on Transplantable Mouse, Rat, and Hamster Tumors", GANN, Vol. 55, pp. 57-60 (1964) OF Suzuki, H, "The History of Tatrogenite Diseases in Japan", Furst Department of Internal Medictinie, University of Envir. And Occup. Health, Kitakyushu, Japan, pp. 35-40 OG Swift, T.R., "Thalidomide in Erythema Nodosum Leprosum", Lancet, Vol. 2, No. 35, p. 966 (1973) OH Szydlowska, et al., "On the Application of Thalidomide as a Block of Functional Groups of Proteins in Histochemical Investigations", Folia Histo. Cytochem., Vol. 16, No. 3, pp. 233-240 (1978) I Tamura, et al., "Combination Thalidomide and Cyclosporine", Transplantation, Vol. 49, No. 1, p. 20-25 (1990) Tanaka, Y. et al., "Vascular Endothelial Growth Factor in Diabetic Retinopathy", The Lancet, Vol. 349, p. 1520 (1997) OK Taylor, S. et al., "Protamine is an Inhibitor of Angiogenesis", Nature, Vol. 297, pp. 307-312 (1982) Teppo, L. et al., "Thalidomide-Type Malformations and Subsequent Osteosarcoma", The Lancet, Vol. 11, No. 8034, p. 405 (1977) "Thalidomide 20 Years On", The Lancet, Vol. 11, No. 8245, pp. 510-511 (1981) ON "Thalidomide", The Merck Index, 11th ed., p. 1458 (1989) Thomas, et al., "Effect of Thalidomide in Steroid Dependency and Neuritis", Lepr. India, Vol. 52, No. 3, pp. 423-428 (1980) Thomas, et al., "Effect of Thalidomide on Liver Regeneration in Rat", Indian J. Exp. Biol., Vol. 10, pp. 316-317 (1972) Thomas, et al., "Lack of Thalidomide Induced Aplasia in Regenerating Tail of Lizard, Hemidactylus Flavivirdis", Indian J. Exp. Biol., Vol. 10, pp. 316-317 (1972) Thomas, et al., "Lack of Thalidomide Induced Aplasia in Regenerating Tail of Lizard, Hemidactylus Flavivirdis", Indian J. Exp. Biol., Vol. 10, pp. 316-317 (Thandomide and Related Compounds, Chemical Structure and Embryoglating, pp. 194-295. / 10 8 2 20-4
OC 06745734) Style, A., "Early Diagnosis and Treatment of Leprosy in the United States", American Family Physician, Vol. 52, No. 1, 172-178 (1995) Sugiura, et al., "Effect of Thalidomide on Transplantable Mouse, Rat, and Hamster Tumors", GANN, Vol. 55, pp. 575-60 (1964) OF Suzuki, H., "The History of Tatrogenic Diseases in Japan", First Department of Integnal Medicinie, Universit of Envir And Occup. Health, Küdyushu, Japan, pp. 35-40 OG Switt, T.R., "Thalidomide in Erythema Nodosum Leprosum", Lancet, Vol. 2, No. 3835, p. 966 (1973) OH Szydlowska, et al., "On the Application of Thalidomide as a Block of Functional Groups of Proteins in Histochemical Investigations", Folia Histo. Cytochem., Vol. 16, No. 3, pp. 233-240 (1978) Tamura, et al., "Combination Thalidomide and Cyclosporine for Cardiac Allograft Rejection. Comparison with Combination Methylprodnisolone and Cyclosporine", Transplantation, Vol. 49, No. 1, p. 20-25 (1990) Tanaka, Y. et al., "Vascular Endothelial Growth Factor in Diabetic Retinopathy", The Lancet, Vol. 349, p. 1520 (1997) OK Taylor, S. et al., "Protamine is an Inhibitor of Angiogenesis", Nature, Vol. 297, pp. 307-312 (1982) Teppo, L. et al., "Thalidomide-Type Malformations and Subsequent Osteosarcoma", The Lancet, Vol. 11, No. 8034, p. 405 (1977) "Thalidomide 20 Years On", The Lancet, Vol. 11, No. 8245, pp. 510-511 (1981) ON Theophilus, S., "Treatment with Thalidomide in Steroid Dependency and Neuritis", Lepr. India, Vol. 52, No. 3, pp. 423-428 (1980) Thomas, et al., "Effect of Thalidomide in Steroid Dependency and Neuritis", Lepr. India, Vol. 52, No. 3, pp. 423-428 (1980) Thomas, et al., "Lack of Thalidomide in Steroid Dependency and Neuritis", Lepr. India, Vol. 52, No. 3, pp. 423-428 (1980) Thomas, et al., "Lack of Thalidomide in Steroid Dependency and Neuritis", Lepr. India, Vol. 52, No. 3, pp. 423-428 (1980) Thomas, L. et al., "Stereament of Adult's Langerhans Cell Histiocytosis with Thalidomide", Archives of Dermatol., Vol. 129, pp. 1261-1264 (1993) Tradd, et al., "Limpie	0		Srivastava, A. et al., "The Prognostic Significance of Tumor Vascularity in Intermediate-Thickness Skin
Syle, A., "Early Diagnosis and Treatment of Leprosy in the United States", American Family Physician, Vol. 52, No. 1, 172-178 (1995) Sugiura, et al., "Effect of Thalidomide on Transplantable Mouse, Rat, and Hamster Tumors", CANN, Vol. 55, pp. 57-60 (1964) OF Suzuki, H., "The History of Tatrogenic Diseases in Japan", First Department of Integnal Medicinie, University of Emvir And Occup. Health, Kitakyushu, Japan, pp. 35-40 OG Swift, T.R., "Thalidomide in Erythema Nodosum Leprosum", Lancet, Vol. 2, No. 835, p. 966 (1973) OH Szydlowska, et al., "On the Application of Thalidomide as a Block of Functional Groups of Proteins in Histochemical Investigations", Folia Histo. Cytochem., Vol. 16, No. 3, pp. 233-240 (1978) OI Tamura, et al., "Combination Thalidomide and Cyclospornic for Candiac Allograft Rejection. Comparison with Combination Methylprodnisolone and Cyclospornic", Transplantation, Vol. 49, No. 1, p. 20-25 (1990) 1 Tanaka, Y. et al., "Vascular Endothelial Growth Factor in Diabetic Retinopathy", The Lancet, Vol. 349, p. 1520 (1997) OK Taylor, S. et al., "Protamine is an Inhibitor of Angiogenesis", Nature, Vol. 297, pp. 307-312 (1982) Teppo, L. et al., "Thalidomide-Type Malformations and Subsequent Osteosarcoma", The Lancet, Vol. II, No. 8034, p. 405 (1977) ON "Thalidomide 20 Years On", The Lancet, Vol. II, No. 8245, pp. 510-511 (1981) ON "Thalidomide", The Merck Index, 11th ed., p. 1458 (1989) Thomas, et al., "Effect of Thalidomide in Steroid Dependency and Neuritis", Lepr. India, Vol. 52, No. 3, pp. 423-428 (1980) Thomas, et al., "Effect of Thalidomide in Steroid Dependency and Neuritis", Lepr. India, Vol. 52, No. 3, pp. 423-428 (1980) Thomas, et al., "Enfect of Thalidomide Induced Aplasia in Regenerating Tail of Lizard, Hemidactylus Flavivirdis", Indian J. Exp. Biol., Vol. 10, pp. 316-317 (1972) Thomas, et al., "Successful Treatment of Adult's Langerhans Cell Histiocytosis with Thalidomide", Archives of Dermatol., Vol. 129, pp. 1261-1264 (1993) Torry, R. J. et al., "Angiogenesis in the Uterus:	#		
OG Swift, T.R., "Thalidomide in Erythema Nodosum Leprosum", Lancet, Vol. 2, No. 335, p. 966 (1973) OH Szydlowska, et al., "On the Application of Thalidomide as a Block of Functional Groups of Proteins in Histochemical Investigations", Folia Histo. Cytochem., Vol. 16, No. 3, pp. 233-240 (1978) OI Tamura, et al., "Combination Thalidomide and Cyclosporine for Cardiac Allograft Rejection. Comparison with Combination Methylprodnisolone and Cyclosporine", Transplantation, Vol. 49, No. 1, p. 20-25 (1990) Tanaka, Y. et al., "Vascular Endothelial Growth Factor in Diabetic Retinopathy", The Lancet, Vol. 349, p. 1520 (1997) Tanaka, Y. et al., "Protamine is an Inhibitor of Angiogenesis", Nature, Vol. 297, pp. 307-312 (1982) Teppo, L. et al., "Thalidomide-Type Malformations and Subsequent Osteosarcoma", The Lancet, Vol. II, No. 8034, p. 405 (1977) "Thalidomide 20 Years On", The Lancet, Vol. II, No. 8245, pp. 510-511 (1981) "Thalidomide", The Merck Index, 11th ed., p. 1458 (1989) Thomas, et al., "Effect of Thalidomide in Steroid Dependency and Neuritis", Lepr. India, Vol. 52, No. 3, pp. 423-428 (1980) ON Thomas, et al., "Effect of Thalidomide Induced Aplasia in Regenerating Tail of Lizard, Hemidactylus Flavivirdis", Indian J. Exp. Biol., Vol. 10, pp. 316-317 (1972) Thomas, et al., "Lack of Thalidomide Induced Aplasia in Regenerating Tail of Lizard, Hemidactylus Flavivirdis", Indian J. Exp. Biol., Vol. 10, pp. 316-317 (1972) Thomas, et al., "Angiogenesis in the Uterus: Potential Regulation and Relation to Tumor Angiogenesis", Am. J. of Reproductive Immunology, Vol. 27, pp. 171-179 (1992) Tradit, et al., "Timpiego Dell'imide Dell'Acido N'ftaliglutammico (Taildomide) Nella Terapia Sintomatica del Vomito di Molti Pazienti Affeti da Neoplasie Maligne o Causato Dalla Somministrazione di Cloridato di Mecloretamina", Cancro, Vol. 18, pp. 336-341 (1965) OU Trautman, J. R., "Treatment of Hansen's Disease", Cutis, Vol. 18, No. 1, 62-65 (1976) Van den Broek, H., "Treatment of Prurigo Nodularis with Thalidomide", Arch. Derm		OC	06745734)
OG Swift, T.R., "Thalidomide in Erythema Nodosum Leprosum", Lancet, Vol. 2, No. 335, p. 966 (1973) OH Szydlowska, et al., "On the Application of Thalidomide as a Block of Functional Groups of Proteins in Histochemical Investigations", Folia Histo. Cytochem., Vol. 16, No. 3, pp. 233-240 (1978) OI Tamura, et al., "Combination Thalidomide and Cyclosporine for Cardiac Allograft Rejection. Comparison with Combination Methylprodnisolone and Cyclosporine", Transplantation, Vol. 49, No. 1, p. 20-25 (1990) Tanaka, Y. et al., "Vascular Endothelial Growth Factor in Diabetic Retinopathy", The Lancet, Vol. 349, p. 1520 (1997) Tanaka, Y. et al., "Protamine is an Inhibitor of Angiogenesis", Nature, Vol. 297, pp. 307-312 (1982) Teppo, L. et al., "Thalidomide-Type Malformations and Subsequent Osteosarcoma", The Lancet, Vol. II, No. 8034, p. 405 (1977) "Thalidomide 20 Years On", The Lancet, Vol. II, No. 8245, pp. 510-511 (1981) "Thalidomide", The Merck Index, 11th ed., p. 1458 (1989) Thomas, et al., "Effect of Thalidomide in Steroid Dependency and Neuritis", Lepr. India, Vol. 52, No. 3, pp. 423-428 (1980) ON Thomas, et al., "Effect of Thalidomide Induced Aplasia in Regenerating Tail of Lizard, Hemidactylus Flavivirdis", Indian J. Exp. Biol., Vol. 10, pp. 316-317 (1972) Thomas, et al., "Lack of Thalidomide Induced Aplasia in Regenerating Tail of Lizard, Hemidactylus Flavivirdis", Indian J. Exp. Biol., Vol. 10, pp. 316-317 (1972) Thomas, et al., "Angiogenesis in the Uterus: Potential Regulation and Relation to Tumor Angiogenesis", Am. J. of Reproductive Immunology, Vol. 27, pp. 171-179 (1992) Tradit, et al., "Timpiego Dell'imide Dell'Acido N'ftaliglutammico (Taildomide) Nella Terapia Sintomatica del Vomito di Molti Pazienti Affeti da Neoplasie Maligne o Causato Dalla Somministrazione di Cloridato di Mecloretamina", Cancro, Vol. 18, pp. 336-341 (1965) OU Trautman, J. R., "Treatment of Hansen's Disease", Cutis, Vol. 18, No. 1, 62-65 (1976) Van den Broek, H., "Treatment of Prurigo Nodularis with Thalidomide", Arch. Derm	0		
OG Swift, T.R., "Thalidomide in Erythema Nodosum Leprosum", Lancet, Vol. 2, No. 335, p. 966 (1973) OH Szydlowska, et al., "On the Application of Thalidomide as a Block of Functional Groups of Proteins in Histochemical Investigations", Folia Histo. Cytochem., Vol. 16, No. 3, pp. 233-240 (1978) OI Tamura, et al., "Combination Thalidomide and Cyclosporine for Cardiac Allograft Rejection. Comparison with Combination Methylprodnisolone and Cyclosporine", Transplantation, Vol. 49, No. 1, p. 20-25 (1990) Tanaka, Y. et al., "Vascular Endothelial Growth Factor in Diabetic Retinopathy", The Lancet, Vol. 349, p. 1520 (1997) Tanaka, Y. et al., "Protamine is an Inhibitor of Angiogenesis", Nature, Vol. 297, pp. 307-312 (1982) Teppo, L. et al., "Thalidomide-Type Malformations and Subsequent Osteosarcoma", The Lancet, Vol. II, No. 8034, p. 405 (1977) "Thalidomide 20 Years On", The Lancet, Vol. II, No. 8245, pp. 510-511 (1981) "Thalidomide", The Merck Index, 11th ed., p. 1458 (1989) Thomas, et al., "Effect of Thalidomide in Steroid Dependency and Neuritis", Lepr. India, Vol. 52, No. 3, pp. 423-428 (1980) ON Thomas, et al., "Effect of Thalidomide Induced Aplasia in Regenerating Tail of Lizard, Hemidactylus Flavivirdis", Indian J. Exp. Biol., Vol. 10, pp. 316-317 (1972) Thomas, et al., "Lack of Thalidomide Induced Aplasia in Regenerating Tail of Lizard, Hemidactylus Flavivirdis", Indian J. Exp. Biol., Vol. 10, pp. 316-317 (1972) Thomas, et al., "Angiogenesis in the Uterus: Potential Regulation and Relation to Tumor Angiogenesis", Am. J. of Reproductive Immunology, Vol. 27, pp. 171-179 (1992) Tradit, et al., "Timpiego Dell'imide Dell'Acido N'ftaliglutammico (Taildomide) Nella Terapia Sintomatica del Vomito di Molti Pazienti Affeti da Neoplasie Maligne o Causato Dalla Somministrazione di Cloridato di Mecloretamina", Cancro, Vol. 18, pp. 336-341 (1965) OU Trautman, J. R., "Treatment of Hansen's Disease", Cutis, Vol. 18, No. 1, 62-65 (1976) Van den Broek, H., "Treatment of Prurigo Nodularis with Thalidomide", Arch. Derm		OD	Vol. 52, No. 1, 172-178 (1995)
OG Swift, T.R., "Thalidomide in Erythema Nodosum Leprosum", Lancet, Vol. 2, No. 335, p. 966 (1973) OH Szydlowska, et al., "On the Application of Thalidomide as a Block of Functional Groups of Proteins in Histochemical Investigations", Folia Histo. Cytochem., Vol. 16, No. 3, pp. 233-240 (1978) OI Tamura, et al., "Combination Thalidomide and Cyclosporine for Cardiac Allograft Rejection. Comparison with Combination Methylprodnisolone and Cyclosporine", Transplantation, Vol. 49, No. 1, p. 20-25 (1990) Tanaka, Y. et al., "Vascular Endothelial Growth Factor in Diabetic Retinopathy", The Lancet, Vol. 349, p. 1520 (1997) Tanaka, Y. et al., "Protamine is an Inhibitor of Angiogenesis", Nature, Vol. 297, pp. 307-312 (1982) Teppo, L. et al., "Thalidomide-Type Malformations and Subsequent Osteosarcoma", The Lancet, Vol. II, No. 8034, p. 405 (1977) "Thalidomide 20 Years On", The Lancet, Vol. II, No. 8245, pp. 510-511 (1981) "Thalidomide", The Merck Index, 11th ed., p. 1458 (1989) Thomas, et al., "Effect of Thalidomide in Steroid Dependency and Neuritis", Lepr. India, Vol. 52, No. 3, pp. 423-428 (1980) ON Thomas, et al., "Effect of Thalidomide Induced Aplasia in Regenerating Tail of Lizard, Hemidactylus Flavivirdis", Indian J. Exp. Biol., Vol. 10, pp. 316-317 (1972) Thomas, et al., "Lack of Thalidomide Induced Aplasia in Regenerating Tail of Lizard, Hemidactylus Flavivirdis", Indian J. Exp. Biol., Vol. 10, pp. 316-317 (1972) Thomas, et al., "Angiogenesis in the Uterus: Potential Regulation and Relation to Tumor Angiogenesis", Am. J. of Reproductive Immunology, Vol. 27, pp. 171-179 (1992) Tradit, et al., "Timpiego Dell'imide Dell'Acido N'ftaliglutammico (Taildomide) Nella Terapia Sintomatica del Vomito di Molti Pazienti Affeti da Neoplasie Maligne o Causato Dalla Somministrazione di Cloridato di Mecloretamina", Cancro, Vol. 18, pp. 336-341 (1965) OU Trautman, J. R., "Treatment of Hansen's Disease", Cutis, Vol. 18, No. 1, 62-65 (1976) Van den Broek, H., "Treatment of Prurigo Nodularis with Thalidomide", Arch. Derm			Sugiura, et al., "Effect of Thalidomide on Transplantable Mouse, Rat, and Hamster Tumors", GANN,
OG Swift, T.R., "Thalidomide in Erythema Nodosum Leprosum", Lancet, Vol. 2, No. 335, p. 966 (1973) OH Szydlowska, et al., "On the Application of Thalidomide as a Block of Functional Groups of Proteins in Histochemical Investigations", Folia Histo. Cytochem., Vol. 16, No. 3, pp. 233-240 (1978) OI Tamura, et al., "Combination Thalidomide and Cyclosporine for Cardiac Allograft Rejection. Comparison with Combination Methylprodnisolone and Cyclosporine", Transplantation, Vol. 49, No. 1, p. 20-25 (1990) Tanaka, Y. et al., "Vascular Endothelial Growth Factor in Diabetic Retinopathy", The Lancet, Vol. 349, p. 1520 (1997) Tanaka, Y. et al., "Protamine is an Inhibitor of Angiogenesis", Nature, Vol. 297, pp. 307-312 (1982) Teppo, L. et al., "Thalidomide-Type Malformations and Subsequent Osteosarcoma", The Lancet, Vol. II, No. 8034, p. 405 (1977) "Thalidomide 20 Years On", The Lancet, Vol. II, No. 8245, pp. 510-511 (1981) "Thalidomide", The Merck Index, 11th ed., p. 1458 (1989) Thomas, et al., "Effect of Thalidomide in Steroid Dependency and Neuritis", Lepr. India, Vol. 52, No. 3, pp. 423-428 (1980) ON Thomas, et al., "Effect of Thalidomide Induced Aplasia in Regenerating Tail of Lizard, Hemidactylus Flavivirdis", Indian J. Exp. Biol., Vol. 10, pp. 316-317 (1972) Thomas, et al., "Lack of Thalidomide Induced Aplasia in Regenerating Tail of Lizard, Hemidactylus Flavivirdis", Indian J. Exp. Biol., Vol. 10, pp. 316-317 (1972) Thomas, et al., "Angiogenesis in the Uterus: Potential Regulation and Relation to Tumor Angiogenesis", Am. J. of Reproductive Immunology, Vol. 27, pp. 171-179 (1992) Tradit, et al., "Timpiego Dell'imide Dell'Acido N'ftaliglutammico (Taildomide) Nella Terapia Sintomatica del Vomito di Molti Pazienti Affeti da Neoplasie Maligne o Causato Dalla Somministrazione di Cloridato di Mecloretamina", Cancro, Vol. 18, pp. 336-341 (1965) OU Trautman, J. R., "Treatment of Hansen's Disease", Cutis, Vol. 18, No. 1, 62-65 (1976) Van den Broek, H., "Treatment of Prurigo Nodularis with Thalidomide", Arch. Derm	9	OE	
OG Swift, T.R., "Thalidomide in Erythema Nodosum Leprosum", Lancet, Vol. 2, No. 335, p. 966 (1973) OH Szydlowska, et al., "On the Application of Thalidomide as a Block of Functional Groups of Proteins in Histochemical Investigations", Folia Histo. Cytochem., Vol. 16, No. 3, pp. 233-240 (1978) OI Tamura, et al., "Combination Thalidomide and Cyclosporine for Cardiac Allograft Rejection. Comparison with Combination Methylprodnisolone and Cyclosporine", Transplantation, Vol. 49, No. 1, p. 20-25 (1990) Tanaka, Y. et al., "Vascular Endothelial Growth Factor in Diabetic Retinopathy", The Lancet, Vol. 349, p. 1520 (1997) Tanaka, Y. et al., "Protamine is an Inhibitor of Angiogenesis", Nature, Vol. 297, pp. 307-312 (1982) Teppo, L. et al., "Thalidomide-Type Malformations and Subsequent Osteosarcoma", The Lancet, Vol. II, No. 8034, p. 405 (1977) "Thalidomide 20 Years On", The Lancet, Vol. II, No. 8245, pp. 510-511 (1981) "Thalidomide", The Merck Index, 11th ed., p. 1458 (1989) Thomas, et al., "Effect of Thalidomide in Steroid Dependency and Neuritis", Lepr. India, Vol. 52, No. 3, pp. 423-428 (1980) ON Thomas, et al., "Effect of Thalidomide Induced Aplasia in Regenerating Tail of Lizard, Hemidactylus Flavivirdis", Indian J. Exp. Biol., Vol. 10, pp. 316-317 (1972) Thomas, et al., "Lack of Thalidomide Induced Aplasia in Regenerating Tail of Lizard, Hemidactylus Flavivirdis", Indian J. Exp. Biol., Vol. 10, pp. 316-317 (1972) Thomas, et al., "Angiogenesis in the Uterus: Potential Regulation and Relation to Tumor Angiogenesis", Am. J. of Reproductive Immunology, Vol. 27, pp. 171-179 (1992) Tradit, et al., "Timpiego Dell'imide Dell'Acido N'ftaliglutammico (Taildomide) Nella Terapia Sintomatica del Vomito di Molti Pazienti Affeti da Neoplasie Maligne o Causato Dalla Somministrazione di Cloridato di Mecloretamina", Cancro, Vol. 18, pp. 336-341 (1965) OU Trautman, J. R., "Treatment of Hansen's Disease", Cutis, Vol. 18, No. 1, 62-65 (1976) Van den Broek, H., "Treatment of Prurigo Nodularis with Thalidomide", Arch. Derm		OF	
OG Swift, T.R., "Thalidomide in Erythema Nodosum Leprosum", Lancet, Vol. 2, No. 835, p. 966 (1973) OH Szydlowska, et al., "On the Application of Thalidomide as a Block of Functional Groups of Proteins in Histochemical Investigations", Folia Histo. Cytochem., Vol. 16, No. 3, pp. 233-240 (1978) OI Tamura, et al., "Combination Thalidomide and Cyclosporine for Cardiac Allograft Rejection. Comparison with Combination Methylprodnisolone and Cyclosporine", Transplantation, Vol. 49, No. 1, p. 20-25 (1990) Tanka, Y. et al., "Vascular Endothelial Growth Factor in Diabetic Retinopathy", The Lancet, Vol. 349, p. 1520 (1997) OK Taylor, S. et al., "Protamine is an Inhibitor of Angiogenesis", Nature, Vol. 297, pp. 307-312 (1982) Teppo, L. et al., "Thalidomide-Type Malformations and Subsequent Osteosarcoma", The Lancet, Vol. II, No. 8034, p. 405 (1977) "Thalidomide 20 Years On", The Lancet, Vol. II, No. 8245, pp. 510-511 (1981) ON "Thalidomide", The Merck Index, 11th ed., p. 1458 (1989) Theophilus, S., "Treatment with Thalidomide in Steroid Dependency and Neuritis", Lepr. India, Vol. 52, No. 3, pp. 423-428 (1980) Thomas, et al., "Effect of Thalidomide Induced Aplasia in Regenerating Tail of Lizard, Hemidactylus Flaviviridis", Indian J. Exp. Biol., Vol. 10, pp. 316-317 (1972) Thomas, et al., "Lack of Thalidomide Induced Aplasia in Regenerating Tail of Lizard, Hemidactylus Flaviviridis", Indian J. Exp. Biol., Vol. 10, pp. 316-317 (1972) Thomas, et al., "Successful Treatment of Adult's Langerhans Cell Histiocytosis with Thalidomide", Archives of Dermatol., Vol. 129, pp. 1261-1264 (1993) Torry, R. J. et al., "Angiogenesis in the Uterus: Potential Regulation and Relation to Tumor Angiogenesis", Am. J. of Reproductive Immunology, Vol. 27, pp. 171-179 (1992) Traidi, et al., "Timpiego Dell'mide Dell'Acido N'ftalilglutammico (Talidomide) Nella Terapia Sintomatica del Vomito di Molti Pazienti Affeti da Neoplasie Maligne o Causato Dalla Somministrazione di Cloridato di Mecloretamina", Cancro, Vol. 18, pp. 336-341 (1965) OU Trautm			
OH Szydlowska, et al., "On the Application of Thalidomide as a Block of Functional Groups of Proteins in Histochemical Investigations", Folia Histo. Cytochem., Vol. 16, No. 3, pp. 233-240 (1978) Tamura, et al., "Combination Thalidomide and Cyclosporine for Cardiac Allograft Rejection. Comparison with Combination Methylprodnisolone and Cyclosporine", Transplantation, Vol. 49, No. 1, p. 20-25 (1990) Tanaka, Y. et al., "Vascular Endothelial Growth Factor in Diabetic Retinopathy", The Lancet, Vol. 349, p. 1520 (1997) OK Taylor, S. et al., "Protamine is an Inhibitor of Angiogenesis", Nature, Vol. 297, pp. 307-312 (1982) Teppo, L. et al., "Thalidomide-Type Malformations and Subsequent Osteosarcoma", The Lancet, Vol. II, No. 8034, p. 405 (1977) "Thalidomide 20 Years On", The Lancet, Vol. II, No. 8245, pp. 510-511 (1981) ON Theophilus, S., "Treatment with Thalidomide in Steroid Dependency and Neuritis", Lepr. India, Vol. 52, No. 3, pp. 423-428 (1980) Thomas, et al., "Effect of Thalidomide on Liver Regeneration in Rat", Indian J. Exp. Biol., Vol. 10, pp. 314-315 (1972) Thomas, et al., "Lack of Thalidomide Induced Aplasia in Regenerating Tail of Lizard, Hemidactylus Flavivirdis", Indian J. Exp. Biol., Vol. 10, pp. 316-317 (1972) Thomas, et al., "Successful Treatment of Adult's Langerhans Cell Histiocytosis with Thalidomide", Archives of Dermatol., Vol. 129, pp. 1261-1264 (1993) Torry, R. J. et al., "Angiogenesis in the Uterus: Potential Regulation and Relation to Tumor Angiogenesis", Am. J. of Reproductive Immunology, Vol. 27, pp. 171-179 (1992) Traldi, et al., "L'impiego Dell'imide Dell'Acido N'ftalliglutammico (Talidomide) Nella Terapia Sintomatica del Vomito di Molti Pazienti Affeti da Neoplasie Maligne o Causato Dalla Somministrazione di Cloridato di Mecloretamina", Cancro, Vol. 18, pp. 336-341 (1965) OU Trauman, J. R., "Treatment of Hansen's Disease", Cuits, Vol. 18, No. 1, 62-65 (1976) Van den Broek, H., "Treatment of Prurigo Nodularis with Thalidomide", Arch. Dermatol, Vol. 116, No. 5, pp. 571-572 (19	0	OG	Swift TR "Thalidomide in Frythema Nodosum Leprosum" Lancet Vol. 2 No. 835, p. 966 (1973.)
Histochemical Investigations", Folia Histo. Cytochem., Vol. 16, No. 3, pp. 233-240 (1978) Tamura, et al., "Combination Thalidomide and Cyclosporine for Cardiac Allograft Rejection. Comparison with Combination Methylprodnisolone and Cyclosporine", Transplantation, Vol. 49, No. 1, p. 20-25 (1990) Tanaka, Y. et al., "Vascular Endothelial Growth Factor in Diabetic Retinopathy", The Lancet, Vol. 349, p. 1520 (1997) OK Taylor, S. et al., "Protamine is an Inhibitor of Angiogenesis", Nature, Vol. 297, pp. 307-312 (1982) Teppo, L. et al., "Thalidomide-Type Malformations and Subsequent Osteosarcoma", The Lancet, Vol. II, No. 8034, p. 405 (1977) "Thalidomide 20 Years On", The Lancet, Vol. II, No. 8245, pp. 510-511 (1981) ON "Thalidomide", The Merck Index, 11th ed., p. 1458 (1989) ON "Theophilus, S., "Treatment with Thalidomide in Steroid Dependency and Neuritis", Lepr. India, Vol. 52, No. 3, pp. 423-428 (1980) Thomas, et al., "Effect of Thalidomide on Liver Regeneration in Rat", Indian J. Exp. Biol., Vol. 10, pp. 314-315 (1972) Thomas, et al., "Lack of Thalidomide Induced Aplasia in Regenerating Tail of Lizard, Hemidactylus Flavivirdis", Indian J. Exp. Biol., Vol. 10, pp. 316-317 (1972) Thomas, et al., "Successful Treatment of Adult's Langerhans Cell Histiocytosis with Thalidomide", Archives of Dermatol., Vol. 129, pp. 1261-1264 (1993) Torry, R. J. et al., "Angiogenesis in the Uterus: Potential Regulation and Relation to Tumor Angiogenesis", Am. J. of Reproductive Immunology, Vol. 27, pp. 171-179 (1992) Traidia, et al., "Limpiego Dell'imide Dell'Acido N'ftalilglutaminico (Talidomide) Nella Terapia Sintomatica del Vomito di Molti Pazienti Affeti da Neoplasie Maligne o Causato Dalla Somministrazione di Cloridato di Mecloretamina", Cancro, Vol. 18, No. 1, 62-65 (1976) Van den Broek, H., "Treatment of Prurigo Nodularis with Thalidomide", Arch. Dermatol, Vol. 116, No. 5, pp. 571-572 (1980)	>>= ,	1 1	
OI Tamura, et al., "Combination Thalidomide and Cyclosporine for Cardiac Allograft Rejection. Comparison with Combination Methylprodnisolone and Cyclosporine", *Transplantation*, Vol. 49, No. 1, p. 20-25 (1990) Tanaka, Y. et al., "Vascular Endothelial Growth Factor in Diabetic Retinopathy", *The Lancet*, Vol. 349, p. 1520 (1997) OK Taylor, S. et al., "Protamine is an Inhibitor of Angiogenesis", *Nature*, Vol. 297, pp. 307-312 (1982) Teppo, L. et al., "Protamine is an Inhibitor of Angiogenesis", *Nature*, Vol. 297, pp. 307-312 (1982) Teppo, L. et al., "Thalidomide-Type Malformations and Subsequent Osteosarcoma", *The Lancet*, Vol. II, No. 8034, p. 405 (1977) "Thalidomide 20 Years On", *The Lancet*, Vol. II, No. 8245, pp. 510-511 (1981) ON "Thalidomide", *The Merck Index*, 11th ed., p. 1458 (1989) ON Theophilus, S., "Treatment with Thalidomide in Steroid Dependency and Neuritis", *Lepr. India*, Vol. 52, No. 3, pp. 423-428 (1980) Thomas, et al., "Effect of Thalidomide on Liver Regeneration in Rat", *Indian J. Exp. Biol., Vol. 10, pp. 316-317 (1972) Thomas, et al., "Lack of Thalidomide Induced Aplasia in Regenerating Tail of Lizard, Hemidactylus Flavivirdis", *Indian J. Exp. Biol., Vol. 10, pp. 316-317 (1972) OR *Indian J. Exp. Biol., Vol. 10, pp. 316-317 (1972) Thomas, L. et al., "Successful Treatment of Adult's Langerhans Cell Histiocytosis with Thalidomide", *Archives of Dermatol., Vol. 129, pp. 1261-1264 (1993) Torry, R. J. et al., "Angiogenesis in the Uterus: Potential Regulation and Relation to Tumor Angiogenesis", *Am. J. of Reproductive Immunology, Vol. 27, pp. 171-179 (1992) Traidi, et al., ""L'impiego Dell'imide Dell'Acido N'Italiguammico (Talidomide) Nella Terapia Sintomatica del Vomito di Molti Pazienti Affeti da Neoplasie Maligne o Causato Dalla Somministrazione di Cloridato di Mecloretamina", *Cancro*, Vol. 18, pp. 336-341 (1965) OU Trautman, J. R., "Treatment of Prurigo Nodularis with Thalidomide", *Arch. Dermatol*, Vol. 116, No. 5, pp. 571-572 (1980)		OII	Histochemical Investigations? Folia Histo Cytochem Vol 16 No 3 nn 233-240 (1978)
with Combination Methylprodnisolone and Cyclosporine", Transplantation, Vol. 49, No. 1, p. 20-25 (1990) Tanaka, Y. et al., "Vascular Endothelial Growth Factor in Diabetic Retinopathy", The Lancet, Vol. 349, p. 1520 (1997) OK Taylor, S. et al., "Protamine is an Inhibitor of Angiogenesis", Nature, Vol. 297, pp. 307-312 (1982) Teppo, L. et al., "Thalidomide-Type Malformations and Subsequent Osteosarcoma", The Lancet, Vol. II, No. 8034, p. 405 (1977) "Thalidomide 20 Years On", The Lancet, Vol. II, No. 8245, pp. 510-511 (1981) ON "Thalidomide", The Merck Index, 11th ed., p. 1458 (1989) ON "Theophilus, S., "Treatment with Thalidomide in Steroid Dependency and Neuritis", Lepr. India, Vol. 52, No. 3, pp. 423-428 (1980) Thomas, et al., "Effect of Thalidomide on Liver Regeneration in Rat", Indian J. Exp. Biol., Vol. 10, pp. 314-315 (1972) Thomas, et al., "Lack of Thalidomide Induced Aplasia in Regenerating Tail of Lizard, Hemidactylus Flavivirdis", Indian J. Exp. Biol., Vol. 10, pp. 316-317 (1972) Thomas, L. et al., "Successful Treatment of Adult's Langerhans Cell Histiocytosis with Thalidomide", Archives of Dermatol., Vol. 129, pp. 1261-1264 (1993) Torry, R. J. et al., "Angiogenesis in the Uterus: Potential Regulation and Relation to Tumor Angiogenesis", OS Am. J. of Reproductive Immunology, Vol. 27, pp. 171-179 (1992) Traldi, et al., "L'impiego Dell'imide Dell'Acido N'ftalligutammico (Talidomide) Nella Terapia Sintomatica del Vomito di Molti Pazienti Affeti da Neoplasie Maligne o Causato Dalla Somministrazione di Cloridato di Mecloretamina", Cancro, Vol. 18, No. 1, 62-65 (1976) Van den Broek, H., "Treatment of Prurigo Nodularis with Thalidomide", Arch. Dermatol, Vol. 116, No. 5, pp. 571-572 (1980)			Transport of all "Combination Theildomide and Cyclesporine for Cardiac Allograft Rejection, Comparison
Theophilus, S., "Treatment with Thalidomide in Steroid Dependency and Neuritis", Lepr. India, Vol. 52, No. 3, pp. 423-428 (1980) Thomas, et al., "Effect of Thalidomide on Liver Regeneration in Rat", Indian J. Exp. Biol., Vol. 10, pp. 314-315 (1972) Thomas, et al., "Lack of Thalidomide Induced Aplasia in Regenerating Tail of Lizard, Hemidactylus Flavivirdis", Indian J. Exp. Biol., Vol. 10, pp. 316-317 (1972) Thomas, L. et al., "Successful Treatment of Adult's Langerhans Cell Histiocytosis with Thalidomide", Archives of Dermatol., Vol. 129, pp. 1261-1264 (1993) Torry, R. J. et al., "Angiogenesis in the Uterus: Potential Regulation and Relation to Tumor Angiogenesis", Am. J. of Reproductive Immunology, Vol. 27, pp. 171-179 (1992) Traidi, et al., "I' impiego Dell'imide Dell'Acido N'ftalilglutammico (Talidomide) Nella Terapia Sintomatica del Vomito di Molti Pazienti Affeti da Neoplasie Maligne o Causato Dalla Somministrazione di Cloridato di Mecloretamina", Cancro, Vol. 18, pp. 336-341 (1965) OU Trautman, J. R., "Treatment of Hansen's Disease", Cutis, Vol. 18, No. 1, 62-65 (1976) Van den Broek, H., "Treatment of Prurigo Nodularis with Thalidomide", Arch. Dermatol, Vol. 116, No. 5, pp. 571-572 (1980)		Oi	
Theophilus, S., "Treatment with Thalidomide in Steroid Dependency and Neuritis", Lepr. India, Vol. 52, No. 3, pp. 423-428 (1980) Thomas, et al., "Effect of Thalidomide on Liver Regeneration in Rat", Indian J. Exp. Biol., Vol. 10, pp. 314-315 (1972) Thomas, et al., "Lack of Thalidomide Induced Aplasia in Regenerating Tail of Lizard, Hemidactylus Flavivirdis", Indian J. Exp. Biol., Vol. 10, pp. 316-317 (1972) Thomas, L. et al., "Successful Treatment of Adult's Langerhans Cell Histiocytosis with Thalidomide", Archives of Dermatol., Vol. 129, pp. 1261-1264 (1993) Torry, R. J. et al., "Angiogenesis in the Uterus: Potential Regulation and Relation to Tumor Angiogenesis", Am. J. of Reproductive Immunology, Vol. 27, pp. 171-179 (1992) Traidi, et al., "I' impiego Dell'imide Dell'Acido N'ftalilglutammico (Talidomide) Nella Terapia Sintomatica del Vomito di Molti Pazienti Affeti da Neoplasie Maligne o Causato Dalla Somministrazione di Cloridato di Mecloretamina", Cancro, Vol. 18, pp. 336-341 (1965) OU Trautman, J. R., "Treatment of Hansen's Disease", Cutis, Vol. 18, No. 1, 62-65 (1976) Van den Broek, H., "Treatment of Prurigo Nodularis with Thalidomide", Arch. Dermatol, Vol. 116, No. 5, pp. 571-572 (1980)	105,		white Contollination Methylprocurisorone and Cyclosporine, 1 Transpiration, vol. 47, 10. 1, p. 20-23 (1994)
Theophilus, S., "Treatment with Thalidomide in Steroid Dependency and Neuritis", Lepr. India, Vol. 52, No. 3, pp. 423-428 (1980) Thomas, et al., "Effect of Thalidomide on Liver Regeneration in Rat", Indian J. Exp. Biol., Vol. 10, pp. 314-315 (1972) Thomas, et al., "Lack of Thalidomide Induced Aplasia in Regenerating Tail of Lizard, Hemidactylus Flavivirdis", Indian J. Exp. Biol., Vol. 10, pp. 316-317 (1972) Thomas, L. et al., "Successful Treatment of Adult's Langerhans Cell Histiocytosis with Thalidomide", Archives of Dermatol., Vol. 129, pp. 1261-1264 (1993) Torry, R. J. et al., "Angiogenesis in the Uterus: Potential Regulation and Relation to Tumor Angiogenesis", Am. J. of Reproductive Immunology, Vol. 27, pp. 171-179 (1992) Traidi, et al., "I' impiego Dell'imide Dell'Acido N'ftalilglutammico (Talidomide) Nella Terapia Sintomatica del Vomito di Molti Pazienti Affeti da Neoplasie Maligne o Causato Dalla Somministrazione di Cloridato di Mecloretamina", Cancro, Vol. 18, pp. 336-341 (1965) OU Trautman, J. R., "Treatment of Hansen's Disease", Cutis, Vol. 18, No. 1, 62-65 (1976) Van den Broek, H., "Treatment of Prurigo Nodularis with Thalidomide", Arch. Dermatol, Vol. 116, No. 5, pp. 571-572 (1980)	<u> </u>	OJ	
Theophilus, S., "Treatment with Thalidomide in Steroid Dependency and Neuritis", Lepr. India, Vol. 52, No. 3, pp. 423-428 (1980) Thomas, et al., "Effect of Thalidomide on Liver Regeneration in Rat", Indian J. Exp. Biol., Vol. 10, pp. 314-315 (1972) Thomas, et al., "Lack of Thalidomide Induced Aplasia in Regenerating Tail of Lizard, Hemidactylus Flavivirdis", Indian J. Exp. Biol., Vol. 10, pp. 316-317 (1972) Thomas, L. et al., "Successful Treatment of Adult's Langerhans Cell Histiocytosis with Thalidomide", Archives of Dermatol., Vol. 129, pp. 1261-1264 (1993) Torry, R. J. et al., "Angiogenesis in the Uterus: Potential Regulation and Relation to Tumor Angiogenesis", Am. J. of Reproductive Immunology, Vol. 27, pp. 171-179 (1992) Traidi, et al., "I' impiego Dell'imide Dell'Acido N'ftalilglutammico (Talidomide) Nella Terapia Sintomatica del Vomito di Molti Pazienti Affeti da Neoplasie Maligne o Causato Dalla Somministrazione di Cloridato di Mecloretamina", Cancro, Vol. 18, pp. 336-341 (1965) OU Trautman, J. R., "Treatment of Hansen's Disease", Cutis, Vol. 18, No. 1, 62-65 (1976) Van den Broek, H., "Treatment of Prurigo Nodularis with Thalidomide", Arch. Dermatol, Vol. 116, No. 5, pp. 571-572 (1980)		-	1320 (1997)
Theophilus, S., "Treatment with Thalidomide in Steroid Dependency and Neuritis", Lepr. India, Vol. 52, No. 3, pp. 423-428 (1980) Thomas, et al., "Effect of Thalidomide on Liver Regeneration in Rat", Indian J. Exp. Biol., Vol. 10, pp. 314-315 (1972) Thomas, et al., "Lack of Thalidomide Induced Aplasia in Regenerating Tail of Lizard, Hemidactylus Flavivirdis", Indian J. Exp. Biol., Vol. 10, pp. 316-317 (1972) Thomas, L. et al., "Successful Treatment of Adult's Langerhans Cell Histiocytosis with Thalidomide", Archives of Dermatol., Vol. 129, pp. 1261-1264 (1993) Torry, R. J. et al., "Angiogenesis in the Uterus: Potential Regulation and Relation to Tumor Angiogenesis", Am. J. of Reproductive Immunology, Vol. 27, pp. 171-179 (1992) Traidi, et al., "I' impiego Dell'imide Dell'Acido N'ftalilglutammico (Talidomide) Nella Terapia Sintomatica del Vomito di Molti Pazienti Affeti da Neoplasie Maligne o Causato Dalla Somministrazione di Cloridato di Mecloretamina", Cancro, Vol. 18, pp. 336-341 (1965) OU Trautman, J. R., "Treatment of Hansen's Disease", Cutis, Vol. 18, No. 1, 62-65 (1976) Van den Broek, H., "Treatment of Prurigo Nodularis with Thalidomide", Arch. Dermatol, Vol. 116, No. 5, pp. 571-572 (1980)		OK	Taylor, S. et al., "Protamine is an Inhibitor of Angiogenesis", <i>Nature</i> , Vol. 297, pp. 307-312 (1982)
Theophilus, S., "Treatment with Thalidomide in Steroid Dependency and Neuritis", Lepr. India, Vol. 52, No. 3, pp. 423-428 (1980) Thomas, et al., "Effect of Thalidomide on Liver Regeneration in Rat", Indian J. Exp. Biol., Vol. 10, pp. 314-315 (1972) Thomas, et al., "Lack of Thalidomide Induced Aplasia in Regenerating Tail of Lizard, Hemidactylus Flavivirdis", Indian J. Exp. Biol., Vol. 10, pp. 316-317 (1972) Thomas, L. et al., "Successful Treatment of Adult's Langerhans Cell Histiocytosis with Thalidomide", Archives of Dermatol., Vol. 129, pp. 1261-1264 (1993) Torry, R. J. et al., "Angiogenesis in the Uterus: Potential Regulation and Relation to Tumor Angiogenesis", Am. J. of Reproductive Immunology, Vol. 27, pp. 171-179 (1992) Traidi, et al., "I' impiego Dell'imide Dell'Acido N'ftalilglutammico (Talidomide) Nella Terapia Sintomatica del Vomito di Molti Pazienti Affeti da Neoplasie Maligne o Causato Dalla Somministrazione di Cloridato di Mecloretamina", Cancro, Vol. 18, pp. 336-341 (1965) OU Trautman, J. R., "Treatment of Hansen's Disease", Cutis, Vol. 18, No. 1, 62-65 (1976) Van den Broek, H., "Treatment of Prurigo Nodularis with Thalidomide", Arch. Dermatol, Vol. 116, No. 5, pp. 571-572 (1980)	11		Teppo, L. et al., "Thalidomide-Type Malformations and Subsequent Osteosarcoma", <i>The Lancet</i> , Vol. II, No.
Theophilus, S., "Treatment with Thalidomide in Steroid Dependency and Neuritis", Lepr. India, Vol. 52, No. 3, pp. 423-428 (1980) Thomas, et al., "Effect of Thalidomide on Liver Regeneration in Rat", Indian J. Exp. Biol., Vol. 10, pp. 314-315 (1972) Thomas, et al., "Lack of Thalidomide Induced Aplasia in Regenerating Tail of Lizard, Hemidactylus Flavivirdis", Indian J. Exp. Biol., Vol. 10, pp. 316-317 (1972) Thomas, L. et al., "Successful Treatment of Adult's Langerhans Cell Histiocytosis with Thalidomide", Archives of Dermatol., Vol. 129, pp. 1261-1264 (1993) Torry, R. J. et al., "Angiogenesis in the Uterus: Potential Regulation and Relation to Tumor Angiogenesis", Am. J. of Reproductive Immunology, Vol. 27, pp. 171-179 (1992) Traidi, et al., "I' impiego Dell'imide Dell'Acido N'ftalilglutammico (Talidomide) Nella Terapia Sintomatica del Vomito di Molti Pazienti Affeti da Neoplasie Maligne o Causato Dalla Somministrazione di Cloridato di Mecloretamina", Cancro, Vol. 18, pp. 336-341 (1965) OU Trautman, J. R., "Treatment of Hansen's Disease", Cutis, Vol. 18, No. 1, 62-65 (1976) Van den Broek, H., "Treatment of Prurigo Nodularis with Thalidomide", Arch. Dermatol, Vol. 116, No. 5, pp. 571-572 (1980)	Z	OL	
Theophilus, S., "Treatment with Thalidomide in Steroid Dependency and Neuritis", Lepr. India, Vol. 52, No. 3, pp. 423-428 (1980) Thomas, et al., "Effect of Thalidomide on Liver Regeneration in Rat", Indian J. Exp. Biol., Vol. 10, pp. 314-315 (1972) Thomas, et al., "Lack of Thalidomide Induced Aplasia in Regenerating Tail of Lizard, Hemidactylus Flavivirdis", Indian J. Exp. Biol., Vol. 10, pp. 316-317 (1972) Thomas, L. et al., "Successful Treatment of Adult's Langerhans Cell Histiocytosis with Thalidomide", Archives of Dermatol., Vol. 129, pp. 1261-1264 (1993) Torry, R. J. et al., "Angiogenesis in the Uterus: Potential Regulation and Relation to Tumor Angiogenesis", Am. J. of Reproductive Immunology, Vol. 27, pp. 171-179 (1992) Traidi, et al., "I' impiego Dell'imide Dell'Acido N'ftalilglutammico (Talidomide) Nella Terapia Sintomatica del Vomito di Molti Pazienti Affeti da Neoplasie Maligne o Causato Dalla Somministrazione di Cloridato di Mecloretamina", Cancro, Vol. 18, pp. 336-341 (1965) OU Trautman, J. R., "Treatment of Hansen's Disease", Cutis, Vol. 18, No. 1, 62-65 (1976) Van den Broek, H., "Treatment of Prurigo Nodularis with Thalidomide", Arch. Dermatol, Vol. 116, No. 5, pp. 571-572 (1980)	The contract of the contract o		"Thalidomide 20 Years On", <i>The Lancet</i> , Vol. II, No. 8245, pp. 510-511 (1981)
Theophilus, S., "Treatment with Thalidomide in Steroid Dependency and Neuritis", Lepr. India, Vol. 52, No. 3, pp. 423-428 (1980) Thomas, et al., "Effect of Thalidomide on Liver Regeneration in Rat", Indian J. Exp. Biol., Vol. 10, pp. 314-315 (1972) Thomas, et al., "Lack of Thalidomide Induced Aplasia in Regenerating Tail of Lizard, Hemidactylus Flavivirdis", Indian J. Exp. Biol., Vol. 10, pp. 316-317 (1972) Thomas, L. et al., "Successful Treatment of Adult's Langerhans Cell Histiocytosis with Thalidomide", Archives of Dermatol., Vol. 129, pp. 1261-1264 (1993) Torry, R. J. et al., "Angiogenesis in the Uterus: Potential Regulation and Relation to Tumor Angiogenesis", Am. J. of Reproductive Immunology, Vol. 27, pp. 171-179 (1992) Traidi, et al., "I' impiego Dell'imide Dell'Acido N'ftalilglutammico (Talidomide) Nella Terapia Sintomatica del Vomito di Molti Pazienti Affeti da Neoplasie Maligne o Causato Dalla Somministrazione di Cloridato di Mecloretamina", Cancro, Vol. 18, pp. 336-341 (1965) OU Trautman, J. R., "Treatment of Hansen's Disease", Cutis, Vol. 18, No. 1, 62-65 (1976) Van den Broek, H., "Treatment of Prurigo Nodularis with Thalidomide", Arch. Dermatol, Vol. 116, No. 5, pp. 571-572 (1980)		OM	
Theophilus, S., "Treatment with Thalidomide in Steroid Dependency and Neuritis", Lepr. India, Vol. 52, No. 3, pp. 423-428 (1980) Thomas, et al., "Effect of Thalidomide on Liver Regeneration in Rat", Indian J. Exp. Biol., Vol. 10, pp. 314-315 (1972) Thomas, et al., "Lack of Thalidomide Induced Aplasia in Regenerating Tail of Lizard, Hemidactylus Flavivirdis", Indian J. Exp. Biol., Vol. 10, pp. 316-317 (1972) Thomas, L. et al., "Successful Treatment of Adult's Langerhans Cell Histiocytosis with Thalidomide", Archives of Dermatol., Vol. 129, pp. 1261-1264 (1993) Torry, R. J. et al., "Angiogenesis in the Uterus: Potential Regulation and Relation to Tumor Angiogenesis", Am. J. of Reproductive Immunology, Vol. 27, pp. 171-179 (1992) Traidi, et al., "L'impiego Dell'imide Dell'Acido N'ftalilglutammico (Talidomide) Nella Terapia Sintomatica del Vomito di Molti Pazienti Affeti da Neoplasie Maligne o Causato Dalla Somministrazione di Cloridato di Mecloretamina", Cancro, Vol. 18, pp. 336-341 (1965) OU Trautman, J. R., "Treatment of Hansen's Disease", Cutis, Vol. 18, No. 1, 62-65 (1976) Van den Broek, H., "Treatment of Prurigo Nodularis with Thalidomide", Arch. Dermatol, Vol. 116, No. 5, pp. 571-572 (1980)			"Thalidomide", The Merck Index, 11th ed., p. 1458 (1989)
Theophilus, S., "Treatment with Thalidomide in Steroid Dependency and Neuritis", Lepr. India, Vol. 52, No. 3, pp. 423-428 (1980) Thomas, et al., "Effect of Thalidomide on Liver Regeneration in Rat", Indian J. Exp. Biol., Vol. 10, pp. 314-315 (1972) Thomas, et al., "Lack of Thalidomide Induced Aplasia in Regenerating Tail of Lizard, Hemidactylus Flavivirdis", Indian J. Exp. Biol., Vol. 10, pp. 316-317 (1972) Thomas, L. et al., "Successful Treatment of Adult's Langerhans Cell Histiocytosis with Thalidomide", Archives of Dermatol., Vol. 129, pp. 1261-1264 (1993) Torry, R. J. et al., "Angiogenesis in the Uterus: Potential Regulation and Relation to Tumor Angiogenesis", Am. J. of Reproductive Immunology, Vol. 27, pp. 171-179 (1992) Traidi, et al., "L'impiego Dell'imide Dell'Acido N'ftalilglutammico (Talidomide) Nella Terapia Sintomatica del Vomito di Molti Pazienti Affeti da Neoplasie Maligne o Causato Dalla Somministrazione di Cloridato di Mecloretamina", Cancro, Vol. 18, pp. 336-341 (1965) OU Trautman, J. R., "Treatment of Hansen's Disease", Cutis, Vol. 18, No. 1, 62-65 (1976) Van den Broek, H., "Treatment of Prurigo Nodularis with Thalidomide", Arch. Dermatol, Vol. 116, No. 5, pp. 571-572 (1980)	()	ON	
OR Archives of Dermatol., Vol. 129, pp. 1261-1264 (1993) Torry, R. J. et al., "Angiogenesis in the Uterus: Potential Regulation and Relation to Tumor Angiogenesis", Am. J. of Reproductive Immunology, Vol. 27, pp. 171-179 (1992) Traldi, et al., ""L'impiego Dell'imide Dell'Acido N'ftalilglutammico (Talidomide) Nella Terapia Sintomatica del Vomito di Molti Pazienti Affeti da Neoplasie Maligne o Causato Dalla Somministrazione di Cloridato di Mecloretamina", Cancro, Vol. 18, pp. 336-341 (1965) OU Trautman, J. R., "Treatment of Hansen's Disease", Cutis, Vol. 18, No. 1, 62-65 (1976) Van den Broek, H., "Treatment of Prurigo Nodularis with Thalidomide", Arch. Dermatol, Vol. 116, No. 5, pp. 571-572 (1980)			Theophilus, S., "Treatment with Thalidomide in Steroid Dependency and Neuritis", Lepr. India, Vol. 52,
OR Archives of Dermatol., Vol. 129, pp. 1261-1264 (1993) Torry, R. J. et al., "Angiogenesis in the Uterus: Potential Regulation and Relation to Tumor Angiogenesis", Am. J. of Reproductive Immunology, Vol. 27, pp. 171-179 (1992) Traldi, et al., ""L'impiego Dell'imide Dell'Acido N'ftalilglutammico (Talidomide) Nella Terapia Sintomatica del Vomito di Molti Pazienti Affeti da Neoplasie Maligne o Causato Dalla Somministrazione di Cloridato di Mecloretamina", Cancro, Vol. 18, pp. 336-341 (1965) OU Trautman, J. R., "Treatment of Hansen's Disease", Cutis, Vol. 18, No. 1, 62-65 (1976) Van den Broek, H., "Treatment of Prurigo Nodularis with Thalidomide", Arch. Dermatol, Vol. 116, No. 5, pp. 571-572 (1980)		00	
OR Archives of Dermatol., Vol. 129, pp. 1261-1264 (1993) Torry, R. J. et al., "Angiogenesis in the Uterus: Potential Regulation and Relation to Tumor Angiogenesis", Am. J. of Reproductive Immunology, Vol. 27, pp. 171-179 (1992) Traldi, et al., ""L'impiego Dell'imide Dell'Acido N'ftalilglutammico (Talidomide) Nella Terapia Sintomatica del Vomito di Molti Pazienti Affeti da Neoplasie Maligne o Causato Dalla Somministrazione di Cloridato di Mecloretamina", Cancro, Vol. 18, pp. 336-341 (1965) OU Trautman, J. R., "Treatment of Hansen's Disease", Cutis, Vol. 18, No. 1, 62-65 (1976) Van den Broek, H., "Treatment of Prurigo Nodularis with Thalidomide", Arch. Dermatol, Vol. 116, No. 5, pp. 571-572 (1980)			
OR Archives of Dermatol., Vol. 129, pp. 1261-1264 (1993) Torry, R. J. et al., "Angiogenesis in the Uterus: Potential Regulation and Relation to Tumor Angiogenesis", Am. J. of Reproductive Immunology, Vol. 27, pp. 171-179 (1992) Traldi, et al., ""L'impiego Dell'imide Dell'Acido N'ftalilglutammico (Talidomide) Nella Terapia Sintomatica del Vomito di Molti Pazienti Affeti da Neoplasie Maligne o Causato Dalla Somministrazione di Cloridato di Mecloretamina", Cancro, Vol. 18, pp. 336-341 (1965) OU Trautman, J. R., "Treatment of Hansen's Disease", Cutis, Vol. 18, No. 1, 62-65 (1976) Van den Broek, H., "Treatment of Prurigo Nodularis with Thalidomide", Arch. Dermatol, Vol. 116, No. 5, pp. 571-572 (1980)	آجي	OP	
OR Archives of Dermatol., Vol. 129, pp. 1261-1264 (1993) Torry, R. J. et al., "Angiogenesis in the Uterus: Potential Regulation and Relation to Tumor Angiogenesis", Am. J. of Reproductive Immunology, Vol. 27, pp. 171-179 (1992) Traldi, et al., ""L'impiego Dell'imide Dell'Acido N'ftalilglutammico (Talidomide) Nella Terapia Sintomatica del Vomito di Molti Pazienti Affeti da Neoplasie Maligne o Causato Dalla Somministrazione di Cloridato di Mecloretamina", Cancro, Vol. 18, pp. 336-341 (1965) OU Trautman, J. R., "Treatment of Hansen's Disease", Cutis, Vol. 18, No. 1, 62-65 (1976) Van den Broek, H., "Treatment of Prurigo Nodularis with Thalidomide", Arch. Dermatol, Vol. 116, No. 5, pp. 571-572 (1980)		01	
OR Archives of Dermatol., Vol. 129, pp. 1261-1264 (1993) Torry, R. J. et al., "Angiogenesis in the Uterus: Potential Regulation and Relation to Tumor Angiogenesis", Am. J. of Reproductive Immunology, Vol. 27, pp. 171-179 (1992) Traldi, et al., ""L'impiego Dell'imide Dell'Acido N'ftalilglutammico (Talidomide) Nella Terapia Sintomatica del Vomito di Molti Pazienti Affeti da Neoplasie Maligne o Causato Dalla Somministrazione di Cloridato di Mecloretamina", Cancro, Vol. 18, pp. 336-341 (1965) OU Trautman, J. R., "Treatment of Hansen's Disease", Cutis, Vol. 18, No. 1, 62-65 (1976) Van den Broek, H., "Treatment of Prurigo Nodularis with Thalidomide", Arch. Dermatol, Vol. 116, No. 5, pp. 571-572 (1980)		00	
Torry, R. J. et al., "Angiogenesis in the Uterus: Potential Regulation and Relation to Tumor Angiogenesis", Am. J. of Reproductive Immunology, Vol. 27, pp. 171-179 (1992) Traldi, et al., "L'impiego Dell'imide Dell'Acido N'ftalilglutammico (Talidomide) Nella Terapia Sintomatica del Vomito di Molti Pazienti Affeti da Neoplasie Maligne o Causato Dalla Somministrazione di Cloridato di Mecloretamina", Cancro, Vol. 18, pp. 336-341 (1965) OU Trautman, J. R., "Treatment of Hansen's Disease", Cutis, Vol. 18, No. 1, 62-65 (1976) Van den Broek, H., "Treatment of Prurigo Nodularis with Thalidomide", Arch. Dermatol, Vol. 116, No. 5, pp. 571-572 (1980)	_	UQ	
Torry, R. J. et al., "Angiogenesis in the Uterus: Potential Regulation and Relation to Tumor Angiogenesis", Am. J. of Reproductive Immunology, Vol. 27, pp. 171-179 (1992) Traldi, et al., "L'impiego Dell'imide Dell'Acido N'ftalilglutammico (Talidomide) Nella Terapia Sintomatica del Vomito di Molti Pazienti Affeti da Neoplasie Maligne o Causato Dalla Somministrazione di Cloridato di Mecloretamina", Cancro, Vol. 18, pp. 336-341 (1965) OU Trautman, J. R., "Treatment of Hansen's Disease", Cutis, Vol. 18, No. 1, 62-65 (1976) Van den Broek, H., "Treatment of Prurigo Nodularis with Thalidomide", Arch. Dermatol, Vol. 116, No. 5, pp. 571-572 (1980)	\mathcal{L}	OP	
Traldi, et al., "L'impiego Dell'imide Dell'Acido N'ftalilglutammico (Talidomide) Nella Terapia OT Sintomatica del Vomito di Molti Pazienti Affeti da Neoplasie Maligne o Causato Dalla Somministrazione di Cloridato di Mecloretamina", Cancro, Vol. 18, pp. 336-341 (1965) OU Trautman, J. R., "Treatment of Hansen's Disease", Cutis, Vol. 18, No. 1, 62-65 (1976) Van den Broek, H., "Treatment of Prurigo Nodularis with Thalidomide", Arch. Dermatol, Vol. 116, No. 5, pp. 571-572 (1980)		OR	Town D. L. et al. "An elegendary in the Uterway Detection Description and Polation to Tumor Angicconogic"
Traldi, et al., "L'impiego Dell'imide Dell'Acido N'ftalilglutammico (Talidomide) Nella Terapia OT Sintomatica del Vomito di Molti Pazienti Affeti da Neoplasie Maligne o Causato Dalla Somministrazione di Cloridato di Mecloretamina", Cancro, Vol. 18, pp. 336-341 (1965) OU Trautman, J. R., "Treatment of Hansen's Disease", Cutis, Vol. 18, No. 1, 62-65 (1976) Van den Broek, H., "Treatment of Prurigo Nodularis with Thalidomide", Arch. Dermatol, Vol. 116, No. 5, pp. 571-572 (1980)		00	forry, R. J. et al., Angiogenesis in the Oterus: Potential Regulation and Relation to Tuniol Angiogenesis,
OT Sintomatica del Vomito di Molti Pazienti Affeti da Neoplasie Maligne o Causato Dalla Somministrazione di Cloridato di Mecloretamina", Cancro, Vol. 18, pp. 336-341 (1965) OU Trautman, J. R., "Treatment of Hansen's Disease", Cutis, Vol. 18, No. 1, 62-65 (1976) Van den Broek, H., "Treatment of Prurigo Nodularis with Thalidomide", Arch. Dermatol, Vol. 116, No. 5, pp. 571-572 (1980)		US	Am. J. of Reproductive Immunology, Vol. 21, pp. 171-179 (1992)
Somministrazione di Cloridato di Mecloretamina", Cancro, Vol. 18, pp. 336-341 (1965) OU Trautman, J. R., "Treatment of Hansen's Disease", Cutis, Vol. 18, No. 1, 62-65 (1976) Van den Broek, H., "Treatment of Prurigo Nodularis with Thalidomide", Arch. Dermatol, Vol. 116, No. 5, pp. 571-572 (1980)	8	OT	Traidi, et al., "L'impiego Dell'imide Dell'Acido N πaniglutammico (Talidomide) Nella Terapia
OU Trautman, J. R., "Treatment of Hansen's Disease", Cutis, Vol. 18, No. 1, 62-65 (1976) Van den Broek, H., "Treatment of Prurigo Nodularis with Thalidomide", Arch. Dermatol, Vol. 116, No. 5, pp. 571-572 (1980)	_	OT	
Van den Broek, H., "Treatment of Prurigo Nodularis with Thalidomide", Arch. Dermatol, Vol. 116, No. 5, pp. 571-572 (1980)			
OV pp. 571-572 (1980)	\gg	OU	Trautman, J. R., "Treatment of Hansen's Disease", Cutis, Vol. 18, No. 1, 62-65 (1976)
OV pp. 571-572 (1980)	$\overline{}$		
0/23/0/	XAMIN	ER	
			0/23/0/
AMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in	XAMIN	VER: Initi	al if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in

conformance and not considered. Include copy of this form with next communication to applicant.

RECEIVED

AUG 0 3 2001 TECH CENTER 1600/2900

PTO/SB/08A (08-00)
Approved for use through 10/31/2002 OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction of 1995, no certains are required to respond to a collection of information unless it contains a valid OMB control number

1449/A/PTO

Substitute for Form 1449/A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary

Sheet | 16 of 17

_		Complete if Known
	Application Number	09/545,139
	Filing Date	April 7, 2000
	First Named Inventor	D'Amato et al.
	Group Art Unit	1614
	Examiner Name	J. Goldberg
	Attorney Docket Number	05213-0650 43170-219681

		U.S. PATENT DOCUMENTS
		OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, Etc.)
$\overline{}$		Vasilescu, et al., "Cercetari Privind Actiunea Talidomidei Asupra Celulelor Cultivate in Vitro", Cerc.
\leq	PA	Fiziol., Vol. 13, No. 4, pp. 293-300 (1968)
$\overline{}$	PB	Verhaul, et al., "Combination Oral Antiangiogenic Therapy with Thalidomide and Sulindac Inhibits Tumor
7	1	Growth in Rabbits", Brit. J. Cancer, Vol. 79, No. 1, pp. 114-118 (1999)
$\overline{}$	PC	Vicente, T. et al., "In Vitro Activity of Thalidomide Against Mycobacterium avium Complex", Archives of
/ /	10	Internal Medicine, Vol. 153, p.334 (1993)
$\overline{}$	PD	Villa, et al., "Antimytotic Effect of Thalidomide and its Metabolites on the Chick Embryo Blood Cells",
	10	Haematol. Latina, Vol. 6, pp. 217-221 (1963)
	PE	Villa, et al., "Cytological Effects of Thalidomide", <i>The Lancet</i> , pp. 725 (1963)
	PF	Vladutiu, A., "Another Chance for Thalidomide?", <i>The Lancet</i> , Vol. I, No. 7444, pp. 981-982 (1966)
<u>∠</u>	PG	Vogelsang, G. B. et al., "Thalidomide for the Treatment of Chronic Graft-Versus-Host Disease", New
\rightarrow	ru	
	DII	England J. of Med., Vol. 326, pp. 1055-1059 (1992)
<u> </u>	PH	Vogelsang, et al., "Therapy of Chronic Graft-v-Host Disease in a Rat Model", <i>Blood</i> , Vol. 74, No. 1,
بيديم	DI .	No. 1, pp. 507-511 (1989)
	PI	Vogelsang, et al., "Thalidomide Induction of Bone Marrow Transplantation Tolerance", Transplant Proc.,
	DI	Vol. 19, No. 1, Pt. 3, pp. 2658-2661 (1987)
	PJ	Vogelsang, et al., "Treatment and Prevention of Acute Graft-versus-Host Disease with Thalidomide in a Rat
	DIZ	Model", Transplantation, Vol. 41, No. 5, pp. 644-647 (1986)
2	PK	Vogt, B. et al., "Inhibition of Angiogenesis in Kaposi's Sarcoma by Captopril", <i>The Lancet</i> , Vol. 349, p.
	N.	1148 (1997)
<u> </u>	PL	Waters, M.F. et al., "Treatment of Ulcerative Colitis with Thalidomide", Brit. Med. J., Vol. 1, No. 6166, pp.
2 -1-12		792 (1979)
<u>کیک</u>	PM	Waters, M., "Use of Thalidomide in Leprosy", <i>BMJ</i> , Vol. 303, No. 6800, p. 470 (1991)
. #	D) I	Waters, M.F., "An Internally-Controlled Double Blind Trial of Thalidomide in Severe Erythema Nodosum
2	PN	Leprosum", Lepro. Rev., Vol. 42, No. 1, pp. 26-42 (1971)
*	PO	Weidner, J. et al., "Tumor Angiogenesis and Metastasis-Correlation in Invasive Breast Carcinoma", The Nev
-	·	England J. of Med., Vol. 324, No. 1, pp. 1-8 (1991)
	PP	Weidner, N. et al., "Tumor Angiogenesis Correlates with Metastasis in Invasive Prostate Cancer", Am. J. of
The state of the s		Pathol., Vol. 143, No. 2, pp. 401-409 (1993)
7	PQ	Weidner, N. et al., "Tumor Angiogenesis: A New Significant and Independent Prognostic Indicator in Early-
-		Stage Breast Carcinoma", J. of Nat. Canc. Inst., Vol. 84, No. 24, 1875-1887 (1992)
1.554	PR	Wesolowski, et al., "Effect of Light on a Murine Model of Retinopathy of Prematurity", Invest. Opthamol. &
_ \		Visual Science, Vol. 33, No. 4, p. 1281 (Abstract only)
\overline{z}	PS	White, C. W. et al., "Treatment of Pulmonary Hemangiomatosis with Recombinant Interferon Alfa-2a", The
-		New England J. of Med., Vol. 32, No. 18, pp. 1197-1200 (1989)
\supset	PT	Williams, K. M., "Enantiomers in Arthritic Disorders", <i>Pharmacol. & Therapeutics</i> , Vol. 46, No. 2, pp. 273-
		295 (1990)
S.	PU	Williams, et al., "Thalidomide Hypersensitivity in AIDS", Lancet, Vol. 337, pp. 436-437 (1991)
		Winkelmann, et al., "Thalidomide Treatment of Prurigo Nodularis", Acta. Derm. Venereol., Vol. 64, No. 5,
	PV	pp. 412-417 (1984)
>	,	
AMINE	,	DATE CONSIDERED ()
AMINE	R 22	0/23/9
AMINE	R ER: Initia	I if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in considered. Include copy of this form with next communication to applicant.

RECEIVED

AUG 0 3 2001

TECH CENTER 1600/2900

PTO/SB/08A (08-00)
Approved for use through 10/31/2002 OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Complete if Known

Application No. 1449/A/PTO

Substitute for Form 1449/A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary

Sheet | 17 of 17 |

	Complete if Known
Application Number	09/545,139
Filing Date	April 7, 2000
First Named Inventor	D'Amato et al.
Group Art Unit	1614
Examiner Name	J. Goldberg
Attorney Docket Number	05213-0650 43170-219681

	U.S. PATENT DOCUMENTS		
		OTHED DEFEDENCES (Including Author Title Date Portingut Dages Via)	
R	QA	Wood, et al., "The Potential use of Thalidomide in the Therapy of Graft-versus-Host Disease – A Review of Clinical and Laboratory Information", Leuk. Res., Vol. 14, No. 5, pp. 395-399 (1990)	
(2)	QB	Woodyatt, P.B., "Thalidomide", The Lancet, p. 750. (1962)	
	QC	Wulff, et al., "Development of Polyneuropathy During Thalidomide Therapy", Br. J. Dermatol., Vol. 112, No. 4, pp. 475-480 (1985)	
9	QD	Yazici, et al., "Practical Treatment Recommendations for Pharmacotherapy of Behcet's Syndrome", <i>Drugs</i> , Vol. 42, No. 5, pp. 796-804 (1991)	
9	QE	Yoshimura, T. et al., "Cloning, Sequencing, and Expression of Human Macrophage Stimulating Protein (MSP, MST1) Confirms MSP as a Member of the Family of Kringle Proteins and Locates the MSP Gene on Chromosome 3", The J. of Biol. Chem., Vol. 268, No. 21, pp. 15461-15468 (1993)	
9	QF	Youle, et al., "Treatment of Resistant Aphthous Ulceration with Thalidomide in Patients Positive for HIV Antibody", BMJ, Vol. 298, No. 6671, p. 432 (1989)	
	QG	Youle, et al., "Thalidomide in Hyperalgic Pharyngeal Ulceration of AIDS", Lancet, Vol. 335, No. 8705, p. 1591 (1990)	
9	QH	Yue, t. et al., "2-Methoxyestradiol, an Endogenous Estrogen Metabolite, Induces Apoptosis in Endothelial Cells and Inhibits Angiogenesis: Possible Role for Stress-Activated Protein Kinase Signaling Pathway and Fas Expression", Molecular Pharmacology, Vol. 51, pp. 951-962 (1997)	
Ql Ziche, M. et al., "Nitric Oxide Synthase Lies Downstream from Vascular Endothelial Growth Factor-induced but Not Basic Fibroblast Growth Factor-Induced Angiogenesis", J. Clin. Invest., Vol. 99, No. 11, pp. 2625-2634 (1997)			
8	QJ	Zwart, D., "Treatment of Grade II Astrocytoma with Thalidomide", ArzneimForsch., Vol. 16, No. 12, pp. 1688-1689 (1966)	
EXAMINI		DATE CONSIDERED \$/23/0)	
		itial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in ot considered. Include copy of this form with next communication to applicant.	

RECEIVED

AUG 6 > 2001 TECH CENTER 1600/2900